Background  ||| S:24 E:43 ||| NN
The  ||| S:43 E:47 ||| DT
actin  ||| S:47 E:53 ||| JJ
cytoskeleton  ||| S:53 E:66 ||| NN
is  ||| S:66 E:69 ||| VBZ
a  ||| S:69 E:71 ||| DT
dynamic  ||| S:71 E:79 ||| JJ
system  ||| S:79 E:86 ||| NN
composed  ||| S:86 E:95 ||| VBN
of  ||| S:95 E:106 ||| IN
actin  ||| S:106 E:112 ||| JJ
filaments ||| S:112 E:121 ||| NN
,  ||| S:121 E:123 ||| ,
proteins  ||| S:123 E:132 ||| NNS
that  ||| S:132 E:137 ||| IN
regulate  ||| S:137 E:146 ||| JJ
filament  ||| S:146 E:155 ||| JJ
dynamics ||| S:155 E:163 ||| NNS
,  ||| S:163 E:173 ||| ,
and  ||| S:173 E:177 ||| CC
proteins  ||| S:177 E:186 ||| NNS
that  ||| S:186 E:191 ||| IN
remodel  ||| S:191 E:199 ||| NN
and  ||| S:199 E:203 ||| CC
make  ||| S:203 E:208 ||| VB
use  ||| S:208 E:212 ||| NN
of  ||| S:212 E:215 ||| IN
the  ||| S:215 E:219 ||| DT
cytoskeletal  ||| S:219 E:240 ||| JJ
network ||| S:240 E:247 ||| NN
.  ||| S:247 E:249 ||| .
An  ||| S:249 E:252 ||| DT
important  ||| S:252 E:262 ||| JJ
aspect  ||| S:262 E:269 ||| NN
of  ||| S:269 E:272 ||| IN
actin  ||| S:272 E:278 ||| JJ
cytoskeletal  ||| S:278 E:291 ||| JJ
research  ||| S:291 E:308 ||| NN
has  ||| S:308 E:312 ||| VBZ
been  ||| S:312 E:317 ||| VBN
the  ||| S:317 E:321 ||| DT
use  ||| S:321 E:325 ||| NN
of  ||| S:325 E:328 ||| IN
small  ||| S:328 E:334 ||| JJ
molecules  ||| S:334 E:344 ||| NNS
that  ||| S:344 E:349 ||| WDT
affect  ||| S:349 E:356 ||| VBP
actin  ||| S:356 E:370 ||| JJ
dynamics  ||| S:370 E:379 ||| NNS
and  ||| S:379 E:383 ||| CC
proteins  ||| S:383 E:392 ||| NNS
that  ||| S:392 E:397 ||| IN
act  ||| S:397 E:401 ||| NN
on  ||| S:401 E:404 ||| IN
the  ||| S:404 E:408 ||| DT
cytoskeleton  ||| S:408 E:421 ||| NN
[  ||| S:421 E:423 ||| -LRB-
1  ||| S:423 E:425 ||| LS
]  ||| S:425 E:427 ||| -RRB-
.  ||| S:427 E:437 ||| .
2,3-butanedione  ||| S:437 E:453 ||| FW
monoxime  ||| S:453 E:462 ||| FW
( ||| S:462 E:463 ||| -LRB-
BDM ||| S:463 E:466 ||| NNP
)  ||| S:466 E:468 ||| -RRB-
is  ||| S:468 E:471 ||| VBZ
a  ||| S:471 E:473 ||| DT
small  ||| S:473 E:479 ||| JJ
molecule  ||| S:479 E:488 ||| NN
that  ||| S:488 E:501 ||| IN
inhibits  ||| S:501 E:510 ||| VBG
the  ||| S:510 E:514 ||| DT
ATPase  ||| S:514 E:521 ||| JJ
activity  ||| S:521 E:530 ||| NN
of  ||| S:530 E:533 ||| IN
muscle  ||| S:533 E:540 ||| NN
myosinII  ||| S:540 E:549 ||| NN
and  ||| S:549 E:553 ||| CC
reduces  ||| S:553 E:569 ||| VBZ
the  ||| S:569 E:573 ||| DT
force  ||| S:573 E:579 ||| NN
generated  ||| S:579 E:589 ||| VBD
by  ||| S:589 E:592 ||| IN
this  ||| S:592 E:597 ||| DT
motor  ||| S:597 E:603 ||| NN
protein  ||| S:603 E:611 ||| NN
[  ||| S:611 E:613 ||| -LRB-
2  ||| S:613 E:615 ||| CD
3  ||| S:615 E:617 ||| CD
]  ||| S:617 E:619 ||| -RRB-
.  ||| S:619 E:621 ||| .
BDM  ||| S:621 E:625 ||| NNP
was  ||| S:625 E:637 ||| VBD
introduced  ||| S:637 E:648 ||| VBN
to  ||| S:648 E:651 ||| TO
the  ||| S:651 E:655 ||| DT
cell  ||| S:655 E:660 ||| NN
biology  ||| S:660 E:668 ||| NN
community  ||| S:668 E:678 ||| NN
as  ||| S:678 E:681 ||| IN
a  ||| S:681 E:683 ||| DT
millimolar  ||| S:683 E:702 ||| JJ
inhibitor  ||| S:702 E:712 ||| NN
of  ||| S:712 E:715 ||| IN
multiple  ||| S:715 E:724 ||| JJ
non-muscle  ||| S:724 E:735 ||| JJ
myosins  ||| S:735 E:743 ||| NN
with  ||| S:743 E:748 ||| IN
greatest  ||| S:748 E:765 ||| JJS
potency  ||| S:765 E:773 ||| NN
in  ||| S:773 E:776 ||| IN
inhibiting  ||| S:776 E:787 ||| JJ
non-muscle  ||| S:787 E:798 ||| JJ
myosinII  ||| S:798 E:807 ||| NN
[  ||| S:807 E:809 ||| -LRB-
4  ||| S:809 E:811 ||| LS
]  ||| S:811 E:813 ||| -RRB-
.  ||| S:813 E:815 ||| .
It  ||| S:815 E:818 ||| PRP
was  ||| S:818 E:830 ||| VBD
subsequently  ||| S:830 E:843 ||| RB
used ||| S:843 E:847 ||| VBN
,  ||| S:847 E:849 ||| ,
in  ||| S:849 E:852 ||| IN
concert  ||| S:852 E:860 ||| NN
with  ||| S:860 E:865 ||| IN
other  ||| S:865 E:871 ||| JJ
approaches ||| S:871 E:881 ||| NNS
,  ||| S:881 E:883 ||| ,
to  ||| S:883 E:894 ||| TO
study  ||| S:894 E:900 ||| VB
nm-myosinII  ||| S:900 E:912 ||| JJ
function  ||| S:912 E:921 ||| NN
in  ||| S:921 E:924 ||| IN
a  ||| S:924 E:926 ||| DT
variety  ||| S:926 E:934 ||| NN
of  ||| S:934 E:937 ||| IN
biological  ||| S:937 E:956 ||| JJ
processes  ||| S:956 E:966 ||| NNS
[  ||| S:966 E:968 ||| -LRB-
5  ||| S:968 E:970 ||| CD
6  ||| S:970 E:972 ||| CD
7  ||| S:972 E:974 ||| CD
8  ||| S:974 E:976 ||| CD
]  ||| S:976 E:978 ||| -RRB-
.  ||| S:978 E:980 ||| .
BDM  ||| S:980 E:984 ||| NNP
was  ||| S:984 E:988 ||| VBD
recently  ||| S:988 E:997 ||| RB
shown  ||| S:997 E:1003 ||| VBN
not  ||| S:1003 E:1007 ||| RB
to  ||| S:1007 E:1018 ||| TO
inhibit  ||| S:1018 E:1026 ||| VB
any  ||| S:1026 E:1030 ||| DT
non-muscle  ||| S:1030 E:1041 ||| JJ
myosins  ||| S:1041 E:1049 ||| NNS
so  ||| S:1049 E:1052 ||| RB
far  ||| S:1052 E:1056 ||| RB
tested ||| S:1056 E:1062 ||| VBN
,  ||| S:1062 E:1064 ||| ,
leaving  ||| S:1064 E:1072 ||| VBG
the  ||| S:1072 E:1084 ||| DT
question  ||| S:1084 E:1093 ||| NN
of  ||| S:1093 E:1096 ||| IN
how  ||| S:1096 E:1100 ||| WRB
it  ||| S:1100 E:1103 ||| PRP
affects  ||| S:1103 E:1111 ||| VBZ
cells  ||| S:1111 E:1117 ||| JJ
unanswered  ||| S:1117 E:1128 ||| NNS
[  ||| S:1128 E:1130 ||| -LRB-
9  ||| S:1130 E:1132 ||| CD
10  ||| S:1132 E:1135 ||| CD
]  ||| S:1135 E:1137 ||| -RRB-
.  ||| S:1137 E:1147 ||| .
One  ||| S:1147 E:1151 ||| CD
process  ||| S:1151 E:1159 ||| NN
inhibited  ||| S:1159 E:1169 ||| NN
by  ||| S:1169 E:1172 ||| IN
BDM  ||| S:1172 E:1176 ||| NNP
is  ||| S:1176 E:1179 ||| VBZ
the  ||| S:1179 E:1183 ||| DT
centripetal  ||| S:1183 E:1195 ||| JJ
flow  ||| S:1195 E:1200 ||| NN
of  ||| S:1200 E:1211 ||| IN
actin  ||| S:1211 E:1217 ||| NN
from  ||| S:1217 E:1222 ||| IN
the  ||| S:1222 E:1226 ||| DT
leading  ||| S:1226 E:1234 ||| JJ
edge  ||| S:1234 E:1239 ||| NN
into  ||| S:1239 E:1244 ||| IN
the  ||| S:1244 E:1248 ||| DT
cell  ||| S:1248 E:1253 ||| NN
body ||| S:1253 E:1257 ||| NN
,  ||| S:1257 E:1259 ||| ,
known  ||| S:1259 E:1265 ||| VBN
as  ||| S:1265 E:1276 ||| IN
retrograde  ||| S:1276 E:1287 ||| JJ
flow  ||| S:1287 E:1292 ||| NN
[  ||| S:1292 E:1294 ||| -LRB-
11  ||| S:1294 E:1297 ||| CD
12  ||| S:1297 E:1300 ||| CD
]  ||| S:1300 E:1302 ||| -RRB-
.  ||| S:1302 E:1304 ||| .
Retrograde  ||| S:1304 E:1315 ||| JJ
flow  ||| S:1315 E:1320 ||| NN
is  ||| S:1320 E:1323 ||| VBZ
thought  ||| S:1323 E:1331 ||| VBN
to  ||| S:1331 E:1342 ||| TO
be  ||| S:1342 E:1345 ||| VB
driven  ||| S:1345 E:1352 ||| VBN
by  ||| S:1352 E:1355 ||| IN
a  ||| S:1355 E:1357 ||| DT
"push-pull ||| S:1357 E:1367 ||| NN
"  ||| S:1367 E:1369 ||| ''
mechanism  ||| S:1369 E:1379 ||| NN
of  ||| S:1379 E:1382 ||| IN
polymerization  ||| S:1382 E:1397 ||| NN
of  ||| S:1397 E:1408 ||| IN
actin  ||| S:1408 E:1414 ||| NN
at  ||| S:1414 E:1417 ||| IN
the  ||| S:1417 E:1421 ||| DT
leading  ||| S:1421 E:1429 ||| JJ
edge  ||| S:1429 E:1434 ||| NN
of  ||| S:1434 E:1437 ||| IN
the  ||| S:1437 E:1441 ||| DT
cell  ||| S:1441 E:1446 ||| NN
and  ||| S:1446 E:1450 ||| CC
contractile  ||| S:1450 E:1470 ||| JJ
activity  ||| S:1470 E:1479 ||| NN
of  ||| S:1479 E:1482 ||| IN
myosin  ||| S:1482 E:1489 ||| JJ
motor  ||| S:1489 E:1495 ||| NN
proteins  ||| S:1495 E:1504 ||| NNS
[  ||| S:1504 E:1506 ||| -LRB-
13  ||| S:1506 E:1509 ||| CD
14  ||| S:1509 E:1512 ||| CD
]  ||| S:1512 E:1514 ||| -RRB-
.  ||| S:1514 E:1516 ||| .
Formation  ||| S:1516 E:1526 ||| NN
of  ||| S:1526 E:1537 ||| IN
new  ||| S:1537 E:1541 ||| JJ
actin  ||| S:1541 E:1547 ||| JJ
filaments  ||| S:1547 E:1557 ||| NN
is  ||| S:1557 E:1560 ||| VBZ
predominantly  ||| S:1560 E:1574 ||| RB
mediated  ||| S:1574 E:1583 ||| VBN
by  ||| S:1583 E:1586 ||| IN
the  ||| S:1586 E:1598 ||| DT
nucleation  ||| S:1598 E:1609 ||| JJ
activity  ||| S:1609 E:1618 ||| NN
of  ||| S:1618 E:1621 ||| IN
the  ||| S:1621 E:1625 ||| DT
Arp2 ||| S:1625 E:1629 ||| CD
/ ||| S:1629 E:1630 ||| CD
3  ||| S:1630 E:1632 ||| CD
complex  ||| S:1632 E:1640 ||| NN
[  ||| S:1640 E:1642 ||| -LRB-
15  ||| S:1642 E:1645 ||| CD
]  ||| S:1645 E:1647 ||| -RRB-
.  ||| S:1647 E:1649 ||| .
Members  ||| S:1649 E:1665 ||| NNS
of  ||| S:1665 E:1668 ||| IN
the  ||| S:1668 E:1672 ||| DT
WASP ||| S:1672 E:1676 ||| NNP
/ ||| S:1676 E:1677 ||| NNP
WAVE  ||| S:1677 E:1682 ||| NNP
family  ||| S:1682 E:1689 ||| NN
of  ||| S:1689 E:1692 ||| IN
proteins ||| S:1692 E:1700 ||| NNS
,  ||| S:1700 E:1702 ||| ,
among  ||| S:1702 E:1708 ||| IN
others ||| S:1708 E:1714 ||| NNS
,  ||| S:1714 E:1724 ||| ,
stimulate  ||| S:1724 E:1734 ||| NN
and  ||| S:1734 E:1738 ||| CC
regulate  ||| S:1738 E:1747 ||| VB
the  ||| S:1747 E:1751 ||| DT
Arp2 ||| S:1751 E:1755 ||| CD
/ ||| S:1755 E:1756 ||| CD
3  ||| S:1756 E:1758 ||| CD
complex  ||| S:1758 E:1766 ||| NN
for  ||| S:1766 E:1770 ||| IN
spatial  ||| S:1770 E:1778 ||| NN
and  ||| S:1778 E:1790 ||| CC
temporal  ||| S:1790 E:1799 ||| JJ
control  ||| S:1799 E:1807 ||| NN
of  ||| S:1807 E:1810 ||| IN
filament  ||| S:1810 E:1819 ||| JJ
nucleation  ||| S:1819 E:1830 ||| NNS
[  ||| S:1830 E:1832 ||| -LRB-
15  ||| S:1832 E:1835 ||| CD
]  ||| S:1835 E:1837 ||| -RRB-
.  ||| S:1837 E:1847 ||| .
Localization  ||| S:1847 E:1860 ||| NNP
of  ||| S:1860 E:1863 ||| IN
these  ||| S:1863 E:1869 ||| DT
proteins  ||| S:1869 E:1878 ||| NNS
to  ||| S:1878 E:1881 ||| TO
the  ||| S:1881 E:1885 ||| DT
leading  ||| S:1885 E:1893 ||| JJ
edge ||| S:1893 E:1897 ||| NN
,  ||| S:1897 E:1899 ||| ,
though  ||| S:1899 E:1914 ||| RB
not  ||| S:1914 E:1918 ||| RB
completely  ||| S:1918 E:1929 ||| RB
understood ||| S:1929 E:1939 ||| VBN
,  ||| S:1939 E:1941 ||| ,
is  ||| S:1941 E:1944 ||| VBZ
probably  ||| S:1944 E:1953 ||| RB
mediated  ||| S:1953 E:1962 ||| VBN
through  ||| S:1962 E:1978 ||| IN
their  ||| S:1978 E:1984 ||| PRP$
interactions  ||| S:1984 E:1997 ||| NNS
with  ||| S:1997 E:2002 ||| IN
the  ||| S:2002 E:2006 ||| DT
actin  ||| S:2006 E:2012 ||| NN
cytoskeleton  ||| S:2012 E:2025 ||| VBD
itself  ||| S:2025 E:2032 ||| PRP
and  ||| S:2032 E:2044 ||| CC
membrane-associated  ||| S:2044 E:2064 ||| JJ
binding  ||| S:2064 E:2072 ||| JJ
partners  ||| S:2072 E:2081 ||| NNS
[  ||| S:2081 E:2083 ||| -LRB-
15  ||| S:2083 E:2086 ||| CD
16  ||| S:2086 E:2089 ||| CD
]  ||| S:2089 E:2091 ||| -RRB-
.  ||| S:2091 E:2101 ||| .
Inhibition  ||| S:2101 E:2112 ||| NNP
of  ||| S:2112 E:2115 ||| IN
retrograde  ||| S:2115 E:2126 ||| JJ
flow  ||| S:2126 E:2131 ||| NN
by  ||| S:2131 E:2134 ||| IN
BDM  ||| S:2134 E:2138 ||| NNP
has  ||| S:2138 E:2142 ||| VBZ
been  ||| S:2142 E:2147 ||| VBN
used  ||| S:2147 E:2152 ||| VBN
as  ||| S:2152 E:2163 ||| IN
evidence  ||| S:2163 E:2172 ||| NN
for  ||| S:2172 E:2176 ||| IN
the  ||| S:2176 E:2180 ||| DT
role  ||| S:2180 E:2185 ||| NN
of  ||| S:2185 E:2188 ||| IN
nm-myosins  ||| S:2188 E:2199 ||| JJ
in  ||| S:2199 E:2202 ||| IN
retrograde  ||| S:2202 E:2213 ||| JJ
flow  ||| S:2213 E:2218 ||| NN
[  ||| S:2218 E:2220 ||| -LRB-
12  ||| S:2220 E:2231 ||| CD
]  ||| S:2231 E:2233 ||| -RRB-
.  ||| S:2233 E:2235 ||| .
Though  ||| S:2235 E:2242 ||| RB
not  ||| S:2242 E:2246 ||| RB
explicitly  ||| S:2246 E:2257 ||| RB
stated ||| S:2257 E:2263 ||| VBN
,  ||| S:2263 E:2265 ||| ,
the  ||| S:2265 E:2269 ||| DT
localization  ||| S:2269 E:2282 ||| NN
and  ||| S:2282 E:2294 ||| CC
importance  ||| S:2294 E:2305 ||| NN
of  ||| S:2305 E:2308 ||| IN
nm-myosinII  ||| S:2308 E:2320 ||| JJ
in  ||| S:2320 E:2323 ||| IN
multiple  ||| S:2323 E:2332 ||| JJ
cell  ||| S:2332 E:2337 ||| NN
types ||| S:2337 E:2342 ||| NNS
,  ||| S:2342 E:2344 ||| ,
and  ||| S:2344 E:2348 ||| CC
the  ||| S:2348 E:2360 ||| DT
fact  ||| S:2360 E:2365 ||| NN
that  ||| S:2365 E:2370 ||| IN
BDM  ||| S:2370 E:2374 ||| NNP
was  ||| S:2374 E:2378 ||| VBD
thought  ||| S:2378 E:2386 ||| VBN
to  ||| S:2386 E:2389 ||| TO
have  ||| S:2389 E:2394 ||| VB
greatest  ||| S:2394 E:2403 ||| JJS
potency  ||| S:2403 E:2411 ||| NN
in  ||| S:2411 E:2422 ||| IN
inhibiting  ||| S:2422 E:2433 ||| JJ
nm-myosinII  ||| S:2433 E:2445 ||| NN
has  ||| S:2445 E:2449 ||| VBZ
led  ||| S:2449 E:2453 ||| VBN
most  ||| S:2453 E:2458 ||| RBS
to  ||| S:2458 E:2461 ||| TO
look  ||| S:2461 E:2466 ||| VB
at  ||| S:2466 E:2469 ||| IN
BDM ||| S:2469 E:2472 ||| NNP
's  ||| S:2472 E:2475 ||| POS
effect  ||| S:2475 E:2490 ||| NN
on  ||| S:2490 E:2493 ||| IN
retrograde  ||| S:2493 E:2504 ||| JJ
flow  ||| S:2504 E:2509 ||| NN
as  ||| S:2509 E:2512 ||| IN
a  ||| S:2512 E:2514 ||| DT
result  ||| S:2514 E:2521 ||| NN
of  ||| S:2521 E:2524 ||| IN
inhibiting  ||| S:2524 E:2535 ||| VBG
this  ||| S:2535 E:2540 ||| DT
protein.  ||| S:2540 E:2557 ||| NNP
[  ||| S:2557 E:2559 ||| -LRB-
11  ||| S:2559 E:2562 ||| CD
17  ||| S:2562 E:2565 ||| CD
18  ||| S:2565 E:2568 ||| CD
]  ||| S:2568 E:2570 ||| -RRB-
.  ||| S:2570 E:2572 ||| .
A  ||| S:2572 E:2574 ||| DT
role  ||| S:2574 E:2579 ||| NN
for  ||| S:2579 E:2583 ||| IN
nm-myosinII  ||| S:2583 E:2595 ||| NNP
may  ||| S:2595 E:2599 ||| MD
exist ||| S:2599 E:2604 ||| VB
,  ||| S:2604 E:2606 ||| ,
given  ||| S:2606 E:2612 ||| VBN
its  ||| S:2612 E:2624 ||| PRP$
localization  ||| S:2624 E:2637 ||| NN
and  ||| S:2637 E:2641 ||| CC
that  ||| S:2641 E:2646 ||| DT
other  ||| S:2646 E:2652 ||| JJ
perturbations  ||| S:2652 E:2666 ||| NN
that  ||| S:2666 E:2671 ||| WDT
affect  ||| S:2671 E:2686 ||| VBP
myosin  ||| S:2686 E:2693 ||| JJ
function  ||| S:2693 E:2702 ||| NN
-  ||| S:2702 E:2704 ||| :
myosin  ||| S:2704 E:2711 ||| CD
S1  ||| S:2711 E:2714 ||| CD
microinjection ||| S:2714 E:2728 ||| NN
,  ||| S:2728 E:2730 ||| ,
ML-7  ||| S:2730 E:2735 ||| CD
treatment ||| S:2735 E:2744 ||| NN
,  ||| S:2744 E:2754 ||| ,
and  ||| S:2754 E:2758 ||| CC
expression  ||| S:2758 E:2769 ||| NN
of  ||| S:2769 E:2772 ||| IN
dominant  ||| S:2772 E:2781 ||| JJ
negative  ||| S:2781 E:2790 ||| JJ
nm-myosinII  ||| S:2790 E:2802 ||| JJ
constructs  ||| S:2802 E:2821 ||| NN
and  ||| S:2821 E:2825 ||| CC
have  ||| S:2825 E:2830 ||| VBP
similar  ||| S:2830 E:2838 ||| JJ
effects  ||| S:2838 E:2846 ||| NNS
to  ||| S:2846 E:2849 ||| TO
BDM  ||| S:2849 E:2853 ||| NNP
treatment  ||| S:2853 E:2863 ||| NN
[  ||| S:2863 E:2865 ||| -LRB-
5  ||| S:2865 E:2867 ||| CD
7  ||| S:2867 E:2869 ||| CD
12  ||| S:2869 E:2872 ||| CD
]  ||| S:2872 E:2874 ||| -RRB-
.  ||| S:2874 E:2884 ||| .
However ||| S:2884 E:2891 ||| RB
,  ||| S:2891 E:2893 ||| ,
a  ||| S:2893 E:2895 ||| DT
study  ||| S:2895 E:2901 ||| NN
in  ||| S:2901 E:2904 ||| IN
chick  ||| S:2904 E:2910 ||| JJ
dorsal  ||| S:2910 E:2917 ||| NNS
root  ||| S:2917 E:2922 ||| VBP
ganglia  ||| S:2922 E:2930 ||| JJ
neurons  ||| S:2930 E:2938 ||| NN
where  ||| S:2938 E:2952 ||| WRB
nm-myosinII  ||| S:2952 E:2964 ||| NNP
was  ||| S:2964 E:2968 ||| VBD
inactivated  ||| S:2968 E:2980 ||| VBN
using  ||| S:2980 E:2986 ||| VBG
chromophore  ||| S:2986 E:2998 ||| JJ
assisted  ||| S:2998 E:3015 ||| JJ
laser  ||| S:3015 E:3021 ||| NN
inactivation  ||| S:3021 E:3034 ||| NN
saw  ||| S:3034 E:3038 ||| VBD
no  ||| S:3038 E:3041 ||| DT
effect  ||| S:3041 E:3048 ||| NN
on  ||| S:3048 E:3051 ||| IN
retrograde  ||| S:3051 E:3062 ||| JJ
flow  ||| S:3062 E:3067 ||| NN
rates  ||| S:3067 E:3073 ||| NNS
[  ||| S:3073 E:3083 ||| -LRB-
19  ||| S:3083 E:3086 ||| CD
]  ||| S:3086 E:3088 ||| -RRB-
.  ||| S:3088 E:3090 ||| .
We  ||| S:3090 E:3093 ||| PRP
know  ||| S:3093 E:3098 ||| VBP
now  ||| S:3098 E:3102 ||| RB
that  ||| S:3102 E:3107 ||| IN
BDM  ||| S:3107 E:3111 ||| NNP
does  ||| S:3111 E:3116 ||| VBZ
not  ||| S:3116 E:3120 ||| RB
in  ||| S:3120 E:3123 ||| IN
fact  ||| S:3123 E:3128 ||| NN
inhibit  ||| S:3128 E:3144 ||| VBP
nm-myosinII ||| S:3144 E:3155 ||| JJ
.  ||| S:3155 E:3157 ||| .
So ||| S:3157 E:3159 ||| RB
,  ||| S:3159 E:3161 ||| ,
is  ||| S:3161 E:3164 ||| VBZ
this  ||| S:3164 E:3169 ||| DT
effect  ||| S:3169 E:3176 ||| NN
that  ||| S:3176 E:3181 ||| IN
we  ||| S:3181 E:3184 ||| PRP
see  ||| S:3184 E:3188 ||| VBP
with  ||| S:3188 E:3193 ||| IN
BDM  ||| S:3193 E:3205 ||| NNP
mediated  ||| S:3205 E:3214 ||| NN
by  ||| S:3214 E:3217 ||| IN
other  ||| S:3217 E:3223 ||| JJ
proteins  ||| S:3223 E:3232 ||| NNS
involved  ||| S:3232 E:3241 ||| VBN
in  ||| S:3241 E:3244 ||| IN
retrograde  ||| S:3244 E:3255 ||| JJ
flow ||| S:3255 E:3259 ||| NN
?  ||| S:3259 E:3261 ||| .
And  ||| S:3261 E:3273 ||| CC
what  ||| S:3273 E:3278 ||| WP
can  ||| S:3278 E:3282 ||| MD
this  ||| S:3282 E:3287 ||| RB
tell  ||| S:3287 E:3292 ||| VB
us  ||| S:3292 E:3295 ||| PRP
about  ||| S:3295 E:3301 ||| IN
the  ||| S:3301 E:3305 ||| DT
mechanism  ||| S:3305 E:3315 ||| NN
of  ||| S:3315 E:3318 ||| IN
retrograde  ||| S:3318 E:3337 ||| JJ
flow ||| S:3337 E:3341 ||| NN
?  ||| S:3341 E:3343 ||| .
How  ||| S:3343 E:3347 ||| WRB
similar  ||| S:3347 E:3355 ||| JJ
is  ||| S:3355 E:3358 ||| VBZ
this  ||| S:3358 E:3363 ||| DT
process  ||| S:3363 E:3371 ||| NN
to  ||| S:3371 E:3374 ||| TO
other  ||| S:3374 E:3380 ||| JJ
actin  ||| S:3380 E:3386 ||| JJ
mediated  ||| S:3386 E:3403 ||| JJ
processes  ||| S:3403 E:3413 ||| NNS
that  ||| S:3413 E:3418 ||| WDT
use  ||| S:3418 E:3422 ||| VBP
these  ||| S:3422 E:3428 ||| DT
same  ||| S:3428 E:3433 ||| JJ
proteins ||| S:3433 E:3441 ||| NNS
,  ||| S:3441 E:3443 ||| ,
such  ||| S:3443 E:3448 ||| JJ
as  ||| S:3448 E:3451 ||| IN
Listeria  ||| S:3451 E:3468 ||| NNP
motility ||| S:3468 E:3476 ||| NN
?  ||| S:3476 E:3478 ||| .
BDM  ||| S:3478 E:3482 ||| NNP
has  ||| S:3482 E:3486 ||| VBZ
a  ||| S:3486 E:3488 ||| DT
clear  ||| S:3488 E:3494 ||| JJ
effect  ||| S:3494 E:3501 ||| NN
on  ||| S:3501 E:3504 ||| IN
a  ||| S:3504 E:3506 ||| DT
number  ||| S:3506 E:3513 ||| NN
of  ||| S:3513 E:3516 ||| IN
cell  ||| S:3516 E:3529 ||| NN
biological  ||| S:3529 E:3540 ||| JJ
processes ||| S:3540 E:3549 ||| NNS
.  ||| S:3549 E:3551 ||| .
Understanding  ||| S:3551 E:3565 ||| NN
how  ||| S:3565 E:3569 ||| WRB
these  ||| S:3569 E:3575 ||| DT
effects  ||| S:3575 E:3583 ||| NNS
are  ||| S:3583 E:3595 ||| VBP
mediated  ||| S:3595 E:3604 ||| NNS
can  ||| S:3604 E:3608 ||| MD
help  ||| S:3608 E:3613 ||| VB
us  ||| S:3613 E:3616 ||| PRP
learn  ||| S:3616 E:3622 ||| VBP
from  ||| S:3622 E:3627 ||| IN
BDM  ||| S:3627 E:3631 ||| NNP
and  ||| S:3631 E:3635 ||| CC
reinterpret  ||| S:3635 E:3655 ||| JJ
experiments  ||| S:3655 E:3667 ||| NNS
that  ||| S:3667 E:3672 ||| WDT
made  ||| S:3672 E:3677 ||| VBD
use  ||| S:3677 E:3681 ||| NN
of  ||| S:3681 E:3684 ||| IN
it ||| S:3684 E:3686 ||| PRP
,  ||| S:3686 E:3688 ||| ,
while  ||| S:3688 E:3694 ||| IN
working  ||| S:3694 E:3702 ||| VBG
to  ||| S:3702 E:3705 ||| TO
find  ||| S:3705 E:3710 ||| VB
new  ||| S:3710 E:3722 ||| JJ
and  ||| S:3722 E:3726 ||| CC
better  ||| S:3726 E:3733 ||| JJR
inhibitors ||| S:3733 E:3743 ||| NN
.  ||| S:3743 E:3767 ||| .
Results  ||| S:3767 E:3794 ||| FW
BDM  ||| S:3794 E:3798 ||| FW
inhibits  ||| S:3798 E:3807 ||| FW
actin  ||| S:3807 E:3813 ||| FW
incorporation  ||| S:3813 E:3827 ||| FW
in  ||| S:3827 E:3830 ||| FW
mammalian  ||| S:3830 E:3850 ||| FW
cells  ||| S:3850 E:3866 ||| FW
BDM  ||| S:3866 E:3870 ||| FW
has  ||| S:3870 E:3874 ||| VBZ
been  ||| S:3874 E:3879 ||| VBN
reported  ||| S:3879 E:3888 ||| VBN
to  ||| S:3888 E:3891 ||| TO
not  ||| S:3891 E:3895 ||| RB
inhibit  ||| S:3895 E:3903 ||| VB
nm-myosinII  ||| S:3903 E:3925 ||| JJ
ATPase  ||| S:3925 E:3932 ||| JJ
activity  ||| S:3932 E:3941 ||| NN
[  ||| S:3941 E:3943 ||| -LRB-
9  ||| S:3943 E:3945 ||| CD
]  ||| S:3945 E:3947 ||| -RRB-
.  ||| S:3947 E:3949 ||| .
We  ||| S:3949 E:3952 ||| PRP
show  ||| S:3952 E:3957 ||| VBP
data  ||| S:3957 E:3962 ||| NNS
[ ||| S:3962 E:3963 ||| -LRB-
Figure  ||| S:3963 E:3970 ||| NNP
1A ||| S:3970 E:3972 ||| NNP
]  ||| S:3972 E:3974 ||| -RRB-
that  ||| S:3974 E:3989 ||| WDT
supports  ||| S:3989 E:3998 ||| VBZ
this  ||| S:3998 E:4003 ||| DT
report ||| S:4003 E:4009 ||| NN
.  ||| S:4009 E:4011 ||| .
The  ||| S:4011 E:4015 ||| DT
ATPase  ||| S:4015 E:4022 ||| JJ
activity  ||| S:4022 E:4031 ||| NN
of  ||| S:4031 E:4034 ||| IN
platelet  ||| S:4034 E:4053 ||| JJ
nm-myosinII  ||| S:4053 E:4065 ||| JJ
S1  ||| S:4065 E:4068 ||| CD
fragment ||| S:4068 E:4076 ||| NN
,  ||| S:4076 E:4078 ||| ,
is  ||| S:4078 E:4081 ||| VBZ
not  ||| S:4081 E:4085 ||| RB
inhibited  ||| S:4085 E:4095 ||| VBN
by  ||| S:4095 E:4098 ||| IN
BDM  ||| S:4098 E:4102 ||| NNP
while  ||| S:4102 E:4118 ||| IN
the  ||| S:4118 E:4122 ||| DT
inhibitor ||| S:4122 E:4131 ||| NN
,  ||| S:4131 E:4133 ||| ,
blebbistatin ||| S:4133 E:4145 ||| NN
,  ||| S:4145 E:4147 ||| ,
decreases  ||| S:4147 E:4157 ||| VBZ
ATPase  ||| S:4157 E:4164 ||| JJ
activity  ||| S:4164 E:4173 ||| NN
by  ||| S:4173 E:4186 ||| IN
more  ||| S:4186 E:4191 ||| JJR
than  ||| S:4191 E:4196 ||| IN
90 ||| S:4196 E:4198 ||| CD
% ||| S:4198 E:4199 ||| NN
.  ||| S:4199 E:4201 ||| .
The  ||| S:4201 E:4205 ||| DT
stimulation  ||| S:4205 E:4217 ||| NN
of  ||| S:4217 E:4220 ||| IN
ATPase  ||| S:4220 E:4227 ||| JJ
activity  ||| S:4227 E:4236 ||| NN
by  ||| S:4236 E:4239 ||| IN
BDM  ||| S:4239 E:4253 ||| NNP
[ ||| S:4253 E:4254 ||| -LRB-
Figure  ||| S:4254 E:4261 ||| NNP
1A ||| S:4261 E:4263 ||| NNP
]  ||| S:4263 E:4265 ||| -RRB-
is  ||| S:4265 E:4268 ||| VBZ
similar  ||| S:4268 E:4276 ||| JJ
to  ||| S:4276 E:4279 ||| TO
a  ||| S:4279 E:4281 ||| DT
~2  ||| S:4281 E:4284 ||| JJ
fold  ||| S:4284 E:4289 ||| JJ
increase  ||| S:4289 E:4298 ||| NN
seen  ||| S:4298 E:4313 ||| VBN
previously  ||| S:4313 E:4324 ||| RB
( ||| S:4324 E:4325 ||| -LRB-
A ||| S:4325 E:4326 ||| NNP
.  ||| S:4326 E:4328 ||| .
Straight  ||| S:4328 E:4337 ||| RB
personal  ||| S:4337 E:4346 ||| JJ
communication ||| S:4346 E:4359 ||| NN
) ||| S:4359 E:4360 ||| -RRB-
.  ||| S:4360 E:4372 ||| .
Though  ||| S:4372 E:4379 ||| IN
BDM  ||| S:4379 E:4383 ||| NNP
does  ||| S:4383 E:4388 ||| VBZ
not  ||| S:4388 E:4392 ||| RB
inhibit  ||| S:4392 E:4400 ||| VB
nm-myosinII ||| S:4400 E:4411 ||| JJ
,  ||| S:4411 E:4413 ||| ,
in  ||| S:4413 E:4426 ||| IN
permeabilized  ||| S:4426 E:4440 ||| JJ
yeast  ||| S:4440 E:4446 ||| NN
(  ||| S:4446 E:4459 ||| -LRB-
S.  ||| S:4459 E:4462 ||| NNP
cerviseae  ||| S:4462 E:4472 ||| CD
)  ||| S:4472 E:4474 ||| -RRB-
BDM  ||| S:4474 E:4478 ||| NNP
has  ||| S:4478 E:4482 ||| VBZ
been  ||| S:4482 E:4487 ||| VBN
shown  ||| S:4487 E:4503 ||| VBN
to  ||| S:4503 E:4506 ||| TO
decrease  ||| S:4506 E:4515 ||| VB
incorporation  ||| S:4515 E:4529 ||| VBN
of  ||| S:4529 E:4532 ||| IN
exogenous  ||| S:4532 E:4542 ||| JJ
actin  ||| S:4542 E:4548 ||| NN
into  ||| S:4548 E:4553 ||| IN
the  ||| S:4553 E:4567 ||| DT
cytoskeleton  ||| S:4567 E:4580 ||| NN
[  ||| S:4580 E:4582 ||| -LRB-
20  ||| S:4582 E:4585 ||| CD
]  ||| S:4585 E:4587 ||| -RRB-
.  ||| S:4587 E:4589 ||| .
This  ||| S:4589 E:4594 ||| DT
process  ||| S:4594 E:4602 ||| NN
of  ||| S:4602 E:4605 ||| IN
actin  ||| S:4605 E:4611 ||| JJ
incorporation  ||| S:4611 E:4635 ||| NN
requires  ||| S:4635 E:4644 ||| VBZ
proteins  ||| S:4644 E:4653 ||| NNS
involved  ||| S:4653 E:4662 ||| VBN
in  ||| S:4662 E:4665 ||| IN
actin  ||| S:4665 E:4671 ||| JJ
filament  ||| S:4671 E:4680 ||| JJ
formation  ||| S:4680 E:4700 ||| NN
and  ||| S:4700 E:4704 ||| CC
proteins  ||| S:4704 E:4713 ||| NNS
that  ||| S:4713 E:4718 ||| WDT
may  ||| S:4718 E:4722 ||| MD
localize  ||| S:4722 E:4731 ||| VB
a  ||| S:4731 E:4733 ||| DT
nucleation  ||| S:4733 E:4744 ||| JJ
complex  ||| S:4744 E:4752 ||| NN
[  ||| S:4752 E:4754 ||| -LRB-
20  ||| S:4754 E:4767 ||| CD
21  ||| S:4767 E:4770 ||| CD
]  ||| S:4770 E:4772 ||| -RRB-
.  ||| S:4772 E:4774 ||| .
To  ||| S:4774 E:4777 ||| TO
determine  ||| S:4777 E:4787 ||| VB
if  ||| S:4787 E:4790 ||| IN
BDM  ||| S:4790 E:4794 ||| NNP
has  ||| S:4794 E:4798 ||| VBZ
a  ||| S:4798 E:4800 ||| DT
similar  ||| S:4800 E:4808 ||| JJ
effect  ||| S:4808 E:4815 ||| NN
on  ||| S:4815 E:4818 ||| IN
actin  ||| S:4818 E:4834 ||| JJ
incorporation  ||| S:4834 E:4848 ||| NN
in  ||| S:4848 E:4851 ||| IN
mammalian  ||| S:4851 E:4861 ||| JJ
cells ||| S:4861 E:4866 ||| NNS
,  ||| S:4866 E:4868 ||| ,
and  ||| S:4868 E:4872 ||| CC
if  ||| S:4872 E:4875 ||| IN
so  ||| S:4875 E:4878 ||| RB
an  ||| S:4878 E:4881 ||| DT
effect  ||| S:4881 E:4888 ||| NN
on  ||| S:4888 E:4901 ||| IN
actin  ||| S:4901 E:4907 ||| JJ
nucleation ||| S:4907 E:4917 ||| NN
,  ||| S:4917 E:4919 ||| ,
spreading  ||| S:4919 E:4929 ||| VBG
Swiss3T3  ||| S:4929 E:4938 ||| CD
cells  ||| S:4938 E:4944 ||| NNS
were  ||| S:4944 E:4949 ||| VBD
treated  ||| S:4949 E:4967 ||| VBN
briefly  ||| S:4967 E:4975 ||| NN
with  ||| S:4975 E:4980 ||| IN
a  ||| S:4980 E:4982 ||| DT
media  ||| S:4982 E:4988 ||| NN
control  ||| S:4988 E:4996 ||| NN
or  ||| S:4996 E:4999 ||| CC
15  ||| S:4999 E:5002 ||| CD
mM  ||| S:5002 E:5005 ||| JJ
BDM  ||| S:5005 E:5009 ||| NNP
and  ||| S:5009 E:5013 ||| CC
then  ||| S:5013 E:5028 ||| RB
permeabilized  ||| S:5028 E:5042 ||| VBN
with  ||| S:5042 E:5047 ||| IN
the  ||| S:5047 E:5051 ||| DT
detergent  ||| S:5051 E:5061 ||| NN
saponin  ||| S:5061 E:5069 ||| NN
in  ||| S:5069 E:5072 ||| IN
the  ||| S:5072 E:5076 ||| DT
presence  ||| S:5076 E:5095 ||| NN
of  ||| S:5095 E:5098 ||| IN
fluorescently  ||| S:5098 E:5112 ||| JJ
labeled  ||| S:5112 E:5120 ||| JJ
actin ||| S:5120 E:5125 ||| NN
.  ||| S:5125 E:5127 ||| .
The  ||| S:5127 E:5131 ||| DT
cells  ||| S:5131 E:5137 ||| NNS
were  ||| S:5137 E:5142 ||| VBD
then  ||| S:5142 E:5147 ||| RB
fixed  ||| S:5147 E:5163 ||| VBN
and  ||| S:5163 E:5167 ||| CC
incorporation  ||| S:5167 E:5181 ||| NN
of  ||| S:5181 E:5184 ||| IN
exogenous  ||| S:5184 E:5194 ||| JJ
actin  ||| S:5194 E:5200 ||| NN
was  ||| S:5200 E:5204 ||| VBD
determined  ||| S:5204 E:5215 ||| VBN
by  ||| S:5215 E:5228 ||| IN
fluorescence  ||| S:5228 E:5241 ||| JJ
microscopy  ||| S:5241 E:5252 ||| NNS
[  ||| S:5252 E:5254 ||| -LRB-
22  ||| S:5254 E:5257 ||| CD
]  ||| S:5257 E:5259 ||| -RRB-
.  ||| S:5259 E:5261 ||| .
Control  ||| S:5261 E:5269 ||| NN
cells  ||| S:5269 E:5275 ||| NNS
show  ||| S:5275 E:5290 ||| VBP
fluorescent  ||| S:5290 E:5302 ||| JJ
incorporation  ||| S:5302 E:5316 ||| NN
at  ||| S:5316 E:5319 ||| IN
the  ||| S:5319 E:5323 ||| DT
periphery ||| S:5323 E:5332 ||| NN
,  ||| S:5332 E:5334 ||| ,
or  ||| S:5334 E:5337 ||| CC
leading  ||| S:5337 E:5355 ||| JJ
edge ||| S:5355 E:5359 ||| NN
,  ||| S:5359 E:5361 ||| ,
of  ||| S:5361 E:5364 ||| IN
the  ||| S:5364 E:5368 ||| DT
cell  ||| S:5368 E:5373 ||| NN
[ ||| S:5373 E:5374 ||| -LRB-
Figure  ||| S:5374 E:5381 ||| NNP
1B ||| S:5381 E:5383 ||| NNP
] ||| S:5383 E:5384 ||| -RRB-
.  ||| S:5384 E:5386 ||| .
Treatment  ||| S:5386 E:5396 ||| NN
of  ||| S:5396 E:5399 ||| IN
cells  ||| S:5399 E:5405 ||| NNS
with  ||| S:5405 E:5410 ||| IN
15  ||| S:5410 E:5423 ||| CD
mM  ||| S:5423 E:5426 ||| JJ
BDM  ||| S:5426 E:5430 ||| NN
for  ||| S:5430 E:5434 ||| IN
one  ||| S:5434 E:5438 ||| CD
minute  ||| S:5438 E:5445 ||| NN
blocked  ||| S:5445 E:5453 ||| VBD
incorporation  ||| S:5453 E:5467 ||| VBN
at  ||| S:5467 E:5470 ||| IN
the  ||| S:5470 E:5484 ||| DT
leading  ||| S:5484 E:5492 ||| JJ
edge ||| S:5492 E:5496 ||| NN
,  ||| S:5496 E:5498 ||| ,
as  ||| S:5498 E:5501 ||| RB
seen  ||| S:5501 E:5506 ||| VBN
by  ||| S:5506 E:5509 ||| IN
the  ||| S:5509 E:5513 ||| DT
lack  ||| S:5513 E:5518 ||| NN
of  ||| S:5518 E:5521 ||| IN
fluorescence  ||| S:5521 E:5544 ||| JJ
intensity ||| S:5544 E:5553 ||| NN
,  ||| S:5553 E:5555 ||| ,
without  ||| S:5555 E:5563 ||| IN
significant  ||| S:5563 E:5575 ||| JJ
effects  ||| S:5575 E:5583 ||| NNS
on  ||| S:5583 E:5586 ||| IN
cell  ||| S:5586 E:5591 ||| NN
morphology  ||| S:5591 E:5612 ||| NNS
[ ||| S:5612 E:5613 ||| -LRB-
Figure  ||| S:5613 E:5620 ||| NNP
1B ||| S:5620 E:5622 ||| NNP
] ||| S:5622 E:5623 ||| -RRB-
.  ||| S:5623 E:5625 ||| .
Cells  ||| S:5625 E:5631 ||| NNS
that  ||| S:5631 E:5636 ||| WDT
remained  ||| S:5636 E:5645 ||| VBD
flat  ||| S:5645 E:5650 ||| JJ
and  ||| S:5650 E:5654 ||| CC
were  ||| S:5654 E:5659 ||| VBD
not  ||| S:5659 E:5673 ||| RB
disrupted  ||| S:5673 E:5683 ||| VBN
by  ||| S:5683 E:5686 ||| IN
the  ||| S:5686 E:5690 ||| DT
permeabilization  ||| S:5690 E:5707 ||| JJ
process  ||| S:5707 E:5715 ||| NN
were  ||| S:5715 E:5720 ||| VBD
counted ||| S:5720 E:5727 ||| VBN
,  ||| S:5727 E:5739 ||| ,
and  ||| S:5739 E:5743 ||| CC
more  ||| S:5743 E:5748 ||| JJR
than  ||| S:5748 E:5753 ||| IN
75 ||| S:5753 E:5755 ||| CD
%  ||| S:5755 E:5757 ||| NN
( ||| S:5757 E:5758 ||| -LRB-
3  ||| S:5758 E:5760 ||| CD
trials ||| S:5760 E:5766 ||| NNS
)  ||| S:5766 E:5768 ||| -RRB-
showed  ||| S:5768 E:5775 ||| VBD
decreased  ||| S:5775 E:5795 ||| VBN
fluorescence  ||| S:5795 E:5808 ||| JJ
similar  ||| S:5808 E:5816 ||| JJ
to  ||| S:5816 E:5819 ||| TO
that  ||| S:5819 E:5824 ||| DT
seen  ||| S:5824 E:5829 ||| VBN
in  ||| S:5829 E:5832 ||| IN
Figure  ||| S:5832 E:5839 ||| NNP
1B ||| S:5839 E:5841 ||| NNP
( ||| S:5841 E:5842 ||| -LRB-
cells  ||| S:5842 E:5848 ||| NNS
that  ||| S:5848 E:5863 ||| WDT
showed  ||| S:5863 E:5870 ||| VBD
significant  ||| S:5870 E:5882 ||| JJ
perturbation  ||| S:5882 E:5895 ||| NN
by  ||| S:5895 E:5898 ||| IN
the  ||| S:5898 E:5902 ||| DT
permeabilization  ||| S:5902 E:5929 ||| JJ
process  ||| S:5929 E:5937 ||| NN
did  ||| S:5937 E:5941 ||| VBD
not  ||| S:5941 E:5945 ||| RB
show  ||| S:5945 E:5950 ||| VB
greater  ||| S:5950 E:5958 ||| JJR
actin  ||| S:5958 E:5964 ||| JJ
incorporation ||| S:5964 E:5977 ||| NN
) ||| S:5977 E:5978 ||| -RRB-
.  ||| S:5978 E:5990 ||| .
Incubation  ||| S:5990 E:6001 ||| NNP
in  ||| S:6001 E:6004 ||| IN
BDM  ||| S:6004 E:6008 ||| NNP
for  ||| S:6008 E:6012 ||| IN
longer  ||| S:6012 E:6019 ||| JJR
than  ||| S:6019 E:6024 ||| IN
1  ||| S:6024 E:6026 ||| CD
minute  ||| S:6026 E:6033 ||| NN
caused  ||| S:6033 E:6040 ||| VBD
more  ||| S:6040 E:6055 ||| RBR
pronounced  ||| S:6055 E:6066 ||| JJ
morphological  ||| S:6066 E:6080 ||| JJ
change  ||| S:6080 E:6087 ||| NN
upon  ||| S:6087 E:6092 ||| IN
permeabilization ||| S:6092 E:6108 ||| NN
,  ||| S:6108 E:6120 ||| ,
and  ||| S:6120 E:6124 ||| CC
one-minute  ||| S:6124 E:6135 ||| JJ
treatment  ||| S:6135 E:6145 ||| NN
was  ||| S:6145 E:6149 ||| VBD
used  ||| S:6149 E:6154 ||| VBN
for  ||| S:6154 E:6158 ||| IN
subsequent  ||| S:6158 E:6179 ||| JJ
experiments ||| S:6179 E:6190 ||| NNS
.  ||| S:6190 E:6202 ||| .
As  ||| S:6202 E:6205 ||| IN
a  ||| S:6205 E:6207 ||| DT
control ||| S:6207 E:6214 ||| NN
,  ||| S:6214 E:6216 ||| ,
cytochalasin  ||| S:6216 E:6229 ||| VBG
D ||| S:6229 E:6230 ||| NNP
,  ||| S:6230 E:6232 ||| ,
a  ||| S:6232 E:6234 ||| DT
small  ||| S:6234 E:6240 ||| JJ
molecule  ||| S:6240 E:6249 ||| NN
that  ||| S:6249 E:6264 ||| IN
inhibits  ||| S:6264 E:6273 ||| JJ
actin  ||| S:6273 E:6279 ||| JJ
dynamics  ||| S:6279 E:6288 ||| NNS
by  ||| S:6288 E:6291 ||| IN
capping  ||| S:6291 E:6299 ||| VBG
the  ||| S:6299 E:6303 ||| DT
growing  ||| S:6303 E:6311 ||| VBG
ends  ||| S:6311 E:6316 ||| NNS
of  ||| S:6316 E:6329 ||| IN
actin  ||| S:6329 E:6335 ||| JJ
filaments ||| S:6335 E:6344 ||| NN
,  ||| S:6344 E:6346 ||| ,
was  ||| S:6346 E:6350 ||| VBD
added  ||| S:6350 E:6356 ||| VBN
to  ||| S:6356 E:6359 ||| TO
cells ||| S:6359 E:6364 ||| NNS
.  ||| S:6364 E:6366 ||| .
If  ||| S:6366 E:6369 ||| IN
added  ||| S:6369 E:6375 ||| VBD
prior  ||| S:6375 E:6381 ||| RB
to  ||| S:6381 E:6394 ||| TO
permeabilization  ||| S:6394 E:6411 ||| VB
but  ||| S:6411 E:6415 ||| CC
not  ||| S:6415 E:6419 ||| RB
during ||| S:6419 E:6425 ||| IN
,  ||| S:6425 E:6427 ||| ,
exogenous  ||| S:6427 E:6437 ||| JJ
actin  ||| S:6437 E:6443 ||| NN
was  ||| S:6443 E:6457 ||| VBD
still  ||| S:6457 E:6463 ||| RB
able  ||| S:6463 E:6468 ||| JJ
to  ||| S:6468 E:6471 ||| TO
incorporate  ||| S:6471 E:6483 ||| VB
into  ||| S:6483 E:6488 ||| IN
permeabilized  ||| S:6488 E:6502 ||| JJ
cells  ||| S:6502 E:6508 ||| NNS
and  ||| S:6508 E:6522 ||| CC
fluorescence  ||| S:6522 E:6535 ||| JJ
incorporation  ||| S:6535 E:6549 ||| NN
was  ||| S:6549 E:6553 ||| VBD
high ||| S:6553 E:6557 ||| JJ
,  ||| S:6557 E:6559 ||| ,
similar  ||| S:6559 E:6567 ||| JJ
to  ||| S:6567 E:6570 ||| TO
control  ||| S:6570 E:6588 ||| VB
cells  ||| S:6588 E:6594 ||| NNS
[ ||| S:6594 E:6595 ||| -LRB-
Figure  ||| S:6595 E:6602 ||| NNP
1 ||| S:6602 E:6603 ||| CD
] ||| S:6603 E:6604 ||| -RRB-
.  ||| S:6604 E:6606 ||| .
As  ||| S:6606 E:6609 ||| IN
cytochalasin  ||| S:6609 E:6622 ||| JJ
D  ||| S:6622 E:6624 ||| NNP
has  ||| S:6624 E:6628 ||| VBZ
a  ||| S:6628 E:6630 ||| DT
high  ||| S:6630 E:6635 ||| JJ
affinity  ||| S:6635 E:6654 ||| NNS
( ||| S:6654 E:6655 ||| -LRB-
50  ||| S:6655 E:6658 ||| CD
nM ||| S:6658 E:6660 ||| NN
)  ||| S:6660 E:6662 ||| -RRB-
for  ||| S:6662 E:6666 ||| IN
the  ||| S:6666 E:6670 ||| DT
growing  ||| S:6670 E:6678 ||| VBG
ends  ||| S:6678 E:6683 ||| NNS
of  ||| S:6683 E:6686 ||| IN
actin  ||| S:6686 E:6692 ||| JJ
filaments ||| S:6692 E:6701 ||| NN
,  ||| S:6701 E:6703 ||| ,
this  ||| S:6703 E:6718 ||| DT
treatment  ||| S:6718 E:6728 ||| NN
should  ||| S:6728 E:6735 ||| MD
inhibit  ||| S:6735 E:6743 ||| VB
polymerization  ||| S:6743 E:6758 ||| VBN
of  ||| S:6758 E:6761 ||| IN
existing  ||| S:6761 E:6780 ||| VBG
filaments  ||| S:6780 E:6790 ||| NNS
but  ||| S:6790 E:6794 ||| CC
should  ||| S:6794 E:6801 ||| MD
not  ||| S:6801 E:6805 ||| RB
block  ||| S:6805 E:6811 ||| VB
new  ||| S:6811 E:6815 ||| JJ
filament  ||| S:6815 E:6824 ||| JJ
formation  ||| S:6824 E:6834 ||| NN
[  ||| S:6834 E:6846 ||| -LRB-
23  ||| S:6846 E:6849 ||| CD
]  ||| S:6849 E:6851 ||| -RRB-
.  ||| S:6851 E:6853 ||| .
Thus  ||| S:6853 E:6858 ||| RB
the  ||| S:6858 E:6862 ||| DT
actin  ||| S:6862 E:6868 ||| NN
incorporated  ||| S:6868 E:6881 ||| VBN
most  ||| S:6881 E:6886 ||| RBS
likely  ||| S:6886 E:6893 ||| RB
reflects  ||| S:6893 E:6912 ||| VBZ
nucleation  ||| S:6912 E:6923 ||| VBN
of  ||| S:6923 E:6926 ||| IN
new  ||| S:6926 E:6930 ||| JJ
filaments ||| S:6930 E:6939 ||| NN
,  ||| S:6939 E:6941 ||| ,
as  ||| S:6941 E:6944 ||| RB
previously  ||| S:6944 E:6955 ||| RB
discussed  ||| S:6955 E:6965 ||| VBN
[  ||| S:6965 E:6967 ||| -LRB-
24  ||| S:6967 E:6980 ||| CD
]  ||| S:6980 E:6982 ||| -RRB-
.  ||| S:6982 E:6984 ||| .
As  ||| S:6984 E:6987 ||| RB
expected ||| S:6987 E:6995 ||| VBN
,  ||| S:6995 E:6997 ||| ,
cells  ||| S:6997 E:7003 ||| NNS
treated  ||| S:7003 E:7011 ||| VBN
with  ||| S:7011 E:7016 ||| IN
cytochalasin  ||| S:7016 E:7029 ||| JJ
D  ||| S:7029 E:7031 ||| NNP
during  ||| S:7031 E:7048 ||| IN
permeabilization  ||| S:7048 E:7065 ||| NN
showed  ||| S:7065 E:7072 ||| VBD
no  ||| S:7072 E:7075 ||| DT
actin  ||| S:7075 E:7081 ||| JJ
incorporation  ||| S:7081 E:7095 ||| NNS
( ||| S:7095 E:7096 ||| -LRB-
data  ||| S:7096 E:7101 ||| NNS
not  ||| S:7101 E:7115 ||| RB
shown ||| S:7115 E:7120 ||| VBN
) ||| S:7120 E:7121 ||| -RRB-
.  ||| S:7121 E:7133 ||| .
To  ||| S:7133 E:7136 ||| TO
determine  ||| S:7136 E:7146 ||| VB
if  ||| S:7146 E:7149 ||| IN
BDM  ||| S:7149 E:7153 ||| NNP
was  ||| S:7153 E:7157 ||| VBD
affecting  ||| S:7157 E:7167 ||| VBG
actin  ||| S:7167 E:7173 ||| JJ
dynamics  ||| S:7173 E:7192 ||| NNS
directly ||| S:7192 E:7200 ||| RB
,  ||| S:7200 E:7202 ||| ,
we  ||| S:7202 E:7205 ||| PRP
assayed  ||| S:7205 E:7213 ||| VBD
its  ||| S:7213 E:7217 ||| PRP$
ability  ||| S:7217 E:7225 ||| NN
to  ||| S:7225 E:7228 ||| TO
inhibit  ||| S:7228 E:7247 ||| VB
in  ||| S:7247 E:7250 ||| IN
vitro  ||| S:7250 E:7256 ||| JJ
actin  ||| S:7256 E:7262 ||| JJ
assembly ||| S:7262 E:7270 ||| NN
.  ||| S:7270 E:7272 ||| .
No  ||| S:7272 E:7275 ||| DT
effect  ||| S:7275 E:7292 ||| NN
was  ||| S:7292 E:7296 ||| VBD
seen  ||| S:7296 E:7301 ||| VBN
on  ||| S:7301 E:7304 ||| IN
the  ||| S:7304 E:7308 ||| DT
polymerization  ||| S:7308 E:7323 ||| NN
of  ||| S:7323 E:7326 ||| IN
actin  ||| S:7326 E:7332 ||| VBG
alone  ||| S:7332 E:7338 ||| RB
or  ||| S:7338 E:7341 ||| CC
as  ||| S:7341 E:7354 ||| RB
stimulated  ||| S:7354 E:7365 ||| VBN
by  ||| S:7365 E:7368 ||| IN
VCA-activated  ||| S:7368 E:7382 ||| JJ
Arp2 ||| S:7382 E:7386 ||| CD
/ ||| S:7386 E:7387 ||| CD
3  ||| S:7387 E:7389 ||| CD
complex ||| S:7389 E:7396 ||| NN
,  ||| S:7396 E:7398 ||| ,
using  ||| S:7398 E:7404 ||| VBG
a  ||| S:7404 E:7416 ||| DT
pyrene-actin  ||| S:7416 E:7429 ||| JJ
polymerization  ||| S:7429 E:7444 ||| JJ
assay  ||| S:7444 E:7450 ||| NNS
( ||| S:7450 E:7451 ||| -LRB-
data  ||| S:7451 E:7456 ||| NNS
not  ||| S:7456 E:7460 ||| RB
shown ||| S:7460 E:7465 ||| VBN
) ||| S:7465 E:7466 ||| -RRB-
.  ||| S:7466 E:7468 ||| .
This  ||| S:7468 E:7483 ||| DT
result  ||| S:7483 E:7490 ||| NN
was  ||| S:7490 E:7494 ||| VBD
supported  ||| S:7494 E:7504 ||| VBN
by  ||| S:7504 E:7507 ||| IN
the  ||| S:7507 E:7511 ||| DT
observation  ||| S:7511 E:7523 ||| NN
that  ||| S:7523 E:7539 ||| IN
Listeria  ||| S:7539 E:7548 ||| NNP
monocytogenes  ||| S:7548 E:7562 ||| NNS
continue  ||| S:7562 E:7571 ||| VBP
to  ||| S:7571 E:7584 ||| TO
move  ||| S:7584 E:7589 ||| VB
intracellularly ||| S:7589 E:7604 ||| NNS
,  ||| S:7604 E:7606 ||| ,
as  ||| S:7606 E:7609 ||| RB
described  ||| S:7609 E:7619 ||| VBN
below ||| S:7619 E:7624 ||| RB
.  ||| S:7624 E:7654 ||| .
Arp3  ||| S:7654 E:7659 ||| NNP
is  ||| S:7659 E:7662 ||| VBZ
no  ||| S:7662 E:7665 ||| RB
longer  ||| S:7665 E:7672 ||| RB
localized  ||| S:7672 E:7682 ||| VBN
at  ||| S:7682 E:7685 ||| IN
the  ||| S:7685 E:7689 ||| DT
leading  ||| S:7689 E:7697 ||| JJ
edge  ||| S:7697 E:7712 ||| NN
with  ||| S:7712 E:7717 ||| IN
BDM  ||| S:7717 E:7721 ||| NNP
treatment  ||| S:7721 E:7741 ||| NN
Since  ||| S:7741 E:7747 ||| IN
actin  ||| S:7747 E:7753 ||| JJ
incorporation  ||| S:7753 E:7767 ||| NN
is  ||| S:7767 E:7770 ||| VBZ
not  ||| S:7770 E:7774 ||| RB
due  ||| S:7774 E:7778 ||| JJ
to  ||| S:7778 E:7781 ||| TO
elongation  ||| S:7781 E:7792 ||| VB
of  ||| S:7792 E:7805 ||| IN
existing  ||| S:7805 E:7814 ||| VBG
filaments  ||| S:7814 E:7824 ||| NNS
and  ||| S:7824 E:7828 ||| CC
BDM  ||| S:7828 E:7832 ||| NNP
does  ||| S:7832 E:7837 ||| VBZ
not  ||| S:7837 E:7841 ||| RB
affect  ||| S:7841 E:7848 ||| VB
pure  ||| S:7848 E:7853 ||| JJ
actin  ||| S:7853 E:7869 ||| JJ
dynamics  ||| S:7869 E:7878 ||| NNS
in  ||| S:7878 E:7881 ||| IN
vitro ||| S:7881 E:7886 ||| NN
,  ||| S:7886 E:7888 ||| ,
we  ||| S:7888 E:7891 ||| PRP
examined  ||| S:7891 E:7900 ||| VBD
the  ||| S:7900 E:7904 ||| DT
localization  ||| S:7904 E:7917 ||| NN
of  ||| S:7917 E:7920 ||| IN
Arp3 ||| S:7920 E:7924 ||| NNP
,  ||| S:7924 E:7936 ||| ,
a  ||| S:7936 E:7938 ||| DT
subunit  ||| S:7938 E:7946 ||| NN
of  ||| S:7946 E:7949 ||| IN
the  ||| S:7949 E:7953 ||| DT
actin  ||| S:7953 E:7959 ||| JJ
nucleation  ||| S:7959 E:7970 ||| NN
Arp2 ||| S:7970 E:7974 ||| CD
/ ||| S:7974 E:7975 ||| CD
3  ||| S:7975 E:7977 ||| CD
complex ||| S:7977 E:7984 ||| NN
.  ||| S:7984 E:7986 ||| .
In  ||| S:7986 E:7999 ||| IN
spreading  ||| S:7999 E:8009 ||| VBG
Swiss3T3  ||| S:8009 E:8018 ||| CD
cells  ||| S:8018 E:8024 ||| NNS
and  ||| S:8024 E:8028 ||| CC
spread  ||| S:8028 E:8035 ||| VBD
BS-C-1  ||| S:8035 E:8042 ||| CD
cells ||| S:8042 E:8047 ||| NNS
,  ||| S:8047 E:8049 ||| ,
Arp3  ||| S:8049 E:8064 ||| RB
localized  ||| S:8064 E:8074 ||| VBN
to  ||| S:8074 E:8077 ||| TO
the  ||| S:8077 E:8081 ||| DT
leading  ||| S:8081 E:8089 ||| JJ
edge  ||| S:8089 E:8094 ||| NN
of  ||| S:8094 E:8097 ||| IN
the  ||| S:8097 E:8101 ||| DT
cell ||| S:8101 E:8105 ||| NN
.  ||| S:8105 E:8107 ||| .
However ||| S:8107 E:8114 ||| RB
,  ||| S:8114 E:8116 ||| ,
after  ||| S:8116 E:8132 ||| IN
treatment  ||| S:8132 E:8142 ||| NN
with  ||| S:8142 E:8147 ||| IN
20  ||| S:8147 E:8150 ||| CD
mM  ||| S:8150 E:8153 ||| JJ
BDM  ||| S:8153 E:8157 ||| NN
for  ||| S:8157 E:8161 ||| IN
one  ||| S:8161 E:8165 ||| CD
minute ||| S:8165 E:8171 ||| NN
,  ||| S:8171 E:8173 ||| ,
localization  ||| S:8173 E:8186 ||| NN
was  ||| S:8186 E:8200 ||| VBD
lost  ||| S:8200 E:8205 ||| VBN
in  ||| S:8205 E:8208 ||| IN
over  ||| S:8208 E:8213 ||| IN
90 ||| S:8213 E:8215 ||| CD
%  ||| S:8215 E:8217 ||| NN
of  ||| S:8217 E:8220 ||| IN
the  ||| S:8220 E:8224 ||| DT
cells  ||| S:8224 E:8230 ||| NNS
[ ||| S:8230 E:8231 ||| -LRB-
Figure  ||| S:8231 E:8238 ||| NNP
2A ||| S:8238 E:8240 ||| NNP
] ||| S:8240 E:8241 ||| -RRB-
.  ||| S:8241 E:8243 ||| .
Results  ||| S:8243 E:8251 ||| NNS
for  ||| S:8251 E:8265 ||| IN
BS-C-1  ||| S:8265 E:8272 ||| NNP
and  ||| S:8272 E:8276 ||| CC
Swiss3T3  ||| S:8276 E:8285 ||| CD
cells  ||| S:8285 E:8291 ||| NNS
lines  ||| S:8291 E:8297 ||| NNS
were  ||| S:8297 E:8302 ||| VBD
equivalent  ||| S:8302 E:8313 ||| JJ
and  ||| S:8313 E:8317 ||| CC
the  ||| S:8317 E:8331 ||| DT
results  ||| S:8331 E:8339 ||| NNS
from  ||| S:8339 E:8344 ||| IN
BS-C-1  ||| S:8344 E:8351 ||| CD
cells  ||| S:8351 E:8357 ||| NNS
are  ||| S:8357 E:8361 ||| VBP
shown  ||| S:8361 E:8367 ||| VBN
here ||| S:8367 E:8371 ||| RB
,  ||| S:8371 E:8373 ||| ,
as  ||| S:8373 E:8376 ||| IN
they  ||| S:8376 E:8381 ||| PRP
are  ||| S:8381 E:8395 ||| VBP
used  ||| S:8395 E:8400 ||| VBN
in  ||| S:8400 E:8403 ||| IN
subsequent  ||| S:8403 E:8414 ||| JJ
time-lapse  ||| S:8414 E:8425 ||| JJ
experiments ||| S:8425 E:8436 ||| NNS
.  ||| S:8436 E:8438 ||| .
Consistent  ||| S:8438 E:8459 ||| JJ
with  ||| S:8459 E:8464 ||| IN
the  ||| S:8464 E:8468 ||| DT
inhibition  ||| S:8468 E:8479 ||| NN
of  ||| S:8479 E:8482 ||| IN
actin  ||| S:8482 E:8488 ||| JJ
polymerization  ||| S:8488 E:8503 ||| NN
in  ||| S:8503 E:8506 ||| IN
the  ||| S:8506 E:8520 ||| DT
permeabilized  ||| S:8520 E:8534 ||| JJ
cell  ||| S:8534 E:8539 ||| NN
assay ||| S:8539 E:8544 ||| NN
,  ||| S:8544 E:8546 ||| ,
cells  ||| S:8546 E:8552 ||| NNS
treated  ||| S:8552 E:8560 ||| VBN
with  ||| S:8560 E:8565 ||| IN
BDM  ||| S:8565 E:8569 ||| NNP
do  ||| S:8569 E:8572 ||| VBP
not  ||| S:8572 E:8586 ||| RB
show  ||| S:8586 E:8591 ||| VB
a  ||| S:8591 E:8593 ||| DT
brightly  ||| S:8593 E:8602 ||| JJ
staining  ||| S:8602 E:8611 ||| JJ
actin  ||| S:8611 E:8617 ||| JJ
network  ||| S:8617 E:8625 ||| NN
at  ||| S:8625 E:8628 ||| IN
the  ||| S:8628 E:8632 ||| DT
leading  ||| S:8632 E:8650 ||| JJ
edge  ||| S:8650 E:8655 ||| NN
[ ||| S:8655 E:8656 ||| -LRB-
Figure  ||| S:8656 E:8663 ||| NNP
2A ||| S:8663 E:8665 ||| NNP
, ||| S:8665 E:8666 ||| ,
2B ||| S:8666 E:8668 ||| CD
] ||| S:8668 E:8669 ||| -RRB-
.  ||| S:8669 E:8671 ||| .
Titration  ||| S:8671 E:8681 ||| NNP
of  ||| S:8681 E:8684 ||| IN
BDM  ||| S:8684 E:8688 ||| NNP
down  ||| S:8688 E:8693 ||| RB
to  ||| S:8693 E:8696 ||| TO
10  ||| S:8696 E:8699 ||| CD
mM  ||| S:8699 E:8712 ||| NN
showed  ||| S:8712 E:8719 ||| VBD
the  ||| S:8719 E:8723 ||| DT
same  ||| S:8723 E:8728 ||| JJ
loss  ||| S:8728 E:8733 ||| NN
of  ||| S:8733 E:8736 ||| IN
localization ||| S:8736 E:8748 ||| NNS
;  ||| S:8748 E:8750 ||| :
however ||| S:8750 E:8757 ||| RB
,  ||| S:8757 E:8759 ||| ,
2  ||| S:8759 E:8761 ||| CD
minutes  ||| S:8761 E:8779 ||| NNS
of  ||| S:8779 E:8782 ||| IN
treatment  ||| S:8782 E:8792 ||| NN
was  ||| S:8792 E:8796 ||| VBD
required  ||| S:8796 E:8805 ||| VBN
to  ||| S:8805 E:8808 ||| TO
see  ||| S:8808 E:8812 ||| VB
equivalent  ||| S:8812 E:8823 ||| JJ
loss  ||| S:8823 E:8828 ||| NN
( ||| S:8828 E:8829 ||| -LRB-
data  ||| S:8829 E:8844 ||| NNS
not  ||| S:8844 E:8848 ||| RB
shown ||| S:8848 E:8853 ||| VBN
) ||| S:8853 E:8854 ||| -RRB-
.  ||| S:8854 E:8856 ||| .
To  ||| S:8856 E:8859 ||| TO
control  ||| S:8859 E:8867 ||| VB
for  ||| S:8867 E:8871 ||| IN
possible  ||| S:8871 E:8880 ||| JJ
osmotic  ||| S:8880 E:8888 ||| JJ
effects  ||| S:8888 E:8896 ||| NNS
of  ||| S:8896 E:8909 ||| IN
BDM  ||| S:8909 E:8913 ||| NNP
treatment ||| S:8913 E:8922 ||| NN
,  ||| S:8922 E:8924 ||| ,
we  ||| S:8924 E:8927 ||| PRP
treated  ||| S:8927 E:8935 ||| VBD
cells  ||| S:8935 E:8941 ||| NNS
with  ||| S:8941 E:8946 ||| IN
20  ||| S:8946 E:8949 ||| CD
mM  ||| S:8949 E:8952 ||| JJ
urea ||| S:8952 E:8956 ||| NN
,  ||| S:8956 E:8958 ||| ,
and  ||| S:8958 E:8962 ||| CC
as  ||| S:8962 E:8975 ||| RB
with  ||| S:8975 E:8980 ||| IN
a  ||| S:8980 E:8982 ||| DT
media  ||| S:8982 E:8988 ||| NN
control ||| S:8988 E:8995 ||| NN
,  ||| S:8995 E:8997 ||| ,
more  ||| S:8997 E:9002 ||| JJR
than  ||| S:9002 E:9007 ||| IN
90 ||| S:9007 E:9009 ||| CD
%  ||| S:9009 E:9011 ||| NN
of  ||| S:9011 E:9014 ||| IN
the  ||| S:9014 E:9018 ||| DT
cells  ||| S:9018 E:9024 ||| NNS
showed  ||| S:9024 E:9041 ||| VBD
localization  ||| S:9041 E:9054 ||| VBN
of  ||| S:9054 E:9057 ||| IN
Arp3  ||| S:9057 E:9062 ||| CD
at  ||| S:9062 E:9065 ||| IN
the  ||| S:9065 E:9069 ||| DT
leading  ||| S:9069 E:9077 ||| JJ
edge ||| S:9077 E:9081 ||| NN
.  ||| S:9081 E:9093 ||| .
To  ||| S:9093 E:9096 ||| TO
determine  ||| S:9096 E:9106 ||| VB
if  ||| S:9106 E:9109 ||| IN
inhibition  ||| S:9109 E:9120 ||| NN
of  ||| S:9120 E:9123 ||| IN
actin  ||| S:9123 E:9129 ||| JJ
dynamics  ||| S:9129 E:9138 ||| NNS
alone  ||| S:9138 E:9144 ||| RB
was  ||| S:9144 E:9158 ||| VBD
sufficient  ||| S:9158 E:9169 ||| JJ
for  ||| S:9169 E:9173 ||| IN
the  ||| S:9173 E:9177 ||| DT
loss  ||| S:9177 E:9182 ||| NN
of  ||| S:9182 E:9185 ||| IN
Arp3  ||| S:9185 E:9190 ||| CD
localization ||| S:9190 E:9202 ||| NN
,  ||| S:9202 E:9204 ||| ,
we  ||| S:9204 E:9207 ||| PRP
treated  ||| S:9207 E:9225 ||| VBD
cells  ||| S:9225 E:9231 ||| NNS
with  ||| S:9231 E:9236 ||| IN
cytochalasin  ||| S:9236 E:9249 ||| JJ
D  ||| S:9249 E:9251 ||| NNP
and  ||| S:9251 E:9255 ||| CC
examined  ||| S:9255 E:9264 ||| VBD
the  ||| S:9264 E:9268 ||| DT
localization  ||| S:9268 E:9291 ||| NN
of  ||| S:9291 E:9294 ||| IN
Arp3 ||| S:9294 E:9298 ||| CD
.  ||| S:9298 E:9300 ||| .
Within  ||| S:9300 E:9307 ||| IN
one  ||| S:9307 E:9311 ||| CD
minute  ||| S:9311 E:9318 ||| NN
at  ||| S:9318 E:9321 ||| IN
1  ||| S:9321 E:9323 ||| CD
uM  ||| S:9323 E:9326 ||| JJ
cytochalasin  ||| S:9326 E:9339 ||| JJ
D ||| S:9339 E:9340 ||| NNP
,  ||| S:9340 E:9342 ||| ,
cell  ||| S:9342 E:9357 ||| NN
ruffling  ||| S:9357 E:9366 ||| NNS
ceased ||| S:9366 E:9372 ||| VBD
,  ||| S:9372 E:9374 ||| ,
yet  ||| S:9374 E:9378 ||| CC
Arp3  ||| S:9378 E:9383 ||| NNP
remained  ||| S:9383 E:9392 ||| VBD
at  ||| S:9392 E:9395 ||| IN
the  ||| S:9395 E:9399 ||| DT
leading  ||| S:9399 E:9407 ||| JJ
edge  ||| S:9407 E:9422 ||| NN
[ ||| S:9422 E:9423 ||| -LRB-
Figure  ||| S:9423 E:9430 ||| NNP
2A ||| S:9430 E:9432 ||| NNP
] ||| S:9432 E:9433 ||| -RRB-
.  ||| S:9433 E:9435 ||| .
In  ||| S:9435 E:9438 ||| IN
fact ||| S:9438 E:9442 ||| NN
,  ||| S:9442 E:9444 ||| ,
Arp3  ||| S:9444 E:9449 ||| CD
staining  ||| S:9449 E:9458 ||| NN
at  ||| S:9458 E:9461 ||| IN
the  ||| S:9461 E:9465 ||| DT
leading  ||| S:9465 E:9473 ||| JJ
edge  ||| S:9473 E:9488 ||| NN
was  ||| S:9488 E:9492 ||| VBD
consistently  ||| S:9492 E:9505 ||| RB
higher ||| S:9505 E:9511 ||| JJR
.  ||| S:9511 E:9513 ||| .
Combining  ||| S:9513 E:9523 ||| VBG
cytochalasin  ||| S:9523 E:9536 ||| JJ
D  ||| S:9536 E:9538 ||| NNP
and  ||| S:9538 E:9552 ||| CC
BDM ||| S:9552 E:9555 ||| NNP
,  ||| S:9555 E:9557 ||| ,
we  ||| S:9557 E:9560 ||| PRP
saw  ||| S:9560 E:9564 ||| VBD
localization  ||| S:9564 E:9577 ||| JJ
equivalent  ||| S:9577 E:9588 ||| NN
to  ||| S:9588 E:9591 ||| TO
or  ||| S:9591 E:9594 ||| CC
greater  ||| S:9594 E:9602 ||| JJR
than  ||| S:9602 E:9607 ||| IN
no  ||| S:9607 E:9620 ||| DT
drug  ||| S:9620 E:9625 ||| NN
treatment  ||| S:9625 E:9635 ||| NN
[ ||| S:9635 E:9636 ||| -LRB-
Figure  ||| S:9636 E:9643 ||| NNP
2A ||| S:9643 E:9645 ||| NNP
] ||| S:9645 E:9646 ||| -RRB-
.  ||| S:9646 E:9648 ||| .
Thus ||| S:9648 E:9652 ||| RB
,  ||| S:9652 E:9654 ||| ,
actin  ||| S:9654 E:9660 ||| JJ
dynamics  ||| S:9660 E:9669 ||| NNS
may  ||| S:9669 E:9673 ||| MD
be  ||| S:9673 E:9686 ||| VB
required  ||| S:9686 E:9695 ||| VBN
for  ||| S:9695 E:9699 ||| IN
the  ||| S:9699 E:9703 ||| DT
loss  ||| S:9703 E:9708 ||| NN
of  ||| S:9708 E:9711 ||| IN
Arp3  ||| S:9711 E:9716 ||| CD
at  ||| S:9716 E:9719 ||| IN
the  ||| S:9719 E:9723 ||| DT
leading  ||| S:9723 E:9731 ||| JJ
edge  ||| S:9731 E:9736 ||| NN
upon  ||| S:9736 E:9751 ||| IN
BDM  ||| S:9751 E:9755 ||| NNP
treatment ||| S:9755 E:9764 ||| NN
.  ||| S:9764 E:9776 ||| .
As  ||| S:9776 E:9779 ||| RB
mentioned ||| S:9779 E:9788 ||| VBN
,  ||| S:9788 E:9801 ||| ,
Listeria  ||| S:9801 E:9810 ||| NNP
infected  ||| S:9810 E:9819 ||| JJ
cells  ||| S:9819 E:9825 ||| NNS
were  ||| S:9825 E:9830 ||| VBD
used  ||| S:9830 E:9845 ||| VBN
to  ||| S:9845 E:9848 ||| TO
confirm  ||| S:9848 E:9856 ||| VB
that  ||| S:9856 E:9861 ||| IN
BDM  ||| S:9861 E:9865 ||| NNP
does  ||| S:9865 E:9870 ||| VBZ
not  ||| S:9870 E:9874 ||| RB
directly  ||| S:9874 E:9883 ||| RB
affect  ||| S:9883 E:9890 ||| VB
actin  ||| S:9890 E:9906 ||| JJ
dynamics ||| S:9906 E:9914 ||| NNS
.  ||| S:9914 E:9927 ||| .
Listeria  ||| S:9927 E:9936 ||| RB
exploit  ||| S:9936 E:9944 ||| VB
cellular  ||| S:9944 E:9953 ||| JJ
-  ||| S:9953 E:9955 ||| :
actin  ||| S:9955 E:9971 ||| JJ
polymerization  ||| S:9971 E:9986 ||| NN
and  ||| S:9986 E:9990 ||| CC
organization  ||| S:9990 E:10003 ||| NN
-  ||| S:10003 E:10005 ||| :
proteins  ||| S:10005 E:10014 ||| NNS
to  ||| S:10014 E:10017 ||| TO
move  ||| S:10017 E:10032 ||| VB
intracellularly ||| S:10032 E:10047 ||| NNS
.  ||| S:10047 E:10049 ||| .
We  ||| S:10049 E:10052 ||| PRP
found  ||| S:10052 E:10058 ||| VBD
that  ||| S:10058 E:10063 ||| IN
20  ||| S:10063 E:10066 ||| CD
mM  ||| S:10066 E:10069 ||| JJ
BDM  ||| S:10069 E:10073 ||| NNP
does  ||| S:10073 E:10078 ||| VBZ
not  ||| S:10078 E:10082 ||| RB
affect  ||| S:10082 E:10099 ||| VB
movement  ||| S:10099 E:10108 ||| NN
of  ||| S:10108 E:10111 ||| IN
bacteria  ||| S:10111 E:10120 ||| NNS
inside  ||| S:10120 E:10127 ||| IN
treated  ||| S:10127 E:10135 ||| JJ
cells  ||| S:10135 E:10141 ||| NNS
[ ||| S:10141 E:10142 ||| -LRB-
Figure  ||| S:10142 E:10149 ||| NNP
3A ||| S:10149 E:10151 ||| NNP
]  ||| S:10151 E:10163 ||| -RRB-
consistent  ||| S:10163 E:10174 ||| JJ
with  ||| S:10174 E:10179 ||| IN
a  ||| S:10179 E:10181 ||| DT
previous  ||| S:10181 E:10190 ||| JJ
report  ||| S:10190 E:10197 ||| NN
[  ||| S:10197 E:10199 ||| -LRB-
4  ||| S:10199 E:10201 ||| LS
]  ||| S:10201 E:10203 ||| -RRB-
.  ||| S:10203 E:10205 ||| .
Interestingly ||| S:10205 E:10218 ||| RB
,  ||| S:10218 E:10230 ||| ,
localization  ||| S:10230 E:10243 ||| VBG
of  ||| S:10243 E:10246 ||| IN
Arp3  ||| S:10246 E:10251 ||| CD
in  ||| S:10251 E:10265 ||| IN
Listeria  ||| S:10265 E:10274 ||| NNP
comet  ||| S:10274 E:10280 ||| JJ
tails  ||| S:10280 E:10286 ||| NN
is  ||| S:10286 E:10289 ||| VBZ
unaffected  ||| S:10289 E:10310 ||| VBN
with  ||| S:10310 E:10315 ||| IN
BDM  ||| S:10315 E:10319 ||| NNP
treatment  ||| S:10319 E:10329 ||| NN
[ ||| S:10329 E:10330 ||| -LRB-
Figure  ||| S:10330 E:10337 ||| NNP
3B ||| S:10337 E:10339 ||| NNP
]  ||| S:10339 E:10341 ||| -RRB-
though  ||| S:10341 E:10348 ||| IN
Arp3  ||| S:10348 E:10353 ||| CD
localization  ||| S:10353 E:10376 ||| NN
at  ||| S:10376 E:10379 ||| IN
the  ||| S:10379 E:10383 ||| DT
leading  ||| S:10383 E:10391 ||| JJ
edge  ||| S:10391 E:10396 ||| NN
of  ||| S:10396 E:10399 ||| IN
these  ||| S:10399 E:10405 ||| DT
cells  ||| S:10405 E:10411 ||| NNS
is  ||| S:10411 E:10414 ||| VBZ
disrupted ||| S:10414 E:10423 ||| VBN
.  ||| S:10423 E:10453 ||| .
VASP  ||| S:10453 E:10458 ||| NNP
and  ||| S:10458 E:10462 ||| CC
WAVE  ||| S:10462 E:10467 ||| NNP
are  ||| S:10467 E:10471 ||| VBP
no  ||| S:10471 E:10474 ||| RB
longer  ||| S:10474 E:10481 ||| RB
localized  ||| S:10481 E:10491 ||| VBN
to  ||| S:10491 E:10494 ||| TO
the  ||| S:10494 E:10508 ||| DT
leading  ||| S:10508 E:10516 ||| JJ
edge  ||| S:10516 E:10521 ||| NN
with  ||| S:10521 E:10526 ||| IN
BDM  ||| S:10526 E:10530 ||| NNP
treatment  ||| S:10530 E:10550 ||| NN
To  ||| S:10550 E:10553 ||| TO
ask  ||| S:10553 E:10557 ||| VB
whether  ||| S:10557 E:10565 ||| IN
the  ||| S:10565 E:10569 ||| DT
loss  ||| S:10569 E:10574 ||| NN
of  ||| S:10574 E:10577 ||| IN
leading  ||| S:10577 E:10585 ||| VBG
edge  ||| S:10585 E:10590 ||| NN
localization  ||| S:10590 E:10613 ||| NNS
was  ||| S:10613 E:10617 ||| VBD
specific  ||| S:10617 E:10626 ||| JJ
to  ||| S:10626 E:10629 ||| TO
the  ||| S:10629 E:10633 ||| DT
Arp  ||| S:10633 E:10637 ||| JJ
complex ||| S:10637 E:10644 ||| NN
,  ||| S:10644 E:10646 ||| ,
we  ||| S:10646 E:10649 ||| PRP
examined  ||| S:10649 E:10658 ||| VBD
the  ||| S:10658 E:10672 ||| DT
localization  ||| S:10672 E:10685 ||| NN
of  ||| S:10685 E:10688 ||| IN
VASP  ||| S:10688 E:10693 ||| NNP
and  ||| S:10693 E:10697 ||| CC
WAVE1  ||| S:10697 E:10703 ||| CD
with  ||| S:10703 E:10708 ||| IN
BDM  ||| S:10708 E:10712 ||| NNP
treatment ||| S:10712 E:10721 ||| NN
.  ||| S:10721 E:10723 ||| .
Both  ||| S:10723 E:10738 ||| DT
VASP  ||| S:10738 E:10743 ||| NNP
and  ||| S:10743 E:10747 ||| CC
WAVE  ||| S:10747 E:10752 ||| NNP
function  ||| S:10752 E:10761 ||| NN
in  ||| S:10761 E:10764 ||| IN
controlling  ||| S:10764 E:10776 ||| VBG
actin  ||| S:10776 E:10782 ||| JJ
dynamics  ||| S:10782 E:10791 ||| NNS
at  ||| S:10791 E:10804 ||| IN
the  ||| S:10804 E:10808 ||| DT
leading  ||| S:10808 E:10816 ||| JJ
edge  ||| S:10816 E:10821 ||| NN
-  ||| S:10821 E:10823 ||| :
VASP  ||| S:10823 E:10828 ||| NNP
is  ||| S:10828 E:10831 ||| VBZ
thought  ||| S:10831 E:10839 ||| VBN
to  ||| S:10839 E:10842 ||| TO
promote  ||| S:10842 E:10850 ||| VB
filament  ||| S:10850 E:10869 ||| JJ
elongation ||| S:10869 E:10879 ||| NN
,  ||| S:10879 E:10881 ||| ,
and  ||| S:10881 E:10885 ||| CC
WAVE ||| S:10885 E:10889 ||| NNP
,  ||| S:10889 E:10891 ||| ,
actin  ||| S:10891 E:10897 ||| FW
nucleation  ||| S:10897 E:10908 ||| FW
[  ||| S:10908 E:10910 ||| -LRB-
25  ||| S:10910 E:10913 ||| CD
26  ||| S:10913 E:10916 ||| CD
]  ||| S:10916 E:10918 ||| -RRB-
.  ||| S:10918 E:10920 ||| .
Both  ||| S:10920 E:10935 ||| DT
VASP  ||| S:10935 E:10940 ||| NNP
and  ||| S:10940 E:10944 ||| CC
WAVE1  ||| S:10944 E:10950 ||| NNP
were  ||| S:10950 E:10955 ||| VBD
de-localized  ||| S:10955 E:10968 ||| JJ
from  ||| S:10968 E:10973 ||| IN
the  ||| S:10973 E:10977 ||| DT
leading  ||| S:10977 E:10985 ||| JJ
edge  ||| S:10985 E:11000 ||| NN
after  ||| S:11000 E:11006 ||| IN
1  ||| S:11006 E:11008 ||| CD
min  ||| S:11008 E:11012 ||| NN
of  ||| S:11012 E:11015 ||| IN
BDM  ||| S:11015 E:11019 ||| NNP
treatment  ||| S:11019 E:11029 ||| NN
[ ||| S:11029 E:11030 ||| -LRB-
Figure  ||| S:11030 E:11037 ||| NNP
4 ||| S:11037 E:11038 ||| CD
] ||| S:11038 E:11039 ||| -RRB-
.  ||| S:11039 E:11041 ||| .
Similar  ||| S:11041 E:11049 ||| JJ
to  ||| S:11049 E:11052 ||| TO
Arp3 ||| S:11052 E:11056 ||| CD
,  ||| S:11056 E:11068 ||| ,
the  ||| S:11068 E:11072 ||| DT
localization  ||| S:11072 E:11085 ||| NN
of  ||| S:11085 E:11088 ||| IN
these  ||| S:11088 E:11094 ||| DT
proteins  ||| S:11094 E:11103 ||| NNS
was  ||| S:11103 E:11107 ||| VBD
not  ||| S:11107 E:11111 ||| RB
disrupted  ||| S:11111 E:11121 ||| VBN
by  ||| S:11121 E:11134 ||| IN
cytochalasin  ||| S:11134 E:11147 ||| JJ
D  ||| S:11147 E:11149 ||| NNP
treatment ||| S:11149 E:11158 ||| NN
,  ||| S:11158 E:11160 ||| ,
or  ||| S:11160 E:11163 ||| CC
by  ||| S:11163 E:11166 ||| IN
the  ||| S:11166 E:11170 ||| DT
combination  ||| S:11170 E:11182 ||| NN
of  ||| S:11182 E:11195 ||| IN
cytochalasin  ||| S:11195 E:11208 ||| JJ
D  ||| S:11208 E:11210 ||| NNP
and  ||| S:11210 E:11214 ||| CC
BDM  ||| S:11214 E:11218 ||| NNP
[ ||| S:11218 E:11219 ||| -LRB-
Figure  ||| S:11219 E:11226 ||| NNP
4 ||| S:11226 E:11227 ||| CD
] ||| S:11227 E:11228 ||| -RRB-
.  ||| S:11228 E:11258 ||| .
Dynamics  ||| S:11258 E:11267 ||| NNP
of  ||| S:11267 E:11270 ||| IN
the  ||| S:11270 E:11274 ||| DT
loss  ||| S:11274 E:11279 ||| NN
of  ||| S:11279 E:11282 ||| IN
Arp-3  ||| S:11282 E:11288 ||| CD
localization  ||| S:11288 E:11311 ||| CD
Two  ||| S:11311 E:11315 ||| CD
possible  ||| S:11315 E:11324 ||| JJ
mechanisms  ||| S:11324 E:11335 ||| NNS
for  ||| S:11335 E:11339 ||| IN
Arp2 ||| S:11339 E:11343 ||| CD
/ ||| S:11343 E:11344 ||| CD
3  ||| S:11344 E:11346 ||| CD
complex  ||| S:11346 E:11364 ||| JJ
de-localization  ||| S:11364 E:11380 ||| NN
were  ||| S:11380 E:11385 ||| VBD
considered ||| S:11385 E:11395 ||| VBN
:  ||| S:11395 E:11397 ||| :
Arp2 ||| S:11397 E:11401 ||| CD
/ ||| S:11401 E:11402 ||| CD
3  ||| S:11402 E:11404 ||| CD
could  ||| S:11404 E:11410 ||| MD
move  ||| S:11410 E:11415 ||| VB
back  ||| S:11415 E:11430 ||| RP
from  ||| S:11430 E:11435 ||| IN
the  ||| S:11435 E:11439 ||| DT
leading  ||| S:11439 E:11447 ||| JJ
edge  ||| S:11447 E:11452 ||| NN
with  ||| S:11452 E:11457 ||| IN
retrograde  ||| S:11457 E:11468 ||| JJ
flow  ||| S:11468 E:11473 ||| NN
of  ||| S:11473 E:11476 ||| IN
actin  ||| S:11476 E:11482 ||| NN
and  ||| S:11482 E:11496 ||| CC
then  ||| S:11496 E:11501 ||| RB
be  ||| S:11501 E:11504 ||| VB
lost  ||| S:11504 E:11509 ||| VBN
from  ||| S:11509 E:11514 ||| IN
the  ||| S:11514 E:11518 ||| DT
filaments ||| S:11518 E:11527 ||| NN
,  ||| S:11527 E:11529 ||| ,
or  ||| S:11529 E:11532 ||| CC
it  ||| S:11532 E:11535 ||| PRP
could  ||| S:11535 E:11541 ||| MD
simply  ||| S:11541 E:11558 ||| RB
diffuse  ||| S:11558 E:11566 ||| VBN
from  ||| S:11566 E:11571 ||| IN
the  ||| S:11571 E:11575 ||| DT
leading  ||| S:11575 E:11583 ||| JJ
edge ||| S:11583 E:11587 ||| NN
.  ||| S:11587 E:11589 ||| .
To  ||| S:11589 E:11592 ||| TO
determine  ||| S:11592 E:11602 ||| VB
the  ||| S:11602 E:11606 ||| DT
dynamics  ||| S:11606 E:11625 ||| NNS
of  ||| S:11625 E:11628 ||| IN
loss  ||| S:11628 E:11633 ||| NN
of  ||| S:11633 E:11636 ||| IN
Arp2 ||| S:11636 E:11640 ||| CD
/ ||| S:11640 E:11641 ||| CD
3  ||| S:11641 E:11643 ||| CD
complex  ||| S:11643 E:11651 ||| JJ
localization ||| S:11651 E:11663 ||| NN
,  ||| S:11663 E:11665 ||| ,
we  ||| S:11665 E:11668 ||| PRP
generated  ||| S:11668 E:11678 ||| VBD
a  ||| S:11678 E:11690 ||| DT
stable  ||| S:11690 E:11697 ||| JJ
cell  ||| S:11697 E:11702 ||| NN
line  ||| S:11702 E:11707 ||| NN
expressing  ||| S:11707 E:11718 ||| VBG
Arp3-GFP ||| S:11718 E:11726 ||| CD
.  ||| S:11726 E:11728 ||| .
After  ||| S:11728 E:11734 ||| IN
BDM  ||| S:11734 E:11748 ||| NNP
treatment ||| S:11748 E:11757 ||| NN
,  ||| S:11757 E:11759 ||| ,
we  ||| S:11759 E:11762 ||| PRP
observed  ||| S:11762 E:11771 ||| VBD
a  ||| S:11771 E:11773 ||| DT
uniform  ||| S:11773 E:11781 ||| JJ
decrease  ||| S:11781 E:11790 ||| NN
in  ||| S:11790 E:11793 ||| IN
fluorescence  ||| S:11793 E:11816 ||| JJ
suggestive  ||| S:11816 E:11827 ||| NN
of  ||| S:11827 E:11830 ||| IN
dissociation  ||| S:11830 E:11843 ||| NN
and  ||| S:11843 E:11847 ||| CC
diffusion  ||| S:11847 E:11857 ||| NN
of  ||| S:11857 E:11860 ||| IN
Arp3 ||| S:11860 E:11864 ||| NNP
,  ||| S:11864 E:11866 ||| ,
rather  ||| S:11866 E:11883 ||| RB
than  ||| S:11883 E:11888 ||| IN
de-localization  ||| S:11888 E:11904 ||| JJ
driven  ||| S:11904 E:11911 ||| VBN
by  ||| S:11911 E:11914 ||| IN
retrograde  ||| S:11914 E:11925 ||| JJ
flow  ||| S:11925 E:11930 ||| NN
[ ||| S:11930 E:11931 ||| -LRB-
Figure  ||| S:11931 E:11948 ||| NNP
5A ||| S:11948 E:11950 ||| NNP
] ||| S:11950 E:11951 ||| -RRB-
.  ||| S:11951 E:11953 ||| .
A  ||| S:11953 E:11955 ||| DT
linescan  ||| S:11955 E:11964 ||| NN
of  ||| S:11964 E:11967 ||| IN
the  ||| S:11967 E:11971 ||| DT
leading  ||| S:11971 E:11979 ||| JJ
edge  ||| S:11979 E:11984 ||| NN
shown  ||| S:11984 E:11990 ||| VBN
in  ||| S:11990 E:11993 ||| IN
Figure  ||| S:11993 E:12000 ||| NNP
5A ||| S:12000 E:12002 ||| NNP
,  ||| S:12002 E:12014 ||| ,
plotted  ||| S:12014 E:12022 ||| VBD
across  ||| S:12022 E:12029 ||| IN
time  ||| S:12029 E:12034 ||| NN
shows  ||| S:12034 E:12040 ||| VBZ
the  ||| S:12040 E:12044 ||| DT
pattern  ||| S:12044 E:12052 ||| NN
and  ||| S:12052 E:12056 ||| CC
extent  ||| S:12056 E:12063 ||| NN
of  ||| S:12063 E:12066 ||| IN
loss  ||| S:12066 E:12081 ||| NN
of  ||| S:12081 E:12084 ||| IN
fluorescence  ||| S:12084 E:12097 ||| JJ
signal  ||| S:12097 E:12104 ||| NN
[ ||| S:12104 E:12105 ||| -LRB-
Figure  ||| S:12105 E:12112 ||| NNP
5B ||| S:12112 E:12114 ||| NNP
] ||| S:12114 E:12115 ||| -RRB-
.  ||| S:12115 E:12117 ||| .
Fluorescence  ||| S:12117 E:12130 ||| JJ
levels  ||| S:12130 E:12147 ||| NNS
decrease  ||| S:12147 E:12156 ||| VBP
gradually  ||| S:12156 E:12166 ||| RB
with  ||| S:12166 E:12171 ||| IN
little  ||| S:12171 E:12178 ||| JJ
or  ||| S:12178 E:12181 ||| CC
no  ||| S:12181 E:12184 ||| DT
shift  ||| S:12184 E:12190 ||| NN
in  ||| S:12190 E:12193 ||| IN
the  ||| S:12193 E:12197 ||| DT
peak  ||| S:12197 E:12202 ||| NN
of  ||| S:12202 E:12215 ||| IN
fluorescence  ||| S:12215 E:12228 ||| JJ
backward ||| S:12228 E:12236 ||| NN
.  ||| S:12236 E:12238 ||| .
By  ||| S:12238 E:12241 ||| IN
two  ||| S:12241 E:12245 ||| CD
minutes ||| S:12245 E:12252 ||| NNS
,  ||| S:12252 E:12254 ||| ,
fluorescence  ||| S:12254 E:12277 ||| JJ
levels  ||| S:12277 E:12284 ||| NNS
at  ||| S:12284 E:12287 ||| IN
the  ||| S:12287 E:12291 ||| DT
leading  ||| S:12291 E:12299 ||| JJ
edge  ||| S:12299 E:12304 ||| NN
are  ||| S:12304 E:12308 ||| VBP
equivalent  ||| S:12308 E:12319 ||| JJ
to  ||| S:12319 E:12322 ||| TO
background ||| S:12322 E:12332 ||| NN
.  ||| S:12332 E:12344 ||| .
After  ||| S:12344 E:12350 ||| IN
washout  ||| S:12350 E:12358 ||| NN
of  ||| S:12358 E:12361 ||| IN
BDM ||| S:12361 E:12364 ||| NNP
,  ||| S:12364 E:12366 ||| ,
Arp3-GFP  ||| S:12366 E:12375 ||| CD
localization  ||| S:12375 E:12388 ||| CD
returns  ||| S:12388 E:12396 ||| NNS
in  ||| S:12396 E:12409 ||| IN
just  ||| S:12409 E:12414 ||| RB
over  ||| S:12414 E:12419 ||| IN
one  ||| S:12419 E:12423 ||| CD
minute ||| S:12423 E:12429 ||| NN
.  ||| S:12429 E:12431 ||| .
In  ||| S:12431 E:12434 ||| IN
all  ||| S:12434 E:12438 ||| DT
cases ||| S:12438 E:12443 ||| NNS
,  ||| S:12443 E:12445 ||| ,
the  ||| S:12445 E:12449 ||| DT
loss  ||| S:12449 E:12454 ||| NN
of  ||| S:12454 E:12457 ||| IN
Arp3-GFP  ||| S:12457 E:12476 ||| CD
at  ||| S:12476 E:12479 ||| IN
the  ||| S:12479 E:12483 ||| DT
leading  ||| S:12483 E:12491 ||| JJ
edge  ||| S:12491 E:12496 ||| NN
was  ||| S:12496 E:12500 ||| VBD
seen  ||| S:12500 E:12505 ||| VBN
concomitantly  ||| S:12505 E:12519 ||| RB
with  ||| S:12519 E:12524 ||| IN
loss  ||| S:12524 E:12529 ||| NN
of  ||| S:12529 E:12542 ||| IN
ruffling  ||| S:12542 E:12551 ||| NN
and  ||| S:12551 E:12555 ||| CC
retraction  ||| S:12555 E:12566 ||| NN
of  ||| S:12566 E:12569 ||| IN
the  ||| S:12569 E:12573 ||| DT
leading  ||| S:12573 E:12581 ||| JJ
edge  ||| S:12581 E:12586 ||| NN
or  ||| S:12586 E:12589 ||| CC
as  ||| S:12589 E:12602 ||| IN
de-localization  ||| S:12602 E:12618 ||| JJ
with  ||| S:12618 E:12623 ||| IN
slight  ||| S:12623 E:12630 ||| JJ
retraction ||| S:12630 E:12640 ||| NN
.  ||| S:12640 E:12642 ||| .
We  ||| S:12642 E:12645 ||| PRP
did  ||| S:12645 E:12649 ||| VBD
not  ||| S:12649 E:12653 ||| RB
see  ||| S:12653 E:12667 ||| VB
retrograde  ||| S:12667 E:12678 ||| JJ
flow  ||| S:12678 E:12683 ||| NN
of  ||| S:12683 E:12686 ||| IN
the  ||| S:12686 E:12690 ||| DT
Arp3  ||| S:12690 E:12695 ||| JJ
signal  ||| S:12695 E:12702 ||| NN
in  ||| S:12702 E:12705 ||| IN
an  ||| S:12705 E:12708 ||| DT
otherwise  ||| S:12708 E:12718 ||| RB
stable  ||| S:12718 E:12735 ||| JJ
leading  ||| S:12735 E:12743 ||| JJ
edge ||| S:12743 E:12747 ||| NN
.  ||| S:12747 E:12780 ||| .
Discussion  ||| S:12780 E:12799 ||| NNP
BDM  ||| S:12799 E:12803 ||| NNP
has  ||| S:12803 E:12807 ||| VBZ
been  ||| S:12807 E:12812 ||| VBN
used  ||| S:12812 E:12817 ||| VBN
to  ||| S:12817 E:12820 ||| TO
probe  ||| S:12820 E:12826 ||| VB
actin-dependent  ||| S:12826 E:12842 ||| JJ
processes  ||| S:12842 E:12852 ||| NNS
on  ||| S:12852 E:12863 ||| IN
the  ||| S:12863 E:12867 ||| DT
assumption  ||| S:12867 E:12878 ||| NN
that  ||| S:12878 E:12883 ||| IN
it  ||| S:12883 E:12886 ||| PRP
is  ||| S:12886 E:12889 ||| VBZ
a  ||| S:12889 E:12891 ||| DT
specific  ||| S:12891 E:12900 ||| JJ
inhibitor  ||| S:12900 E:12910 ||| NN
of  ||| S:12910 E:12913 ||| IN
mysosins ||| S:12913 E:12921 ||| NN
.  ||| S:12921 E:12931 ||| .
BDM  ||| S:12931 E:12935 ||| NNP
has  ||| S:12935 E:12939 ||| VBZ
recently  ||| S:12939 E:12948 ||| RB
been  ||| S:12948 E:12953 ||| VBN
found  ||| S:12953 E:12959 ||| VBN
not  ||| S:12959 E:12963 ||| RB
to  ||| S:12963 E:12966 ||| TO
inhibit  ||| S:12966 E:12974 ||| VB
the  ||| S:12974 E:12987 ||| DT
in  ||| S:12987 E:12990 ||| IN
vitro  ||| S:12990 E:12996 ||| JJ
ATPase  ||| S:12996 E:13003 ||| JJ
activity  ||| S:13003 E:13012 ||| NN
of  ||| S:13012 E:13015 ||| IN
human  ||| S:13015 E:13029 ||| JJ
platelet  ||| S:13029 E:13038 ||| JJ
nm-myosinII ||| S:13038 E:13049 ||| NN
,  ||| S:13049 E:13051 ||| ,
Acanthamoeba  ||| S:13051 E:13064 ||| NNP
myosinIc ||| S:13064 E:13072 ||| NNP
,  ||| S:13072 E:13074 ||| ,
human  ||| S:13074 E:13080 ||| JJ
myoIe ||| S:13080 E:13085 ||| NN
,  ||| S:13085 E:13095 ||| ,
chicken  ||| S:13095 E:13103 ||| NN
myosinV ||| S:13103 E:13110 ||| NN
,  ||| S:13110 E:13112 ||| ,
and  ||| S:13112 E:13116 ||| CC
porcine  ||| S:13116 E:13124 ||| JJ
myosinVI ||| S:13124 E:13132 ||| NN
,  ||| S:13132 E:13134 ||| ,
though  ||| S:13134 E:13141 ||| IN
it  ||| S:13141 E:13144 ||| PRP
does  ||| S:13144 E:13157 ||| VBZ
inhibit  ||| S:13157 E:13165 ||| FW
rabbit  ||| S:13165 E:13172 ||| FW
muscle  ||| S:13172 E:13179 ||| FW
myosinII  ||| S:13179 E:13188 ||| FW
[  ||| S:13188 E:13190 ||| -LRB-
9  ||| S:13190 E:13192 ||| CD
10  ||| S:13192 E:13195 ||| CD
]  ||| S:13195 E:13197 ||| -RRB-
.  ||| S:13197 E:13199 ||| .
Thus  ||| S:13199 E:13204 ||| RB
the  ||| S:13204 E:13216 ||| DT
literature ||| S:13216 E:13226 ||| NN
's  ||| S:13226 E:13229 ||| POS
interpretations  ||| S:13229 E:13245 ||| NNS
of  ||| S:13245 E:13248 ||| IN
BDM ||| S:13248 E:13251 ||| NNP
's  ||| S:13251 E:13254 ||| POS
effects  ||| S:13254 E:13262 ||| NNS
are  ||| S:13262 E:13266 ||| VBP
probably  ||| S:13266 E:13283 ||| RB
incorrect ||| S:13283 E:13292 ||| JJ
.  ||| S:13292 E:13294 ||| .
Our  ||| S:13294 E:13298 ||| PRP$
results  ||| S:13298 E:13306 ||| NNS
suggest  ||| S:13306 E:13314 ||| VBP
that  ||| S:13314 E:13319 ||| IN
the  ||| S:13319 E:13323 ||| DT
effects  ||| S:13323 E:13331 ||| NNS
of  ||| S:13331 E:13334 ||| IN
BDM  ||| S:13334 E:13338 ||| NNP
on  ||| S:13338 E:13349 ||| IN
actin-dependent  ||| S:13349 E:13365 ||| JJ
processes  ||| S:13365 E:13375 ||| NNS
such  ||| S:13375 E:13380 ||| JJ
as  ||| S:13380 E:13383 ||| IN
cell  ||| S:13383 E:13388 ||| NN
motility  ||| S:13388 E:13397 ||| NNS
and  ||| S:13397 E:13409 ||| CC
retrograde  ||| S:13409 E:13420 ||| JJ
flow  ||| S:13420 E:13425 ||| NN
may  ||| S:13425 E:13429 ||| MD
result  ||| S:13429 E:13436 ||| VB
from  ||| S:13436 E:13441 ||| IN
effects  ||| S:13441 E:13449 ||| NNS
on  ||| S:13449 E:13452 ||| IN
proteins  ||| S:13452 E:13469 ||| NNS
involved  ||| S:13469 E:13478 ||| VBN
in  ||| S:13478 E:13481 ||| IN
actin  ||| S:13481 E:13487 ||| JJ
polymerization  ||| S:13487 E:13502 ||| NN
and  ||| S:13502 E:13506 ||| CC
the  ||| S:13506 E:13510 ||| DT
leading  ||| S:13510 E:13518 ||| JJ
edge  ||| S:13518 E:13523 ||| NN
actin  ||| S:13523 E:13537 ||| VBD
itself ||| S:13537 E:13543 ||| PRP
.  ||| S:13543 E:13545 ||| .
It  ||| S:13545 E:13548 ||| PRP
is  ||| S:13548 E:13551 ||| VBZ
not  ||| S:13551 E:13555 ||| RB
clear  ||| S:13555 E:13561 ||| JJ
if  ||| S:13561 E:13564 ||| IN
these  ||| S:13564 E:13570 ||| DT
effects  ||| S:13570 E:13578 ||| NNS
on  ||| S:13578 E:13581 ||| IN
leading  ||| S:13581 E:13589 ||| VBG
edge  ||| S:13589 E:13602 ||| NN
components  ||| S:13602 E:13613 ||| NNS
are  ||| S:13613 E:13617 ||| VBP
direct  ||| S:13617 E:13624 ||| JJ
or  ||| S:13624 E:13627 ||| CC
indirect ||| S:13627 E:13635 ||| JJ
.  ||| S:13635 E:13637 ||| .
The  ||| S:13637 E:13641 ||| DT
loss  ||| S:13641 E:13646 ||| NN
of  ||| S:13646 E:13649 ||| IN
actin  ||| S:13649 E:13663 ||| JJ
polymerization  ||| S:13663 E:13678 ||| JJ
machinery ||| S:13678 E:13687 ||| NN
,  ||| S:13687 E:13689 ||| ,
however ||| S:13689 E:13696 ||| RB
,  ||| S:13696 E:13698 ||| ,
is  ||| S:13698 E:13701 ||| VBZ
a  ||| S:13701 E:13703 ||| DT
previously  ||| S:13703 E:13722 ||| RB
un-described  ||| S:13722 E:13735 ||| JJ
effect  ||| S:13735 E:13742 ||| NN
of  ||| S:13742 E:13745 ||| IN
BDM  ||| S:13745 E:13749 ||| NNP
treatment  ||| S:13749 E:13759 ||| NN
and  ||| S:13759 E:13763 ||| CC
this  ||| S:13763 E:13768 ||| DT
highlights  ||| S:13768 E:13787 ||| VBZ
the  ||| S:13787 E:13791 ||| DT
importance  ||| S:13791 E:13802 ||| NN
of  ||| S:13802 E:13805 ||| IN
defining  ||| S:13805 E:13814 ||| VBG
the  ||| S:13814 E:13818 ||| DT
localization  ||| S:13818 E:13831 ||| NN
of  ||| S:13831 E:13834 ||| IN
proteins  ||| S:13834 E:13851 ||| NNS
involved  ||| S:13851 E:13860 ||| VBN
in  ||| S:13860 E:13863 ||| IN
actin  ||| S:13863 E:13869 ||| JJ
dynamics  ||| S:13869 E:13878 ||| NNS
when  ||| S:13878 E:13883 ||| WRB
leading  ||| S:13883 E:13891 ||| JJ
edge  ||| S:13891 E:13896 ||| NN
activity  ||| S:13896 E:13905 ||| NN
is  ||| S:13905 E:13916 ||| VBZ
disrupted ||| S:13916 E:13925 ||| VBN
.  ||| S:13925 E:13935 ||| .
BDM  ||| S:13935 E:13939 ||| NNP
application  ||| S:13939 E:13951 ||| NN
leads  ||| S:13951 E:13957 ||| VBZ
to  ||| S:13957 E:13960 ||| TO
the  ||| S:13960 E:13964 ||| DT
loss  ||| S:13964 E:13969 ||| NN
of  ||| S:13969 E:13972 ||| IN
localization  ||| S:13972 E:13985 ||| NN
of  ||| S:13985 E:13996 ||| IN
leading  ||| S:13996 E:14004 ||| VBG
edge  ||| S:14004 E:14009 ||| NN
components  ||| S:14009 E:14020 ||| NNS
involved  ||| S:14020 E:14029 ||| VBN
in  ||| S:14029 E:14032 ||| IN
actin  ||| S:14032 E:14038 ||| JJ
nucleation ||| S:14038 E:14048 ||| NN
.  ||| S:14048 E:14050 ||| .
We  ||| S:14050 E:14061 ||| PRP
observe  ||| S:14061 E:14069 ||| VBP
that  ||| S:14069 E:14074 ||| IN
within  ||| S:14074 E:14081 ||| IN
two  ||| S:14081 E:14085 ||| CD
minutes ||| S:14085 E:14092 ||| NNS
,  ||| S:14092 E:14094 ||| ,
application  ||| S:14094 E:14106 ||| NN
of  ||| S:14106 E:14109 ||| IN
BDM  ||| S:14109 E:14113 ||| NNP
leads  ||| S:14113 E:14127 ||| VBZ
to  ||| S:14127 E:14130 ||| TO
the  ||| S:14130 E:14134 ||| DT
de-localization  ||| S:14134 E:14150 ||| JJ
of  ||| S:14150 E:14153 ||| IN
the  ||| S:14153 E:14157 ||| DT
leading  ||| S:14157 E:14165 ||| JJ
edge  ||| S:14165 E:14170 ||| NN
components  ||| S:14170 E:14181 ||| NNS
-  ||| S:14181 E:14191 ||| :
Arp3 ||| S:14191 E:14195 ||| CD
,  ||| S:14195 E:14197 ||| ,
VASP ||| S:14197 E:14201 ||| NNP
,  ||| S:14201 E:14203 ||| ,
and  ||| S:14203 E:14207 ||| CC
WAVE  ||| S:14207 E:14212 ||| NNP
-  ||| S:14212 E:14214 ||| :
and  ||| S:14214 E:14218 ||| CC
this  ||| S:14218 E:14223 ||| DT
is  ||| S:14223 E:14226 ||| VBZ
concurrent  ||| S:14226 E:14237 ||| VBN
with  ||| S:14237 E:14242 ||| IN
the  ||| S:14242 E:14246 ||| DT
loss  ||| S:14246 E:14259 ||| NN
of  ||| S:14259 E:14262 ||| IN
the  ||| S:14262 E:14266 ||| DT
actin  ||| S:14266 E:14272 ||| JJ
network  ||| S:14272 E:14280 ||| NN
at  ||| S:14280 E:14283 ||| IN
the  ||| S:14283 E:14287 ||| DT
leading  ||| S:14287 E:14295 ||| JJ
edge ||| S:14295 E:14299 ||| NN
.  ||| S:14299 E:14301 ||| .
Our  ||| S:14301 E:14305 ||| PRP$
data  ||| S:14305 E:14310 ||| NNS
suggest  ||| S:14310 E:14326 ||| VBP
a  ||| S:14326 E:14328 ||| DT
mechanism  ||| S:14328 E:14338 ||| NN
of  ||| S:14338 E:14341 ||| IN
de-localization  ||| S:14341 E:14357 ||| JJ
of  ||| S:14357 E:14360 ||| IN
Arp3  ||| S:14360 E:14365 ||| CD
consistent  ||| S:14365 E:14376 ||| JJ
with  ||| S:14376 E:14389 ||| IN
dissociation  ||| S:14389 E:14402 ||| NN
or  ||| S:14402 E:14405 ||| CC
diffusion  ||| S:14405 E:14415 ||| VBP
rather  ||| S:14415 E:14422 ||| RB
than  ||| S:14422 E:14427 ||| IN
retrograde  ||| S:14427 E:14438 ||| JJ
flow ||| S:14438 E:14442 ||| NN
.  ||| S:14442 E:14444 ||| .
We  ||| S:14444 E:14455 ||| PRP
cannot  ||| S:14455 E:14462 ||| RB
determine  ||| S:14462 E:14472 ||| VB
the  ||| S:14472 E:14476 ||| DT
causal  ||| S:14476 E:14483 ||| JJ
relationship  ||| S:14483 E:14496 ||| NN
between  ||| S:14496 E:14504 ||| IN
loss  ||| S:14504 E:14509 ||| NN
of  ||| S:14509 E:14520 ||| IN
leading  ||| S:14520 E:14528 ||| VBG
edge  ||| S:14528 E:14533 ||| NN
components  ||| S:14533 E:14544 ||| NNS
and  ||| S:14544 E:14548 ||| CC
loss  ||| S:14548 E:14553 ||| NN
of  ||| S:14553 E:14556 ||| IN
the  ||| S:14556 E:14560 ||| DT
leading  ||| S:14560 E:14568 ||| JJ
edge  ||| S:14568 E:14573 ||| NN
actin  ||| S:14573 E:14587 ||| NN
network  ||| S:14587 E:14595 ||| NN
itself ||| S:14595 E:14601 ||| PRP
.  ||| S:14601 E:14603 ||| .
At  ||| S:14603 E:14606 ||| IN
the  ||| S:14606 E:14610 ||| DT
least ||| S:14610 E:14615 ||| JJS
,  ||| S:14615 E:14617 ||| ,
the  ||| S:14617 E:14621 ||| DT
two  ||| S:14621 E:14625 ||| CD
occur  ||| S:14625 E:14639 ||| VBP
simultaneously ||| S:14639 E:14653 ||| RB
.  ||| S:14653 E:14663 ||| .
Interestingly ||| S:14663 E:14676 ||| RB
,  ||| S:14676 E:14687 ||| ,
Listeria  ||| S:14687 E:14696 ||| NNP
bacteria  ||| S:14696 E:14705 ||| NNS
continue  ||| S:14705 E:14714 ||| VBP
to  ||| S:14714 E:14717 ||| TO
move  ||| S:14717 E:14722 ||| VB
in  ||| S:14722 E:14733 ||| IN
the  ||| S:14733 E:14737 ||| DT
presence  ||| S:14737 E:14746 ||| NN
of  ||| S:14746 E:14749 ||| IN
BDM ||| S:14749 E:14752 ||| NNP
,  ||| S:14752 E:14754 ||| ,
while  ||| S:14754 E:14760 ||| IN
the  ||| S:14760 E:14764 ||| DT
leading  ||| S:14764 E:14772 ||| JJ
edge  ||| S:14772 E:14777 ||| NN
of  ||| S:14777 E:14780 ||| IN
the  ||| S:14780 E:14784 ||| DT
infected  ||| S:14784 E:14801 ||| JJ
cell  ||| S:14801 E:14806 ||| NN
stops  ||| S:14806 E:14812 ||| VBZ
ruffling ||| S:14812 E:14820 ||| VBN
.  ||| S:14820 E:14822 ||| .
Both  ||| S:14822 E:14827 ||| DT
processes  ||| S:14827 E:14837 ||| NNS
have  ||| S:14837 E:14842 ||| VBP
been  ||| S:14842 E:14847 ||| VBN
shown  ||| S:14847 E:14853 ||| VBN
to  ||| S:14853 E:14864 ||| TO
involve  ||| S:14864 E:14872 ||| VB
the  ||| S:14872 E:14876 ||| DT
Arp2 ||| S:14876 E:14880 ||| CD
/ ||| S:14880 E:14881 ||| CD
3  ||| S:14881 E:14883 ||| CD
complex ||| S:14883 E:14890 ||| NN
.  ||| S:14890 E:14892 ||| .
That  ||| S:14892 E:14897 ||| IN
BDM  ||| S:14897 E:14901 ||| NNP
inhibits  ||| S:14901 E:14910 ||| VBD
one  ||| S:14910 E:14914 ||| CD
actin  ||| S:14914 E:14928 ||| CD
dependent  ||| S:14928 E:14938 ||| JJ
process  ||| S:14938 E:14946 ||| NN
but  ||| S:14946 E:14950 ||| CC
not  ||| S:14950 E:14954 ||| RB
the  ||| S:14954 E:14958 ||| DT
other ||| S:14958 E:14963 ||| JJ
,  ||| S:14963 E:14965 ||| ,
may  ||| S:14965 E:14969 ||| MD
be  ||| S:14969 E:14972 ||| VB
an  ||| S:14972 E:14975 ||| DT
interesting  ||| S:14975 E:14995 ||| JJ
difference  ||| S:14995 E:15006 ||| NN
in  ||| S:15006 E:15009 ||| IN
the  ||| S:15009 E:15013 ||| DT
location  ||| S:15013 E:15022 ||| NN
of  ||| S:15022 E:15025 ||| IN
polymerization  ||| S:15025 E:15040 ||| NN
within  ||| S:15040 E:15047 ||| IN
the  ||| S:15047 E:15059 ||| DT
cell  ||| S:15059 E:15064 ||| NN
-  ||| S:15064 E:15066 ||| :
actin  ||| S:15066 E:15072 ||| JJ
polymerization  ||| S:15072 E:15087 ||| NN
at  ||| S:15087 E:15090 ||| IN
the  ||| S:15090 E:15094 ||| DT
leading  ||| S:15094 E:15102 ||| JJ
edge  ||| S:15102 E:15107 ||| NN
vs.  ||| S:15107 E:15111 ||| IN
the  ||| S:15111 E:15123 ||| DT
cell  ||| S:15123 E:15128 ||| NN
body ||| S:15128 E:15132 ||| NN
,  ||| S:15132 E:15134 ||| ,
or  ||| S:15134 E:15137 ||| CC
a  ||| S:15137 E:15139 ||| DT
difference  ||| S:15139 E:15150 ||| NN
in  ||| S:15150 E:15153 ||| IN
the  ||| S:15153 E:15157 ||| DT
mechanism  ||| S:15157 E:15167 ||| NN
of  ||| S:15167 E:15170 ||| IN
actin  ||| S:15170 E:15184 ||| JJ
polymerization  ||| S:15184 E:15199 ||| NN
-  ||| S:15199 E:15201 ||| :
the  ||| S:15201 E:15205 ||| DT
leading  ||| S:15205 E:15213 ||| JJ
edge  ||| S:15213 E:15218 ||| NN
vs.  ||| S:15218 E:15222 ||| IN
a  ||| S:15222 E:15233 ||| DT
Listeria  ||| S:15233 E:15242 ||| JJ
bacterium ||| S:15242 E:15251 ||| NN
.  ||| S:15251 E:15253 ||| .
BDM  ||| S:15253 E:15257 ||| NNP
treatment  ||| S:15257 E:15275 ||| NN
thus  ||| S:15275 E:15280 ||| RB
seems  ||| S:15280 E:15286 ||| VBZ
to  ||| S:15286 E:15289 ||| TO
disrupt  ||| S:15289 E:15297 ||| VB
actin  ||| S:15297 E:15303 ||| JJ
dynamics  ||| S:15303 E:15312 ||| NNS
specific  ||| S:15312 E:15321 ||| JJ
to  ||| S:15321 E:15324 ||| TO
the  ||| S:15324 E:15328 ||| DT
plasma  ||| S:15328 E:15343 ||| JJ
membrane  ||| S:15343 E:15352 ||| NN
and  ||| S:15352 E:15356 ||| CC
this  ||| S:15356 E:15361 ||| DT
may  ||| S:15361 E:15365 ||| MD
provide  ||| S:15365 E:15373 ||| VB
a  ||| S:15373 E:15375 ||| DT
clue  ||| S:15375 E:15380 ||| NN
to  ||| S:15380 E:15383 ||| TO
both  ||| S:15383 E:15388 ||| PDT
the  ||| S:15388 E:15392 ||| DT
mechanism  ||| S:15392 E:15410 ||| NN
of  ||| S:15410 E:15413 ||| IN
BDM  ||| S:15413 E:15417 ||| NNP
inhibition  ||| S:15417 E:15428 ||| NN
and  ||| S:15428 E:15432 ||| CC
the  ||| S:15432 E:15436 ||| DT
relationship  ||| S:15436 E:15449 ||| NN
of  ||| S:15449 E:15452 ||| IN
actin  ||| S:15452 E:15458 ||| JJ
dynamics  ||| S:15458 E:15467 ||| NNS
at  ||| S:15467 E:15478 ||| IN
the  ||| S:15478 E:15482 ||| DT
plasma  ||| S:15482 E:15489 ||| JJ
membrane ||| S:15489 E:15497 ||| NN
.  ||| S:15497 E:15507 ||| .
Current  ||| S:15507 E:15515 ||| JJ
understanding  ||| S:15515 E:15529 ||| NN
of  ||| S:15529 E:15532 ||| IN
the  ||| S:15532 E:15536 ||| DT
retrograde  ||| S:15536 E:15547 ||| JJ
flow  ||| S:15547 E:15552 ||| NN
of  ||| S:15552 E:15555 ||| IN
actin  ||| S:15555 E:15569 ||| NN
has  ||| S:15569 E:15573 ||| VBZ
been  ||| S:15573 E:15578 ||| VBN
influenced  ||| S:15578 E:15589 ||| VBN
by  ||| S:15589 E:15592 ||| IN
the  ||| S:15592 E:15596 ||| DT
use  ||| S:15596 E:15600 ||| NN
of  ||| S:15600 E:15603 ||| IN
BDM  ||| S:15603 E:15607 ||| NNP
in  ||| S:15607 E:15610 ||| IN
the  ||| S:15610 E:15614 ||| DT
sea  ||| S:15614 E:15618 ||| NN
urchin  ||| S:15618 E:15633 ||| NN
coelomocyte  ||| S:15633 E:15645 ||| NNS
and  ||| S:15645 E:15658 ||| CC
Aplysia  ||| S:15658 E:15666 ||| NNP
bag  ||| S:15666 E:15670 ||| NN
cell  ||| S:15670 E:15675 ||| NN
neuron  ||| S:15675 E:15682 ||| NN
systems ||| S:15682 E:15689 ||| NNS
.  ||| S:15689 E:15691 ||| .
Our  ||| S:15691 E:15703 ||| PRP$
data  ||| S:15703 E:15708 ||| NNS
are  ||| S:15708 E:15712 ||| VBP
consistent  ||| S:15712 E:15723 ||| JJ
with  ||| S:15723 E:15728 ||| IN
results  ||| S:15728 E:15736 ||| NNS
in  ||| S:15736 E:15739 ||| IN
sea  ||| S:15739 E:15743 ||| NN
urchin  ||| S:15743 E:15750 ||| NN
coelomocytes  ||| S:15750 E:15771 ||| NN
where  ||| S:15771 E:15777 ||| WRB
BDM  ||| S:15777 E:15781 ||| NNP
phenocopies  ||| S:15781 E:15793 ||| VBD
the  ||| S:15793 E:15797 ||| DT
effect  ||| S:15797 E:15804 ||| NN
of  ||| S:15804 E:15807 ||| IN
cytochalasin  ||| S:15807 E:15820 ||| JJ
D ||| S:15820 E:15821 ||| NNP
,  ||| S:15821 E:15831 ||| ,
blocking  ||| S:15831 E:15840 ||| VBG
retrograde  ||| S:15840 E:15851 ||| JJ
flow  ||| S:15851 E:15856 ||| NN
at  ||| S:15856 E:15859 ||| IN
the  ||| S:15859 E:15863 ||| DT
leading  ||| S:15863 E:15871 ||| JJ
edge  ||| S:15871 E:15876 ||| NN
with  ||| S:15876 E:15881 ||| IN
continued  ||| S:15881 E:15899 ||| JJ
contraction  ||| S:15899 E:15911 ||| NN
of  ||| S:15911 E:15914 ||| IN
the  ||| S:15914 E:15918 ||| DT
actin  ||| S:15918 E:15924 ||| JJ
network  ||| S:15924 E:15932 ||| NN
causing  ||| S:15932 E:15940 ||| VBG
a  ||| S:15940 E:15942 ||| DT
clearing  ||| S:15942 E:15951 ||| NN
of  ||| S:15951 E:15962 ||| IN
actin  ||| S:15962 E:15968 ||| NN
at  ||| S:15968 E:15971 ||| IN
the  ||| S:15971 E:15975 ||| DT
leading  ||| S:15975 E:15983 ||| JJ
edge  ||| S:15983 E:15988 ||| NN
[  ||| S:15988 E:15990 ||| -LRB-
11  ||| S:15990 E:15993 ||| CD
]  ||| S:15993 E:15995 ||| -RRB-
.  ||| S:15995 E:15997 ||| .
In  ||| S:15997 E:16000 ||| IN
the  ||| S:16000 E:16004 ||| DT
coelomyocte  ||| S:16004 E:16024 ||| JJ
system ||| S:16024 E:16030 ||| NN
,  ||| S:16030 E:16032 ||| ,
de-localization  ||| S:16032 E:16048 ||| JJ
of  ||| S:16048 E:16051 ||| IN
leading  ||| S:16051 E:16059 ||| VBG
edge  ||| S:16059 E:16064 ||| NN
components  ||| S:16064 E:16075 ||| NNS
by  ||| S:16075 E:16078 ||| IN
BDM  ||| S:16078 E:16090 ||| NNP
could  ||| S:16090 E:16096 ||| MD
account  ||| S:16096 E:16104 ||| VB
for  ||| S:16104 E:16108 ||| IN
the  ||| S:16108 E:16112 ||| DT
inhibition  ||| S:16112 E:16123 ||| NN
of  ||| S:16123 E:16126 ||| IN
actin  ||| S:16126 E:16132 ||| JJ
polymerization  ||| S:16132 E:16155 ||| NN
and  ||| S:16155 E:16159 ||| CC
clearing ||| S:16159 E:16167 ||| NN
.  ||| S:16167 E:16169 ||| .
In  ||| S:16169 E:16172 ||| IN
the  ||| S:16172 E:16185 ||| DT
Aplysia  ||| S:16185 E:16193 ||| JJ
bag  ||| S:16193 E:16197 ||| NN
cell  ||| S:16197 E:16202 ||| NN
neuron ||| S:16202 E:16208 ||| NN
,  ||| S:16208 E:16210 ||| ,
BDM  ||| S:16210 E:16222 ||| NNP
application  ||| S:16222 E:16234 ||| NN
leads  ||| S:16234 E:16240 ||| VBZ
to  ||| S:16240 E:16243 ||| TO
extension  ||| S:16243 E:16253 ||| NN
of  ||| S:16253 E:16256 ||| IN
filopodia  ||| S:16256 E:16266 ||| NN
and  ||| S:16266 E:16270 ||| CC
the  ||| S:16270 E:16274 ||| DT
growth  ||| S:16274 E:16289 ||| NN
cone  ||| S:16289 E:16294 ||| VBD
itself ||| S:16294 E:16300 ||| PRP
.  ||| S:16300 E:16302 ||| .
Filopodial  ||| S:16302 E:16313 ||| JJ
extension  ||| S:16313 E:16323 ||| NN
was  ||| S:16323 E:16327 ||| VBD
interpreted  ||| S:16327 E:16339 ||| VBN
as  ||| S:16339 E:16350 ||| IN
supporting  ||| S:16350 E:16361 ||| VBG
the  ||| S:16361 E:16365 ||| DT
clutch  ||| S:16365 E:16372 ||| JJ
model ||| S:16372 E:16377 ||| NN
,  ||| S:16377 E:16379 ||| ,
with  ||| S:16379 E:16384 ||| IN
myosins  ||| S:16384 E:16392 ||| NNS
pulling  ||| S:16392 E:16400 ||| VBG
filaments  ||| S:16400 E:16418 ||| NN
toward  ||| S:16418 E:16425 ||| IN
the  ||| S:16425 E:16429 ||| DT
growth  ||| S:16429 E:16436 ||| NN
cone  ||| S:16436 E:16441 ||| NN
interior ||| S:16441 E:16449 ||| NN
.  ||| S:16449 E:16451 ||| .
When  ||| S:16451 E:16456 ||| WRB
the  ||| S:16456 E:16460 ||| DT
myosin  ||| S:16460 E:16467 ||| JJ
activity  ||| S:16467 E:16484 ||| NN
was  ||| S:16484 E:16488 ||| VBD
blocked  ||| S:16488 E:16496 ||| VBN
with  ||| S:16496 E:16501 ||| IN
BDM  ||| S:16501 E:16505 ||| NNP
treatment ||| S:16505 E:16514 ||| NN
,  ||| S:16514 E:16516 ||| ,
continued  ||| S:16516 E:16526 ||| VBD
actin  ||| S:16526 E:16540 ||| JJ
polymerization ||| S:16540 E:16554 ||| NN
,  ||| S:16554 E:16556 ||| ,
thought  ||| S:16556 E:16564 ||| VBD
to  ||| S:16564 E:16567 ||| TO
occur  ||| S:16567 E:16573 ||| VB
as  ||| S:16573 E:16576 ||| IN
elongation  ||| S:16576 E:16587 ||| NN
of  ||| S:16587 E:16590 ||| IN
existing  ||| S:16590 E:16607 ||| VBG
filaments ||| S:16607 E:16616 ||| NN
,  ||| S:16616 E:16618 ||| ,
lead  ||| S:16618 E:16623 ||| NN
to  ||| S:16623 E:16626 ||| TO
protrusion  ||| S:16626 E:16637 ||| VB
[  ||| S:16637 E:16639 ||| -LRB-
12  ||| S:16639 E:16642 ||| CD
27  ||| S:16642 E:16645 ||| CD
28  ||| S:16645 E:16648 ||| CD
]  ||| S:16648 E:16650 ||| -RRB-
.  ||| S:16650 E:16652 ||| .
Our  ||| S:16652 E:16664 ||| PRP$
observation  ||| S:16664 E:16676 ||| NN
of  ||| S:16676 E:16679 ||| IN
BDM  ||| S:16679 E:16683 ||| NNP
activity  ||| S:16683 E:16692 ||| NN
suggests  ||| S:16692 E:16701 ||| VBZ
an  ||| S:16701 E:16704 ||| DT
alternative  ||| S:16704 E:16724 ||| JJ
explanation ||| S:16724 E:16735 ||| NN
.  ||| S:16735 E:16737 ||| .
Perhaps  ||| S:16737 E:16745 ||| RB
components  ||| S:16745 E:16756 ||| VB
required  ||| S:16756 E:16765 ||| VBN
for  ||| S:16765 E:16769 ||| IN
nucleation  ||| S:16769 E:16780 ||| NNS
are  ||| S:16780 E:16792 ||| VBP
de-localized  ||| S:16792 E:16805 ||| JJ
by  ||| S:16805 E:16808 ||| IN
BDM  ||| S:16808 E:16812 ||| NNP
allowing  ||| S:16812 E:16821 ||| VBG
new  ||| S:16821 E:16825 ||| JJ
polymerization  ||| S:16825 E:16840 ||| NN
to  ||| S:16840 E:16843 ||| TO
be  ||| S:16843 E:16854 ||| VB
re-directed  ||| S:16854 E:16866 ||| JJ
to  ||| S:16866 E:16869 ||| TO
filopodia ||| S:16869 E:16878 ||| VB
,  ||| S:16878 E:16880 ||| ,
as  ||| S:16880 E:16883 ||| IN
filopodial  ||| S:16883 E:16894 ||| JJ
extension  ||| S:16894 E:16904 ||| NN
is  ||| S:16904 E:16915 ||| VBZ
thought  ||| S:16915 E:16923 ||| VBN
to  ||| S:16923 E:16926 ||| TO
be  ||| S:16926 E:16929 ||| VB
driven  ||| S:16929 E:16936 ||| VBN
by  ||| S:16936 E:16939 ||| IN
elongation  ||| S:16939 E:16950 ||| NN
and  ||| S:16950 E:16954 ||| CC
not  ||| S:16954 E:16958 ||| RB
nucleation  ||| S:16958 E:16969 ||| JJ
[  ||| S:16969 E:16971 ||| -LRB-
27  ||| S:16971 E:16982 ||| CD
]  ||| S:16982 E:16984 ||| -RRB-
.  ||| S:16984 E:16986 ||| .
The  ||| S:16986 E:16990 ||| DT
extension  ||| S:16990 E:17000 ||| NN
of  ||| S:17000 E:17003 ||| IN
the  ||| S:17003 E:17007 ||| DT
growth  ||| S:17007 E:17014 ||| NN
cone  ||| S:17014 E:17019 ||| VBD
itself  ||| S:17019 E:17026 ||| PRP
could  ||| S:17026 E:17032 ||| MD
result  ||| S:17032 E:17047 ||| VB
from  ||| S:17047 E:17052 ||| IN
a  ||| S:17052 E:17054 ||| DT
similar  ||| S:17054 E:17062 ||| JJ
diversion  ||| S:17062 E:17072 ||| NN
of  ||| S:17072 E:17075 ||| IN
actin  ||| S:17075 E:17081 ||| JJ
monomer  ||| S:17081 E:17089 ||| NN
from  ||| S:17089 E:17094 ||| IN
nucleation  ||| S:17094 E:17113 ||| NN
of  ||| S:17113 E:17116 ||| IN
new  ||| S:17116 E:17120 ||| JJ
filaments  ||| S:17120 E:17130 ||| NN
to  ||| S:17130 E:17133 ||| TO
extension  ||| S:17133 E:17143 ||| NN
of  ||| S:17143 E:17146 ||| IN
existing  ||| S:17146 E:17155 ||| VBG
filaments ||| S:17155 E:17164 ||| NNS
.  ||| S:17164 E:17174 ||| .
Treatment  ||| S:17174 E:17184 ||| NN
of  ||| S:17184 E:17187 ||| IN
cells  ||| S:17187 E:17193 ||| NNS
with  ||| S:17193 E:17198 ||| IN
BDM  ||| S:17198 E:17202 ||| NNP
often  ||| S:17202 E:17208 ||| RB
leads  ||| S:17208 E:17214 ||| VBZ
to  ||| S:17214 E:17217 ||| TO
filopodia-like  ||| S:17217 E:17240 ||| JJ
projections  ||| S:17240 E:17252 ||| NNS
as  ||| S:17252 E:17255 ||| RB
seen  ||| S:17255 E:17260 ||| VBN
in  ||| S:17260 E:17263 ||| IN
Figure  ||| S:17263 E:17270 ||| NNP
1Band  ||| S:17270 E:17276 ||| NNP
Figure  ||| S:17276 E:17283 ||| NNP
2B ||| S:17283 E:17285 ||| NNP
.  ||| S:17285 E:17287 ||| .
Data  ||| S:17287 E:17292 ||| NNS
from  ||| S:17292 E:17305 ||| IN
studies  ||| S:17305 E:17313 ||| NNS
of  ||| S:17313 E:17325 ||| IN
in  ||| S:17325 E:17328 ||| IN
vivo  ||| S:17328 E:17333 ||| NN
and  ||| S:17333 E:17346 ||| CC
in  ||| S:17346 E:17349 ||| IN
vitro  ||| S:17349 E:17355 ||| JJ
filopodia  ||| S:17355 E:17365 ||| JJ
formation  ||| S:17365 E:17375 ||| NN
suggest  ||| S:17375 E:17391 ||| VBP
that  ||| S:17391 E:17396 ||| IN
they  ||| S:17396 E:17401 ||| PRP
develop  ||| S:17401 E:17409 ||| VBP
as  ||| S:17409 E:17412 ||| IN
a  ||| S:17412 E:17414 ||| DT
reorganization  ||| S:17414 E:17429 ||| NN
of  ||| S:17429 E:17432 ||| IN
the  ||| S:17432 E:17436 ||| DT
dendritic  ||| S:17436 E:17454 ||| JJ
network  ||| S:17454 E:17462 ||| NN
in  ||| S:17462 E:17465 ||| IN
which  ||| S:17465 E:17471 ||| WDT
they  ||| S:17471 E:17476 ||| PRP
exist  ||| S:17476 E:17482 ||| VBP
[  ||| S:17482 E:17484 ||| -LRB-
29  ||| S:17484 E:17487 ||| CD
30  ||| S:17487 E:17490 ||| CD
]  ||| S:17490 E:17492 ||| -RRB-
.  ||| S:17492 E:17494 ||| .
In  ||| S:17494 E:17497 ||| IN
the  ||| S:17497 E:17501 ||| DT
presence  ||| S:17501 E:17510 ||| NN
of  ||| S:17510 E:17521 ||| IN
proteins  ||| S:17521 E:17530 ||| NNS
that  ||| S:17530 E:17535 ||| IN
bundle  ||| S:17535 E:17542 ||| NN
and  ||| S:17542 E:17546 ||| CC
reorganize  ||| S:17546 E:17557 ||| VB
actin  ||| S:17557 E:17563 ||| JJ
filaments  ||| S:17563 E:17573 ||| NN
into  ||| S:17573 E:17586 ||| IN
filopodial  ||| S:17586 E:17597 ||| JJ
precursors ||| S:17597 E:17607 ||| NN
,  ||| S:17607 E:17609 ||| ,
the  ||| S:17609 E:17613 ||| DT
de-localization  ||| S:17613 E:17629 ||| JJ
of  ||| S:17629 E:17632 ||| IN
Arp2 ||| S:17632 E:17636 ||| CD
/ ||| S:17636 E:17637 ||| CD
3  ||| S:17637 E:17639 ||| CD
and  ||| S:17639 E:17651 ||| CC
other  ||| S:17651 E:17657 ||| JJ
leading  ||| S:17657 E:17665 ||| JJ
edge  ||| S:17665 E:17670 ||| NN
components  ||| S:17670 E:17681 ||| NNS
may  ||| S:17681 E:17685 ||| MD
lead  ||| S:17685 E:17690 ||| VB
to  ||| S:17690 E:17693 ||| TO
the  ||| S:17693 E:17697 ||| DT
formation  ||| S:17697 E:17707 ||| NN
of  ||| S:17707 E:17718 ||| IN
filopodia ||| S:17718 E:17727 ||| NN
,  ||| S:17727 E:17729 ||| ,
which  ||| S:17729 E:17735 ||| WDT
are  ||| S:17735 E:17739 ||| VBP
then  ||| S:17739 E:17744 ||| RB
elongated  ||| S:17744 E:17754 ||| VBN
as  ||| S:17754 E:17757 ||| RB
described  ||| S:17757 E:17767 ||| VBN
above ||| S:17767 E:17772 ||| IN
.  ||| S:17772 E:17782 ||| .
Future  ||| S:17782 E:17789 ||| JJ
studies  ||| S:17789 E:17797 ||| NNS
will  ||| S:17797 E:17802 ||| MD
hopefully  ||| S:17802 E:17812 ||| RB
clarify  ||| S:17812 E:17820 ||| VB
the  ||| S:17820 E:17824 ||| DT
role  ||| S:17824 E:17829 ||| NN
of  ||| S:17829 E:17832 ||| IN
actin  ||| S:17832 E:17846 ||| JJ
nucleation  ||| S:17846 E:17857 ||| NN
in  ||| S:17857 E:17860 ||| IN
the  ||| S:17860 E:17873 ||| DT
Aplysia  ||| S:17873 E:17881 ||| JJ
system  ||| S:17881 E:17888 ||| NN
or  ||| S:17888 E:17891 ||| CC
alternative  ||| S:17891 E:17911 ||| JJ
mechanisms  ||| S:17911 E:17922 ||| NNS
that  ||| S:17922 E:17927 ||| WDT
would  ||| S:17927 E:17933 ||| MD
reconcile  ||| S:17933 E:17943 ||| VB
the  ||| S:17943 E:17947 ||| DT
discrepancies  ||| S:17947 E:17961 ||| NNS
between  ||| S:17961 E:17977 ||| IN
systems ||| S:17977 E:17984 ||| NNS
.  ||| S:17984 E:17994 ||| .
In  ||| S:17994 E:17997 ||| IN
all  ||| S:17997 E:18001 ||| DT
systems ||| S:18001 E:18008 ||| NNS
,  ||| S:18008 E:18010 ||| ,
a  ||| S:18010 E:18012 ||| DT
better  ||| S:18012 E:18019 ||| JJR
understanding  ||| S:18019 E:18033 ||| NN
of  ||| S:18033 E:18036 ||| IN
how  ||| S:18036 E:18040 ||| WRB
the  ||| S:18040 E:18052 ||| DT
leading  ||| S:18052 E:18060 ||| JJ
edge  ||| S:18060 E:18065 ||| NN
is  ||| S:18065 E:18068 ||| VBZ
constructed  ||| S:18068 E:18080 ||| VBN
and  ||| S:18080 E:18084 ||| CC
maintained  ||| S:18084 E:18095 ||| VBN
will  ||| S:18095 E:18100 ||| MD
require  ||| S:18100 E:18116 ||| VB
specific  ||| S:18116 E:18125 ||| JJ
and  ||| S:18125 E:18129 ||| CC
detailed  ||| S:18129 E:18138 ||| JJ
descriptions  ||| S:18138 E:18151 ||| NNS
of  ||| S:18151 E:18154 ||| IN
the  ||| S:18154 E:18158 ||| DT
activity  ||| S:18158 E:18167 ||| NN
and  ||| S:18167 E:18179 ||| CC
localization  ||| S:18179 E:18192 ||| NN
of  ||| S:18192 E:18195 ||| IN
the  ||| S:18195 E:18199 ||| DT
proteins  ||| S:18199 E:18208 ||| NNS
involved ||| S:18208 E:18216 ||| VBN
.  ||| S:18216 E:18218 ||| .
Membrane  ||| S:18218 E:18227 ||| JJ
ruffling ||| S:18227 E:18235 ||| NN
,  ||| S:18235 E:18245 ||| ,
often  ||| S:18245 E:18251 ||| RB
used  ||| S:18251 E:18256 ||| VBN
as  ||| S:18256 E:18259 ||| IN
a  ||| S:18259 E:18261 ||| DT
measure  ||| S:18261 E:18269 ||| NN
of  ||| S:18269 E:18272 ||| IN
actin  ||| S:18272 E:18278 ||| JJ
dynamics  ||| S:18278 E:18287 ||| NNS
at  ||| S:18287 E:18290 ||| IN
the  ||| S:18290 E:18294 ||| DT
leading  ||| S:18294 E:18310 ||| JJ
edge ||| S:18310 E:18314 ||| NN
,  ||| S:18314 E:18316 ||| ,
is  ||| S:18316 E:18319 ||| VBZ
a  ||| S:18319 E:18321 ||| DT
very  ||| S:18321 E:18326 ||| RB
crude  ||| S:18326 E:18332 ||| JJ
readout ||| S:18332 E:18339 ||| NN
.  ||| S:18339 E:18341 ||| .
The  ||| S:18341 E:18345 ||| DT
sensitivity  ||| S:18345 E:18357 ||| NN
of  ||| S:18357 E:18360 ||| IN
the  ||| S:18360 E:18372 ||| DT
leading  ||| S:18372 E:18380 ||| JJ
edge  ||| S:18380 E:18385 ||| NN
is  ||| S:18385 E:18388 ||| VBZ
demonstrated  ||| S:18388 E:18401 ||| VBN
by  ||| S:18401 E:18404 ||| IN
the  ||| S:18404 E:18408 ||| DT
observation  ||| S:18408 E:18420 ||| NN
that  ||| S:18420 E:18425 ||| IN
DMSO  ||| S:18425 E:18438 ||| NNP
treatment  ||| S:18438 E:18448 ||| NN
at  ||| S:18448 E:18451 ||| IN
a  ||| S:18451 E:18453 ||| DT
concentration  ||| S:18453 E:18467 ||| NN
of  ||| S:18467 E:18470 ||| IN
1 ||| S:18470 E:18471 ||| CD
%  ||| S:18471 E:18473 ||| NN
causes  ||| S:18473 E:18480 ||| VBZ
temporary  ||| S:18480 E:18498 ||| JJ
inhibition  ||| S:18498 E:18509 ||| NN
of  ||| S:18509 E:18512 ||| IN
ruffling  ||| S:18512 E:18521 ||| NN
and  ||| S:18521 E:18525 ||| CC
concomitant  ||| S:18525 E:18537 ||| JJ
Arp3  ||| S:18537 E:18542 ||| NNP
de-localization  ||| S:18542 E:18566 ||| NNP
( ||| S:18566 E:18567 ||| -LRB-
Yarrow  ||| S:18567 E:18574 ||| NNP
unpublished  ||| S:18574 E:18586 ||| JJ
results ||| S:18586 E:18593 ||| NNS
) ||| S:18593 E:18594 ||| -RRB-
.  ||| S:18594 E:18596 ||| .
Experimental  ||| S:18596 E:18609 ||| JJ
approaches  ||| S:18609 E:18620 ||| NNS
that  ||| S:18620 E:18633 ||| WDT
may  ||| S:18633 E:18637 ||| MD
help  ||| S:18637 E:18642 ||| VB
address  ||| S:18642 E:18650 ||| VB
how  ||| S:18650 E:18654 ||| WRB
such  ||| S:18654 E:18659 ||| PDT
a  ||| S:18659 E:18661 ||| DT
dynamic  ||| S:18661 E:18669 ||| JJ
and  ||| S:18669 E:18673 ||| CC
sensitive  ||| S:18673 E:18683 ||| JJ
structure  ||| S:18683 E:18701 ||| NN
is  ||| S:18701 E:18704 ||| VBZ
established  ||| S:18704 E:18716 ||| VBN
and  ||| S:18716 E:18720 ||| CC
maintained  ||| S:18720 E:18731 ||| NNS
include  ||| S:18731 E:18739 ||| VBP
combining  ||| S:18739 E:18749 ||| VBG
inhibition  ||| S:18749 E:18768 ||| NN
of  ||| S:18768 E:18771 ||| IN
actin  ||| S:18771 E:18777 ||| JJ
dynamics  ||| S:18777 E:18786 ||| NNS
with  ||| S:18786 E:18791 ||| IN
the  ||| S:18791 E:18795 ||| DT
use  ||| S:18795 E:18799 ||| NN
of  ||| S:18799 E:18802 ||| IN
tools  ||| S:18802 E:18808 ||| NNS
that  ||| S:18808 E:18813 ||| WDT
affect  ||| S:18813 E:18820 ||| VBP
Arp2 ||| S:18820 E:18824 ||| CD
/ ||| S:18824 E:18825 ||| CD
3  ||| S:18825 E:18835 ||| CD
or  ||| S:18835 E:18838 ||| CC
myosin  ||| S:18838 E:18845 ||| JJ
activity  ||| S:18845 E:18854 ||| NN
or  ||| S:18854 E:18857 ||| CC
localization ||| S:18857 E:18869 ||| NN
,  ||| S:18869 E:18871 ||| ,
in  ||| S:18871 E:18874 ||| IN
specific  ||| S:18874 E:18883 ||| JJ
ways ||| S:18883 E:18887 ||| NNS
.  ||| S:18887 E:18897 ||| .
Though  ||| S:18897 E:18904 ||| IN
preliminary ||| S:18904 E:18915 ||| JJ
,  ||| S:18915 E:18917 ||| ,
we  ||| S:18917 E:18920 ||| PRP
have  ||| S:18920 E:18925 ||| VBP
seen  ||| S:18925 E:18930 ||| VBN
that  ||| S:18930 E:18935 ||| IN
Arp3  ||| S:18935 E:18940 ||| NNP
is  ||| S:18940 E:18943 ||| VBZ
still  ||| S:18943 E:18957 ||| RB
localized  ||| S:18957 E:18967 ||| VBN
in  ||| S:18967 E:18970 ||| IN
the  ||| S:18970 E:18974 ||| DT
presence  ||| S:18974 E:18983 ||| NN
of  ||| S:18983 E:18986 ||| IN
latrunculin  ||| S:18986 E:18998 ||| JJ
A  ||| S:18998 E:19000 ||| NN
and  ||| S:19000 E:19012 ||| CC
jasplakinolide ||| S:19012 E:19026 ||| NN
,  ||| S:19026 E:19028 ||| ,
and  ||| S:19028 E:19032 ||| CC
that  ||| S:19032 E:19037 ||| IN
this  ||| S:19037 E:19042 ||| DT
localization  ||| S:19042 E:19055 ||| NN
is  ||| S:19055 E:19058 ||| VBZ
lost  ||| S:19058 E:19063 ||| VBN
with  ||| S:19063 E:19068 ||| IN
BDM  ||| S:19068 E:19080 ||| NNP
treatment  ||| S:19080 E:19090 ||| NN
unlike  ||| S:19090 E:19097 ||| IN
the  ||| S:19097 E:19101 ||| DT
combination  ||| S:19101 E:19113 ||| NN
of  ||| S:19113 E:19116 ||| IN
cytochalasin  ||| S:19116 E:19129 ||| JJ
D  ||| S:19129 E:19131 ||| NNP
and  ||| S:19131 E:19135 ||| CC
BDM  ||| S:19135 E:19147 ||| NNP
( ||| S:19147 E:19148 ||| -LRB-
Yarrow  ||| S:19148 E:19155 ||| NNP
unpublished  ||| S:19155 E:19167 ||| JJ
results ||| S:19167 E:19174 ||| NNS
) ||| S:19174 E:19175 ||| -RRB-
.  ||| S:19175 E:19177 ||| .
These  ||| S:19177 E:19183 ||| DT
results  ||| S:19183 E:19191 ||| NNS
may  ||| S:19191 E:19195 ||| MD
in  ||| S:19195 E:19198 ||| IN
the  ||| S:19198 E:19202 ||| DT
end  ||| S:19202 E:19214 ||| NN
tell  ||| S:19214 E:19219 ||| VBP
us  ||| S:19219 E:19222 ||| PRP
more  ||| S:19222 E:19227 ||| RBR
about  ||| S:19227 E:19233 ||| IN
our  ||| S:19233 E:19237 ||| PRP$
understanding  ||| S:19237 E:19251 ||| NN
of  ||| S:19251 E:19254 ||| IN
what  ||| S:19254 E:19259 ||| WP
latrunculin  ||| S:19259 E:19271 ||| VBD
A  ||| S:19271 E:19281 ||| DT
and  ||| S:19281 E:19285 ||| CC
jasplakinolide  ||| S:19285 E:19300 ||| NNS
do  ||| S:19300 E:19312 ||| VBP
in  ||| S:19312 E:19315 ||| IN
vivo  ||| S:19315 E:19320 ||| NN
than  ||| S:19320 E:19325 ||| IN
the  ||| S:19325 E:19329 ||| DT
leading  ||| S:19329 E:19337 ||| JJ
edge  ||| S:19337 E:19342 ||| NN
itself ||| S:19342 E:19348 ||| PRP
.  ||| S:19348 E:19358 ||| .
Regardless ||| S:19358 E:19368 ||| RB
,  ||| S:19368 E:19370 ||| ,
this  ||| S:19370 E:19375 ||| DT
type  ||| S:19375 E:19380 ||| NN
of  ||| S:19380 E:19383 ||| IN
experiment  ||| S:19383 E:19394 ||| NN
awaits  ||| S:19394 E:19401 ||| VBZ
more  ||| S:19401 E:19406 ||| RBR
specific  ||| S:19406 E:19423 ||| JJ
tools  ||| S:19423 E:19429 ||| NNS
than  ||| S:19429 E:19434 ||| IN
BDM  ||| S:19434 E:19438 ||| NNP
for  ||| S:19438 E:19442 ||| IN
follow  ||| S:19442 E:19449 ||| VB
up ||| S:19449 E:19451 ||| RP
.  ||| S:19451 E:19461 ||| .
Though  ||| S:19461 E:19468 ||| IN
BDM  ||| S:19468 E:19472 ||| NNP
has  ||| S:19472 E:19476 ||| VBZ
a  ||| S:19476 E:19478 ||| DT
relatively  ||| S:19478 E:19489 ||| RB
high  ||| S:19489 E:19494 ||| JJ
effective  ||| S:19494 E:19504 ||| JJ
concentration  ||| S:19504 E:19526 ||| NN
( ||| S:19526 E:19527 ||| -LRB-
in  ||| S:19527 E:19530 ||| IN
the  ||| S:19530 E:19534 ||| DT
millimolar  ||| S:19534 E:19545 ||| JJ
range ||| S:19545 E:19550 ||| NN
) ||| S:19550 E:19551 ||| -RRB-
,  ||| S:19551 E:19553 ||| ,
it  ||| S:19553 E:19556 ||| PRP
was  ||| S:19556 E:19560 ||| VBD
widely  ||| S:19560 E:19567 ||| RB
adopted  ||| S:19567 E:19575 ||| VBN
by  ||| S:19575 E:19578 ||| IN
the  ||| S:19578 E:19590 ||| DT
cell  ||| S:19590 E:19595 ||| NN
biology  ||| S:19595 E:19603 ||| NN
community  ||| S:19603 E:19613 ||| NN
because  ||| S:19613 E:19621 ||| IN
of  ||| S:19621 E:19624 ||| IN
its  ||| S:19624 E:19628 ||| PRP$
rapid  ||| S:19628 E:19634 ||| JJ
and  ||| S:19634 E:19638 ||| CC
reversible  ||| S:19638 E:19657 ||| JJ
effect  ||| S:19657 E:19664 ||| NN
on  ||| S:19664 E:19667 ||| IN
cell  ||| S:19667 E:19672 ||| NN
behaviour ||| S:19672 E:19681 ||| NN
.  ||| S:19681 E:19683 ||| .
BDM  ||| S:19683 E:19687 ||| NNP
has  ||| S:19687 E:19691 ||| VBZ
not  ||| S:19691 E:19695 ||| RB
been  ||| S:19695 E:19700 ||| VBN
exhaustively  ||| S:19700 E:19721 ||| RB
tested  ||| S:19721 E:19728 ||| VBN
on  ||| S:19728 E:19731 ||| IN
all  ||| S:19731 E:19735 ||| DT
myosins ||| S:19735 E:19742 ||| NN
,  ||| S:19742 E:19744 ||| ,
and  ||| S:19744 E:19748 ||| CC
a  ||| S:19748 E:19750 ||| DT
myosin  ||| S:19750 E:19757 ||| JJ
target  ||| S:19757 E:19764 ||| NN
is  ||| S:19764 E:19767 ||| VBZ
not  ||| S:19767 E:19779 ||| RB
unreasonable  ||| S:19779 E:19792 ||| VB
given  ||| S:19792 E:19798 ||| VBN
findings  ||| S:19798 E:19807 ||| NNS
in  ||| S:19807 E:19810 ||| IN
Acanthomoeba  ||| S:19810 E:19823 ||| NNP
and  ||| S:19823 E:19836 ||| CC
S.  ||| S:19836 E:19839 ||| NNP
cerviseae  ||| S:19839 E:19849 ||| NN
though  ||| S:19849 E:19856 ||| IN
it  ||| S:19856 E:19859 ||| PRP
does  ||| S:19859 E:19864 ||| VBZ
not  ||| S:19864 E:19876 ||| RB
inhibit  ||| S:19876 E:19884 ||| VB
Acanthamoeba  ||| S:19884 E:19897 ||| NNP
myosinIc  ||| S:19897 E:19906 ||| NNP
or  ||| S:19906 E:19909 ||| CC
human  ||| S:19909 E:19915 ||| JJ
myoIe  ||| S:19915 E:19930 ||| NN
in  ||| S:19930 E:19933 ||| IN
vitro  ||| S:19933 E:19939 ||| NNS
[  ||| S:19939 E:19941 ||| -LRB-
10  ||| S:19941 E:19944 ||| CD
20  ||| S:19944 E:19947 ||| CD
21  ||| S:19947 E:19950 ||| CD
31  ||| S:19950 E:19953 ||| CD
]  ||| S:19953 E:19955 ||| -RRB-
.  ||| S:19955 E:19965 ||| .
Regardless ||| S:19965 E:19975 ||| RB
,  ||| S:19975 E:19977 ||| ,
we  ||| S:19977 E:19980 ||| PRP
and  ||| S:19980 E:19984 ||| CC
others  ||| S:19984 E:19991 ||| NNS
have  ||| S:19991 E:19996 ||| VBP
shown  ||| S:19996 E:20002 ||| VBN
that  ||| S:20002 E:20007 ||| IN
BDM  ||| S:20007 E:20011 ||| NNP
is  ||| S:20011 E:20014 ||| VBZ
not  ||| S:20014 E:20018 ||| RB
the  ||| S:20018 E:20030 ||| DT
tool  ||| S:20030 E:20035 ||| NN
that  ||| S:20035 E:20040 ||| WDT
should  ||| S:20040 E:20047 ||| MD
be  ||| S:20047 E:20050 ||| VB
used  ||| S:20050 E:20055 ||| VBN
to  ||| S:20055 E:20058 ||| TO
investigate  ||| S:20058 E:20070 ||| VB
these  ||| S:20070 E:20076 ||| DT
behaviours ||| S:20076 E:20086 ||| NN
.  ||| S:20086 E:20096 ||| .
The  ||| S:20096 E:20100 ||| DT
small  ||| S:20100 E:20106 ||| JJ
molecule  ||| S:20106 E:20115 ||| NN
approach  ||| S:20115 E:20124 ||| NN
continues  ||| S:20124 E:20134 ||| VBZ
to  ||| S:20134 E:20137 ||| TO
be  ||| S:20137 E:20140 ||| VB
an  ||| S:20140 E:20143 ||| DT
effective  ||| S:20143 E:20161 ||| JJ
means  ||| S:20161 E:20167 ||| NNS
to  ||| S:20167 E:20170 ||| TO
develop  ||| S:20170 E:20178 ||| VB
tools  ||| S:20178 E:20184 ||| NNS
for  ||| S:20184 E:20188 ||| IN
understanding  ||| S:20188 E:20202 ||| VBG
cell  ||| S:20202 E:20207 ||| NN
biological  ||| S:20207 E:20226 ||| JJ
process  ||| S:20226 E:20234 ||| NN
when  ||| S:20234 E:20239 ||| WRB
used  ||| S:20239 E:20244 ||| VBN
and  ||| S:20244 E:20248 ||| CC
interpreted  ||| S:20248 E:20260 ||| VBD
appropriately ||| S:20260 E:20273 ||| RB
.  ||| S:20273 E:20275 ||| .
One  ||| S:20275 E:20279 ||| CD
new  ||| S:20279 E:20291 ||| JJ
compound  ||| S:20291 E:20300 ||| NN
that  ||| S:20300 E:20305 ||| WDT
will  ||| S:20305 E:20310 ||| MD
help  ||| S:20310 E:20315 ||| VB
clarify  ||| S:20315 E:20323 ||| VB
the  ||| S:20323 E:20327 ||| DT
role  ||| S:20327 E:20332 ||| NN
of  ||| S:20332 E:20335 ||| IN
nm-myosinII  ||| S:20335 E:20347 ||| NNP
is  ||| S:20347 E:20358 ||| VBZ
blebbistatin  ||| S:20358 E:20371 ||| JJ
[  ||| S:20371 E:20373 ||| -LRB-
32  ||| S:20373 E:20376 ||| CD
]  ||| S:20376 E:20378 ||| -RRB-
.  ||| S:20378 E:20380 ||| .
Other  ||| S:20380 E:20386 ||| JJ
small  ||| S:20386 E:20392 ||| JJ
molecules  ||| S:20392 E:20402 ||| NNS
wait  ||| S:20402 E:20407 ||| VBP
to  ||| S:20407 E:20410 ||| TO
be  ||| S:20410 E:20421 ||| VB
found  ||| S:20421 E:20427 ||| VBN
and  ||| S:20427 E:20431 ||| CC
experiments  ||| S:20431 E:20443 ||| NNS
using  ||| S:20443 E:20449 ||| VBG
them  ||| S:20449 E:20454 ||| PRP
will  ||| S:20454 E:20459 ||| MD
continuously  ||| S:20459 E:20472 ||| RB
refine  ||| S:20472 E:20487 ||| VB
our  ||| S:20487 E:20491 ||| PRP$
understanding  ||| S:20491 E:20505 ||| NN
of  ||| S:20505 E:20508 ||| IN
the  ||| S:20508 E:20512 ||| DT
leading  ||| S:20512 E:20520 ||| JJ
edge  ||| S:20520 E:20525 ||| NN
and  ||| S:20525 E:20529 ||| CC
the  ||| S:20529 E:20533 ||| DT
mechanism  ||| S:20533 E:20543 ||| NN
of  ||| S:20543 E:20554 ||| IN
action  ||| S:20554 E:20561 ||| NN
of  ||| S:20561 E:20564 ||| IN
these  ||| S:20564 E:20570 ||| DT
compounds ||| S:20570 E:20579 ||| NN
.  ||| S:20579 E:20603 ||| .
Conclusions  ||| S:20603 E:20623 ||| NNS
De-localization  ||| S:20623 E:20639 ||| JJ
of  ||| S:20639 E:20642 ||| IN
actin  ||| S:20642 E:20648 ||| JJ
leading  ||| S:20648 E:20656 ||| JJ
edge  ||| S:20656 E:20661 ||| NN
components  ||| S:20661 E:20672 ||| NNS
by  ||| S:20672 E:20675 ||| IN
BDM  ||| S:20675 E:20687 ||| NNP
treatment  ||| S:20687 E:20697 ||| NN
is  ||| S:20697 E:20700 ||| VBZ
a  ||| S:20700 E:20702 ||| DT
newly  ||| S:20702 E:20708 ||| RB
described  ||| S:20708 E:20718 ||| VBN
effect  ||| S:20718 E:20725 ||| NN
of  ||| S:20725 E:20728 ||| IN
this  ||| S:20728 E:20733 ||| DT
compound ||| S:20733 E:20741 ||| NN
.  ||| S:20741 E:20743 ||| .
It  ||| S:20743 E:20754 ||| PRP
may  ||| S:20754 E:20758 ||| MD
explain  ||| S:20758 E:20766 ||| VB
results  ||| S:20766 E:20774 ||| NNS
previously  ||| S:20774 E:20785 ||| RB
ascribed  ||| S:20785 E:20794 ||| VBN
to  ||| S:20794 E:20797 ||| TO
inhibition  ||| S:20797 E:20808 ||| VB
of  ||| S:20808 E:20819 ||| IN
non-muscle  ||| S:20819 E:20830 ||| JJ
myosinII  ||| S:20830 E:20839 ||| NN
by  ||| S:20839 E:20842 ||| IN
BDM ||| S:20842 E:20845 ||| NNP
,  ||| S:20845 E:20847 ||| ,
particularly  ||| S:20847 E:20860 ||| RB
in  ||| S:20860 E:20863 ||| IN
retrograde  ||| S:20863 E:20874 ||| JJ
flow  ||| S:20874 E:20887 ||| NN
studies ||| S:20887 E:20894 ||| NNS
.  ||| S:20894 E:20896 ||| .
Though  ||| S:20896 E:20903 ||| IN
this  ||| S:20903 E:20908 ||| DT
effect  ||| S:20908 E:20915 ||| NN
of  ||| S:20915 E:20918 ||| IN
BDM  ||| S:20918 E:20922 ||| NNP
is  ||| S:20922 E:20925 ||| VBZ
intriguing ||| S:20925 E:20935 ||| JJ
,  ||| S:20935 E:20937 ||| ,
future  ||| S:20937 E:20952 ||| JJ
studies  ||| S:20952 E:20960 ||| NNS
that  ||| S:20960 E:20965 ||| WDT
look  ||| S:20965 E:20970 ||| VBP
at  ||| S:20970 E:20973 ||| IN
the  ||| S:20973 E:20977 ||| DT
establishment  ||| S:20977 E:20991 ||| NN
and  ||| S:20991 E:20995 ||| CC
maintenance  ||| S:20995 E:21007 ||| NN
of  ||| S:21007 E:21018 ||| IN
the  ||| S:21018 E:21022 ||| DT
actin  ||| S:21022 E:21028 ||| JJ
leading  ||| S:21028 E:21036 ||| JJ
edge  ||| S:21036 E:21041 ||| NN
should  ||| S:21041 E:21048 ||| MD
use  ||| S:21048 E:21052 ||| VB
more  ||| S:21052 E:21057 ||| RBR
potent  ||| S:21057 E:21064 ||| JJ
and  ||| S:21064 E:21068 ||| CC
specific  ||| S:21068 E:21085 ||| JJ
inhibitors ||| S:21085 E:21095 ||| NN
.  ||| S:21095 E:21119 ||| .
Methods  ||| S:21119 E:21146 ||| NNP
Platelet  ||| S:21146 E:21155 ||| NNP
myosinII  ||| S:21155 E:21164 ||| NNP
ATPase  ||| S:21164 E:21171 ||| NNP
assay  ||| S:21171 E:21187 ||| VBD
The  ||| S:21187 E:21191 ||| DT
assay  ||| S:21191 E:21197 ||| NN
was  ||| S:21197 E:21201 ||| VBD
performed  ||| S:21201 E:21211 ||| VBN
using  ||| S:21211 E:21217 ||| VBG
an  ||| S:21217 E:21220 ||| DT
EnzCheck  ||| S:21220 E:21229 ||| JJ
phosphate  ||| S:21229 E:21249 ||| JJ
release  ||| S:21249 E:21257 ||| NN
assay  ||| S:21257 E:21263 ||| NNS
( ||| S:21263 E:21264 ||| -LRB-
Molecular  ||| S:21264 E:21274 ||| NNP
Probes ||| S:21274 E:21280 ||| NNP
) ||| S:21280 E:21281 ||| -RRB-
.  ||| S:21281 E:21283 ||| .
Platelet  ||| S:21283 E:21292 ||| NNP
myosinII  ||| S:21292 E:21301 ||| NNP
S1  ||| S:21301 E:21314 ||| NNP
was  ||| S:21314 E:21318 ||| VBD
diluted  ||| S:21318 E:21326 ||| VBN
to  ||| S:21326 E:21329 ||| TO
0.050  ||| S:21329 E:21335 ||| CD
mg ||| S:21335 E:21337 ||| CD
/ ||| S:21337 E:21338 ||| CD
ml  ||| S:21338 E:21341 ||| NN
in  ||| S:21341 E:21344 ||| IN
reaction  ||| S:21344 E:21353 ||| NN
buffer  ||| S:21353 E:21360 ||| NN
( ||| S:21360 E:21361 ||| -LRB-
0.2  ||| S:21361 E:21365 ||| CD
M  ||| S:21365 E:21367 ||| NNP
KCl ||| S:21367 E:21370 ||| NNP
,  ||| S:21370 E:21382 ||| ,
10  ||| S:21382 E:21385 ||| CD
mM  ||| S:21385 E:21388 ||| JJ
Tris  ||| S:21388 E:21393 ||| NNP
pH  ||| S:21393 E:21396 ||| NNP
7.0 ||| S:21396 E:21399 ||| NNP
,  ||| S:21399 E:21401 ||| ,
10  ||| S:21401 E:21404 ||| CD
mM  ||| S:21404 E:21407 ||| JJ
CaCl  ||| S:21407 E:21423 ||| JJ
2  ||| S:21423 E:21425 ||| CD
,  ||| S:21425 E:21427 ||| ,
2  ||| S:21427 E:21429 ||| CD
mM  ||| S:21429 E:21432 ||| JJ
MgCl  ||| S:21432 E:21448 ||| JJ
2  ||| S:21448 E:21450 ||| CD
,  ||| S:21450 E:21452 ||| ,
1  ||| S:21452 E:21454 ||| CD
mM  ||| S:21454 E:21457 ||| JJ
DTT ||| S:21457 E:21460 ||| NNP
,  ||| S:21460 E:21462 ||| ,
0.2  ||| S:21462 E:21466 ||| CD
mM  ||| S:21466 E:21479 ||| JJ
2-amino-6-mercapto-7-methyl  ||| S:21479 E:21507 ||| FW
purine  ||| S:21507 E:21514 ||| FW
riboside  ||| S:21514 E:21523 ||| FW
( ||| S:21523 E:21524 ||| -LRB-
MESG ||| S:21524 E:21528 ||| NNP
)  ||| S:21528 E:21530 ||| -RRB-
in  ||| S:21530 E:21533 ||| IN
the  ||| S:21533 E:21547 ||| DT
presence  ||| S:21547 E:21556 ||| NN
of  ||| S:21556 E:21559 ||| IN
1  ||| S:21559 E:21561 ||| CD
U  ||| S:21561 E:21563 ||| NNP
purine  ||| S:21563 E:21570 ||| FW
nucleoside  ||| S:21570 E:21581 ||| FW
phosphorylase  ||| S:21581 E:21595 ||| FW
( ||| S:21595 E:21596 ||| -LRB-
PNP ||| S:21596 E:21599 ||| NNP
) ||| S:21599 E:21600 ||| -RRB-
) ||| S:21600 E:21601 ||| -RRB-
.  ||| S:21601 E:21613 ||| .
DMSO ||| S:21613 E:21617 ||| NNP
,  ||| S:21617 E:21619 ||| ,
20  ||| S:21619 E:21622 ||| CD
mM  ||| S:21622 E:21625 ||| JJ
BDM ||| S:21625 E:21628 ||| NNP
,  ||| S:21628 E:21630 ||| ,
or  ||| S:21630 E:21633 ||| CC
100  ||| S:21633 E:21637 ||| CD
uM  ||| S:21637 E:21640 ||| JJ
blebbistatin  ||| S:21640 E:21653 ||| NN
was  ||| S:21653 E:21657 ||| VBD
added  ||| S:21657 E:21663 ||| VBN
to  ||| S:21663 E:21666 ||| TO
the  ||| S:21666 E:21680 ||| DT
reactions  ||| S:21680 E:21690 ||| NNS
with  ||| S:21690 E:21695 ||| IN
a  ||| S:21695 E:21697 ||| DT
constant  ||| S:21697 E:21706 ||| JJ
DMSO  ||| S:21706 E:21711 ||| NNP
concentration  ||| S:21711 E:21725 ||| NN
of  ||| S:21725 E:21728 ||| IN
1 ||| S:21728 E:21729 ||| CD
% ||| S:21729 E:21730 ||| NN
.  ||| S:21730 E:21732 ||| .
ATP  ||| S:21732 E:21746 ||| NNP
( ||| S:21746 E:21747 ||| -LRB-
100  ||| S:21747 E:21751 ||| CD
uM ||| S:21751 E:21753 ||| NN
)  ||| S:21753 E:21755 ||| -RRB-
was  ||| S:21755 E:21759 ||| VBD
added  ||| S:21759 E:21765 ||| VBN
to  ||| S:21765 E:21768 ||| TO
initiate  ||| S:21768 E:21777 ||| VB
the  ||| S:21777 E:21781 ||| DT
reaction  ||| S:21781 E:21790 ||| NN
and  ||| S:21790 E:21804 ||| CC
absorbance  ||| S:21804 E:21815 ||| NN
at  ||| S:21815 E:21818 ||| IN
360  ||| S:21818 E:21822 ||| CD
nm  ||| S:21822 E:21825 ||| NNS
was  ||| S:21825 E:21829 ||| VBD
read  ||| S:21829 E:21834 ||| VBN
every  ||| S:21834 E:21840 ||| DT
~6  ||| S:21840 E:21843 ||| CD
seconds  ||| S:21843 E:21851 ||| NNS
for  ||| S:21851 E:21855 ||| IN
20  ||| S:21855 E:21868 ||| CD
minutes ||| S:21868 E:21875 ||| NNS
.  ||| S:21875 E:21877 ||| .
BDM  ||| S:21877 E:21881 ||| NNP
showed  ||| S:21881 E:21888 ||| VBD
no  ||| S:21888 E:21891 ||| DT
effect  ||| S:21891 E:21898 ||| NN
on  ||| S:21898 E:21901 ||| IN
ATP  ||| S:21901 E:21905 ||| NNP
hydrolysis  ||| S:21905 E:21916 ||| NN
in  ||| S:21916 E:21919 ||| IN
the  ||| S:21919 E:21933 ||| DT
absence  ||| S:21933 E:21941 ||| NN
of  ||| S:21941 E:21944 ||| IN
myosin ||| S:21944 E:21950 ||| NN
.  ||| S:21950 E:21980 ||| .
Tissue  ||| S:21980 E:21987 ||| NNP
Culture  ||| S:21987 E:22005 ||| NNP
BS-C-1  ||| S:22005 E:22012 ||| NNP
cells  ||| S:22012 E:22018 ||| NNS
and  ||| S:22018 E:22022 ||| CC
Swiss3T3  ||| S:22022 E:22031 ||| CD
cells  ||| S:22031 E:22037 ||| NNS
were  ||| S:22037 E:22042 ||| VBD
acquired  ||| S:22042 E:22051 ||| VBN
from  ||| S:22051 E:22056 ||| IN
the  ||| S:22056 E:22070 ||| DT
ATCC  ||| S:22070 E:22075 ||| NNP
( ||| S:22075 E:22076 ||| -LRB-
CCL-26 ||| S:22076 E:22082 ||| NNP
,  ||| S:22082 E:22084 ||| ,
CCL-92 ||| S:22084 E:22090 ||| CD
) ||| S:22090 E:22091 ||| -RRB-
.  ||| S:22091 E:22093 ||| .
Cells  ||| S:22093 E:22099 ||| NNS
were  ||| S:22099 E:22104 ||| VBD
maintained  ||| S:22104 E:22115 ||| VBN
in  ||| S:22115 E:22128 ||| IN
Dulbecco ||| S:22128 E:22136 ||| NNP
's  ||| S:22136 E:22139 ||| POS
Modified  ||| S:22139 E:22148 ||| NNP
Essential  ||| S:22148 E:22158 ||| NNP
Medium  ||| S:22158 E:22165 ||| NNP
with  ||| S:22165 E:22170 ||| IN
4.5  ||| S:22170 E:22174 ||| CD
g ||| S:22174 E:22175 ||| CD
/ ||| S:22175 E:22176 ||| CD
L  ||| S:22176 E:22188 ||| NNP
glucose ||| S:22188 E:22195 ||| NN
,  ||| S:22195 E:22197 ||| ,
10 ||| S:22197 E:22199 ||| CD
%  ||| S:22199 E:22201 ||| NN
fetal  ||| S:22201 E:22207 ||| JJ
calf  ||| S:22207 E:22212 ||| JJ
serum ||| S:22212 E:22217 ||| NN
,  ||| S:22217 E:22219 ||| ,
and  ||| S:22219 E:22233 ||| CC
penicillin ||| S:22233 E:22243 ||| CD
/ ||| S:22243 E:22244 ||| CD
streptomycin ||| S:22244 E:22256 ||| NNS
.  ||| S:22256 E:22258 ||| .
Cells  ||| S:22258 E:22264 ||| NNS
were  ||| S:22264 E:22269 ||| VBD
maintained  ||| S:22269 E:22280 ||| VBN
at  ||| S:22280 E:22283 ||| IN
37C  ||| S:22283 E:22298 ||| CD
with  ||| S:22298 E:22303 ||| IN
5 ||| S:22303 E:22304 ||| CD
%  ||| S:22304 E:22306 ||| NN
CO  ||| S:22306 E:22320 ||| NNP
2  ||| S:22320 E:22322 ||| CD
.  ||| S:22322 E:22352 ||| .
Permeabilized  ||| S:22352 E:22366 ||| JJ
cell  ||| S:22366 E:22371 ||| NN
assay  ||| S:22371 E:22387 ||| VBZ
Permeabilized  ||| S:22387 E:22401 ||| JJ
cell  ||| S:22401 E:22406 ||| NN
assays  ||| S:22406 E:22413 ||| NNS
were  ||| S:22413 E:22418 ||| VBD
performed  ||| S:22418 E:22428 ||| VBN
in  ||| S:22428 E:22431 ||| IN
flow  ||| S:22431 E:22446 ||| NN
chambers  ||| S:22446 E:22455 ||| NNS
as  ||| S:22455 E:22458 ||| IN
previously  ||| S:22458 E:22469 ||| RB
described  ||| S:22469 E:22479 ||| VBN
[  ||| S:22479 E:22481 ||| -LRB-
22  ||| S:22481 E:22484 ||| CD
]  ||| S:22484 E:22486 ||| -RRB-
.  ||| S:22486 E:22488 ||| .
Swiss3T3  ||| S:22488 E:22497 ||| NNP
cells  ||| S:22497 E:22513 ||| NNS
were  ||| S:22513 E:22518 ||| VBD
flowed  ||| S:22518 E:22525 ||| VBN
into  ||| S:22525 E:22530 ||| IN
the  ||| S:22530 E:22534 ||| DT
chamber ||| S:22534 E:22541 ||| NN
,  ||| S:22541 E:22543 ||| ,
the  ||| S:22543 E:22547 ||| DT
chamber  ||| S:22547 E:22555 ||| NN
inverted ||| S:22555 E:22563 ||| NN
,  ||| S:22563 E:22565 ||| ,
and  ||| S:22565 E:22579 ||| CC
cells  ||| S:22579 E:22585 ||| NNS
allowed  ||| S:22585 E:22593 ||| VBN
to  ||| S:22593 E:22596 ||| TO
spread  ||| S:22596 E:22603 ||| VB
for  ||| S:22603 E:22607 ||| IN
30-45  ||| S:22607 E:22613 ||| CD
minutes  ||| S:22613 E:22621 ||| NNS
in  ||| S:22621 E:22624 ||| IN
a  ||| S:22624 E:22626 ||| DT
humidified  ||| S:22626 E:22647 ||| JJ
environment  ||| S:22647 E:22659 ||| NN
at  ||| S:22659 E:22662 ||| IN
37C ||| S:22662 E:22666 ||| NNP
,  ||| S:22666 E:22668 ||| ,
5 ||| S:22668 E:22669 ||| CD
%  ||| S:22669 E:22671 ||| NN
CO  ||| S:22671 E:22685 ||| NNP
2  ||| S:22685 E:22687 ||| CD
.  ||| S:22687 E:22689 ||| .
The  ||| S:22689 E:22693 ||| DT
assay  ||| S:22693 E:22699 ||| NN
was  ||| S:22699 E:22703 ||| VBD
performed  ||| S:22703 E:22713 ||| VBN
by  ||| S:22713 E:22716 ||| IN
adding  ||| S:22716 E:22733 ||| VBG
50  ||| S:22733 E:22736 ||| CD
ul  ||| S:22736 E:22739 ||| NN
of  ||| S:22739 E:22742 ||| IN
the  ||| S:22742 E:22746 ||| DT
warmed  ||| S:22746 E:22753 ||| JJ
sample  ||| S:22753 E:22760 ||| NN
solution  ||| S:22760 E:22769 ||| NN
to  ||| S:22769 E:22772 ||| TO
the  ||| S:22772 E:22776 ||| DT
chamber  ||| S:22776 E:22784 ||| NN
while  ||| S:22784 E:22800 ||| IN
wicking  ||| S:22800 E:22808 ||| NN
with  ||| S:22808 E:22813 ||| IN
Whatman  ||| S:22813 E:22821 ||| NNP
paper ||| S:22821 E:22826 ||| NN
.  ||| S:22826 E:22828 ||| .
Cells  ||| S:22828 E:22834 ||| NNS
were  ||| S:22834 E:22839 ||| VBD
rinsed  ||| S:22839 E:22846 ||| VBN
with  ||| S:22846 E:22851 ||| IN
PBS ||| S:22851 E:22854 ||| NNP
,  ||| S:22854 E:22866 ||| ,
treated  ||| S:22866 E:22874 ||| VBN
with  ||| S:22874 E:22879 ||| IN
compounds  ||| S:22879 E:22889 ||| NN
or  ||| S:22889 E:22892 ||| CC
media  ||| S:22892 E:22898 ||| NNS
for  ||| S:22898 E:22902 ||| IN
1  ||| S:22902 E:22904 ||| CD
min ||| S:22904 E:22907 ||| NN
,  ||| S:22907 E:22909 ||| ,
permeabilized  ||| S:22909 E:22933 ||| VBG
in  ||| S:22933 E:22936 ||| IN
the  ||| S:22936 E:22940 ||| DT
presence  ||| S:22940 E:22949 ||| NN
or  ||| S:22949 E:22952 ||| CC
absence  ||| S:22952 E:22960 ||| NN
of  ||| S:22960 E:22963 ||| IN
compound  ||| S:22963 E:22972 ||| NN
for  ||| S:22972 E:22976 ||| IN
3  ||| S:22976 E:22978 ||| CD
min  ||| S:22978 E:22982 ||| NN
with  ||| S:22982 E:22997 ||| IN
permeabilization  ||| S:22997 E:23014 ||| JJ
buffer  ||| S:23014 E:23021 ||| NN
( ||| S:23021 E:23022 ||| -LRB-
0.02  ||| S:23022 E:23027 ||| CD
g ||| S:23027 E:23028 ||| CD
/ ||| S:23028 E:23029 ||| CD
ml  ||| S:23029 E:23032 ||| NN
of  ||| S:23032 E:23035 ||| IN
saponin ||| S:23035 E:23042 ||| NN
,  ||| S:23042 E:23044 ||| ,
20  ||| S:23044 E:23047 ||| CD
mM  ||| S:23047 E:23060 ||| JJ
HEPES  ||| S:23060 E:23066 ||| NNP
( ||| S:23066 E:23067 ||| -LRB-
pH  ||| S:23067 E:23070 ||| NNP
7.5 ||| S:23070 E:23073 ||| CD
) ||| S:23073 E:23074 ||| -RRB-
,  ||| S:23074 E:23076 ||| ,
138  ||| S:23076 E:23080 ||| CD
mM  ||| S:23080 E:23083 ||| JJ
KCl ||| S:23083 E:23086 ||| NN
,  ||| S:23086 E:23088 ||| ,
4  ||| S:23088 E:23090 ||| CD
mM  ||| S:23090 E:23093 ||| JJ
MgCl  ||| S:23093 E:23109 ||| JJ
2  ||| S:23109 E:23111 ||| CD
,  ||| S:23111 E:23113 ||| ,
3  ||| S:23113 E:23115 ||| CD
mM  ||| S:23115 E:23118 ||| JJ
ETGA ||| S:23118 E:23122 ||| NNP
,  ||| S:23122 E:23124 ||| ,
1  ||| S:23124 E:23126 ||| CD
mM  ||| S:23126 E:23129 ||| JJ
DTT  ||| S:23129 E:23133 ||| FW
+  ||| S:23133 E:23135 ||| FW
protease  ||| S:23135 E:23154 ||| FW
inhibitors ||| S:23154 E:23164 ||| FW
,  ||| S:23164 E:23166 ||| ,
0.4  ||| S:23166 E:23170 ||| CD
uM  ||| S:23170 E:23173 ||| JJ
rhodamine  ||| S:23173 E:23183 ||| JJ
actin ||| S:23183 E:23188 ||| NN
,  ||| S:23188 E:23190 ||| ,
1  ||| S:23190 E:23192 ||| CD
mM  ||| S:23192 E:23195 ||| JJ
ATP ||| S:23195 E:23198 ||| NNP
) ||| S:23198 E:23199 ||| -RRB-
,  ||| S:23199 E:23201 ||| ,
and  ||| S:23201 E:23205 ||| CC
fixed  ||| S:23205 E:23221 ||| VBN
in  ||| S:23221 E:23224 ||| IN
PBS  ||| S:23224 E:23228 ||| NNP
+  ||| S:23228 E:23230 ||| CD
3.7 ||| S:23230 E:23233 ||| CD
%  ||| S:23233 E:23235 ||| NN
formaldehyde  ||| S:23235 E:23248 ||| NN
for  ||| S:23248 E:23252 ||| IN
10  ||| S:23252 E:23255 ||| CD
min ||| S:23255 E:23258 ||| NNS
.  ||| S:23258 E:23288 ||| .
Listeria  ||| S:23288 E:23297 ||| FW
infection  ||| S:23297 E:23328 ||| FW
Listeria  ||| S:23328 E:23337 ||| FW
monocytogenes  ||| S:23337 E:23351 ||| FW
( ||| S:23351 E:23352 ||| -LRB-
strain  ||| S:23352 E:23369 ||| FW
10403S ||| S:23369 E:23375 ||| FW
)  ||| S:23375 E:23377 ||| -RRB-
were  ||| S:23377 E:23382 ||| VBD
grown  ||| S:23382 E:23388 ||| VBN
overnight  ||| S:23388 E:23398 ||| JJ
in  ||| S:23398 E:23401 ||| IN
3  ||| S:23401 E:23403 ||| CD
mls  ||| S:23403 E:23407 ||| NN
of  ||| S:23407 E:23410 ||| IN
Brain  ||| S:23410 E:23416 ||| NNP
Heart  ||| S:23416 E:23432 ||| NNP
Infusion  ||| S:23432 E:23441 ||| NNP
media  ||| S:23441 E:23447 ||| NNS
at  ||| S:23447 E:23450 ||| IN
room  ||| S:23450 E:23455 ||| NN
temp  ||| S:23455 E:23460 ||| NN
without  ||| S:23460 E:23468 ||| IN
shaking ||| S:23468 E:23475 ||| VBG
.  ||| S:23475 E:23477 ||| .
BS-C-1  ||| S:23477 E:23484 ||| NNP
cells  ||| S:23484 E:23500 ||| NNS
on  ||| S:23500 E:23503 ||| IN
25  ||| S:23503 E:23506 ||| CD
mm  ||| S:23506 E:23509 ||| CD
poly-L-lysine  ||| S:23509 E:23523 ||| NNS
( ||| S:23523 E:23524 ||| -LRB-
PLL ||| S:23524 E:23527 ||| NNP
)  ||| S:23527 E:23529 ||| -RRB-
coverslips  ||| S:23529 E:23540 ||| NN
were  ||| S:23540 E:23545 ||| VBD
rinsed  ||| S:23545 E:23552 ||| VBN
with  ||| S:23552 E:23567 ||| IN
media  ||| S:23567 E:23573 ||| NNS
containing  ||| S:23573 E:23584 ||| VBG
no  ||| S:23584 E:23587 ||| DT
antibiotics  ||| S:23587 E:23599 ||| NN
and  ||| S:23599 E:23603 ||| CC
placed  ||| S:23603 E:23610 ||| VBN
in  ||| S:23610 E:23613 ||| IN
a  ||| S:23613 E:23615 ||| DT
6  ||| S:23615 E:23617 ||| CD
well  ||| S:23617 E:23632 ||| NN
plate ||| S:23632 E:23637 ||| NN
.  ||| S:23637 E:23650 ||| .
Listeria  ||| S:23650 E:23659 ||| NNP
were  ||| S:23659 E:23664 ||| VBD
prepared  ||| S:23664 E:23673 ||| VBN
by  ||| S:23673 E:23676 ||| IN
removing  ||| S:23676 E:23695 ||| VBG
1  ||| S:23695 E:23697 ||| CD
ml  ||| S:23697 E:23700 ||| NN
of  ||| S:23700 E:23703 ||| IN
the  ||| S:23703 E:23707 ||| DT
overnight  ||| S:23707 E:23717 ||| JJ
culture ||| S:23717 E:23724 ||| NN
,  ||| S:23724 E:23726 ||| ,
pelleting  ||| S:23726 E:23736 ||| VBG
by  ||| S:23736 E:23739 ||| IN
a  ||| S:23739 E:23741 ||| DT
1  ||| S:23741 E:23743 ||| CD
min  ||| S:23743 E:23757 ||| FW
Eppendorf  ||| S:23757 E:23767 ||| FW
centrifuge  ||| S:23767 E:23778 ||| FW
spin ||| S:23778 E:23782 ||| FW
,  ||| S:23782 E:23784 ||| ,
washing  ||| S:23784 E:23792 ||| VBG
the  ||| S:23792 E:23796 ||| DT
pellet  ||| S:23796 E:23803 ||| NN
twice  ||| S:23803 E:23809 ||| RB
with  ||| S:23809 E:23824 ||| IN
antibiotic-free  ||| S:23824 E:23840 ||| JJ
media ||| S:23840 E:23845 ||| NNS
,  ||| S:23845 E:23847 ||| ,
and  ||| S:23847 E:23851 ||| CC
resuspending  ||| S:23851 E:23864 ||| NN
in  ||| S:23864 E:23867 ||| IN
1  ||| S:23867 E:23869 ||| CD
ml  ||| S:23869 E:23872 ||| NN
of  ||| S:23872 E:23875 ||| IN
media.  ||| S:23875 E:23892 ||| CD
10  ||| S:23892 E:23895 ||| CD
ul  ||| S:23895 E:23898 ||| NN
of  ||| S:23898 E:23901 ||| IN
Listeria  ||| S:23901 E:23910 ||| NNP
were  ||| S:23910 E:23915 ||| VBD
added  ||| S:23915 E:23921 ||| VBN
to  ||| S:23921 E:23924 ||| TO
each  ||| S:23924 E:23929 ||| DT
well  ||| S:23929 E:23934 ||| RB
and  ||| S:23934 E:23938 ||| CC
were  ||| S:23938 E:23953 ||| VBD
allowed  ||| S:23953 E:23961 ||| VBN
to  ||| S:23961 E:23964 ||| TO
infect  ||| S:23964 E:23971 ||| VB
for  ||| S:23971 E:23975 ||| IN
1.5  ||| S:23975 E:23979 ||| CD
hrs  ||| S:23979 E:23983 ||| NNS
prior  ||| S:23983 E:23989 ||| RB
to  ||| S:23989 E:23992 ||| TO
the  ||| S:23992 E:23996 ||| DT
addition  ||| S:23996 E:24005 ||| NN
of  ||| S:24005 E:24018 ||| IN
media  ||| S:24018 E:24024 ||| NNS
containing  ||| S:24024 E:24035 ||| VBG
50  ||| S:24035 E:24038 ||| CD
ug ||| S:24038 E:24040 ||| FW
/ ||| S:24040 E:24041 ||| FW
ml  ||| S:24041 E:24044 ||| FW
Gentamicin ||| S:24044 E:24054 ||| FW
.  ||| S:24054 E:24056 ||| .
Cells  ||| S:24056 E:24062 ||| NNS
were  ||| S:24062 E:24067 ||| VBD
imaged  ||| S:24067 E:24084 ||| VBN
between  ||| S:24084 E:24092 ||| IN
4  ||| S:24092 E:24094 ||| CD
hrs  ||| S:24094 E:24098 ||| NNS
and  ||| S:24098 E:24102 ||| CC
12  ||| S:24102 E:24105 ||| CD
hrs  ||| S:24105 E:24109 ||| NNS
later ||| S:24109 E:24114 ||| RB
.  ||| S:24114 E:24144 ||| .
Compound  ||| S:24144 E:24153 ||| JJ
treatment  ||| S:24153 E:24163 ||| NN
for  ||| S:24163 E:24167 ||| IN
immunofluorescence  ||| S:24167 E:24196 ||| JJ
Cells  ||| S:24196 E:24202 ||| NNP
were  ||| S:24202 E:24207 ||| VBD
allowed  ||| S:24207 E:24215 ||| VBN
to  ||| S:24215 E:24218 ||| TO
spread  ||| S:24218 E:24225 ||| VB
on  ||| S:24225 E:24228 ||| IN
18  ||| S:24228 E:24231 ||| CD
mm  ||| S:24231 E:24234 ||| JJ
round  ||| S:24234 E:24240 ||| NN
PLL  ||| S:24240 E:24254 ||| NNP
coverslips  ||| S:24254 E:24265 ||| NN
in  ||| S:24265 E:24268 ||| IN
a  ||| S:24268 E:24270 ||| DT
12  ||| S:24270 E:24273 ||| CD
well  ||| S:24273 E:24278 ||| NN
plate  ||| S:24278 E:24284 ||| NN
for  ||| S:24284 E:24288 ||| IN
30-45  ||| S:24288 E:24294 ||| CD
minutes  ||| S:24294 E:24302 ||| NNS
or  ||| S:24302 E:24305 ||| CC
2-4  ||| S:24305 E:24319 ||| CD
hours  ||| S:24319 E:24325 ||| NNS
prior  ||| S:24325 E:24331 ||| RB
to  ||| S:24331 E:24334 ||| TO
treatment ||| S:24334 E:24343 ||| NN
.  ||| S:24343 E:24345 ||| .
BDM  ||| S:24345 E:24349 ||| NNP
( ||| S:24349 E:24350 ||| -LRB-
Calbiochem  ||| S:24350 E:24361 ||| NNP
203984 ||| S:24361 E:24367 ||| CD
)  ||| S:24367 E:24369 ||| -RRB-
stock  ||| S:24369 E:24385 ||| NN
solution  ||| S:24385 E:24394 ||| NN
was  ||| S:24394 E:24398 ||| VBD
made  ||| S:24398 E:24403 ||| VBN
in  ||| S:24403 E:24406 ||| IN
media  ||| S:24406 E:24412 ||| NNS
at  ||| S:24412 E:24415 ||| IN
0.5  ||| S:24415 E:24419 ||| CD
M  ||| S:24419 E:24421 ||| NNP
and  ||| S:24421 E:24425 ||| CC
Cytochalasin  ||| S:24425 E:24438 ||| NNP
D  ||| S:24438 E:24450 ||| NNP
( ||| S:24450 E:24451 ||| -LRB-
Sigma  ||| S:24451 E:24457 ||| NNP
C8273 ||| S:24457 E:24462 ||| NNP
)  ||| S:24462 E:24464 ||| -RRB-
in  ||| S:24464 E:24467 ||| IN
DMSO  ||| S:24467 E:24472 ||| NNP
at  ||| S:24472 E:24475 ||| IN
20  ||| S:24475 E:24478 ||| CD
mM ||| S:24478 E:24480 ||| NN
.  ||| S:24480 E:24482 ||| .
With  ||| S:24482 E:24487 ||| IN
the  ||| S:24487 E:24491 ||| DT
plate  ||| S:24491 E:24497 ||| NN
on  ||| S:24497 E:24500 ||| IN
a  ||| S:24500 E:24502 ||| DT
37C  ||| S:24502 E:24517 ||| JJ
heat  ||| S:24517 E:24522 ||| NN
block ||| S:24522 E:24527 ||| NN
,  ||| S:24527 E:24529 ||| ,
appropriately  ||| S:24529 E:24543 ||| RB
diluted  ||| S:24543 E:24551 ||| VBN
concentrations  ||| S:24551 E:24566 ||| NNS
of  ||| S:24566 E:24569 ||| IN
each  ||| S:24569 E:24584 ||| DT
compound  ||| S:24584 E:24593 ||| NN
( ||| S:24593 E:24594 ||| -LRB-
15  ||| S:24594 E:24597 ||| CD
or  ||| S:24597 E:24600 ||| CC
20  ||| S:24600 E:24603 ||| CD
mM  ||| S:24603 E:24606 ||| JJ
BDM ||| S:24606 E:24609 ||| NNP
,  ||| S:24609 E:24611 ||| ,
1  ||| S:24611 E:24613 ||| CD
uM  ||| S:24613 E:24616 ||| JJ
cytochalasin  ||| S:24616 E:24629 ||| JJ
D ||| S:24629 E:24630 ||| NNP
)  ||| S:24630 E:24632 ||| -RRB-
were  ||| S:24632 E:24637 ||| VBD
made  ||| S:24637 E:24652 ||| VBN
in  ||| S:24652 E:24655 ||| IN
warmed  ||| S:24655 E:24662 ||| JJ
media  ||| S:24662 E:24668 ||| NNS
and  ||| S:24668 E:24672 ||| CC
added  ||| S:24672 E:24678 ||| VBD
to  ||| S:24678 E:24681 ||| TO
cells  ||| S:24681 E:24687 ||| NNS
after  ||| S:24687 E:24693 ||| IN
removal  ||| S:24693 E:24701 ||| NN
of  ||| S:24701 E:24714 ||| IN
existing  ||| S:24714 E:24723 ||| VBG
media ||| S:24723 E:24728 ||| NNS
.  ||| S:24728 E:24730 ||| .
After  ||| S:24730 E:24736 ||| IN
1  ||| S:24736 E:24738 ||| CD
minute ||| S:24738 E:24744 ||| NN
,  ||| S:24744 E:24746 ||| ,
the  ||| S:24746 E:24750 ||| DT
cells  ||| S:24750 E:24756 ||| NNS
were  ||| S:24756 E:24761 ||| VBD
fixed  ||| S:24761 E:24767 ||| VBN
for  ||| S:24767 E:24781 ||| IN
immunoflourescence  ||| S:24781 E:24800 ||| VBG
as  ||| S:24800 E:24803 ||| RB
described  ||| S:24803 E:24813 ||| VBN
below ||| S:24813 E:24818 ||| RB
.  ||| S:24818 E:24848 ||| .
Immunofluorescence  ||| S:24848 E:24877 ||| NNP
Cells  ||| S:24877 E:24883 ||| NNP
were  ||| S:24883 E:24888 ||| VBD
fixed  ||| S:24888 E:24894 ||| VBN
in  ||| S:24894 E:24897 ||| IN
a  ||| S:24897 E:24899 ||| DT
permeabilization ||| S:24899 E:24915 ||| FW
/ ||| S:24915 E:24916 ||| FW
fixation  ||| S:24916 E:24925 ||| FW
buffer  ||| S:24925 E:24942 ||| FW
( ||| S:24942 E:24943 ||| -LRB-
100  ||| S:24943 E:24947 ||| CD
mM  ||| S:24947 E:24950 ||| JJ
K-Pipes  ||| S:24950 E:24958 ||| JJ
pH  ||| S:24958 E:24961 ||| JJ
6.8 ||| S:24961 E:24964 ||| CD
,  ||| S:24964 E:24966 ||| ,
10  ||| S:24966 E:24969 ||| CD
mM  ||| S:24969 E:24972 ||| JJ
EGTA ||| S:24972 E:24976 ||| NNP
,  ||| S:24976 E:24978 ||| ,
1  ||| S:24978 E:24980 ||| CD
mM  ||| S:24980 E:24983 ||| JJ
MgCL2 ||| S:24983 E:24988 ||| NN
,  ||| S:24988 E:24990 ||| ,
0.2 ||| S:24990 E:24993 ||| CD
%  ||| S:24993 E:25005 ||| NN
TritonX-100 ||| S:25005 E:25016 ||| NN
,  ||| S:25016 E:25018 ||| ,
3.7 ||| S:25018 E:25021 ||| CD
%  ||| S:25021 E:25023 ||| NN
formaldehyde ||| S:25023 E:25035 ||| NN
)  ||| S:25035 E:25037 ||| -RRB-
for  ||| S:25037 E:25041 ||| IN
10  ||| S:25041 E:25044 ||| CD
minutes ||| S:25044 E:25051 ||| NNS
.  ||| S:25051 E:25053 ||| .
For  ||| S:25053 E:25057 ||| IN
Arp3  ||| S:25057 E:25072 ||| CD
immunofluorescence ||| S:25072 E:25090 ||| NN
,  ||| S:25090 E:25092 ||| ,
cells  ||| S:25092 E:25098 ||| NNS
were  ||| S:25098 E:25103 ||| VBD
post-fixed  ||| S:25103 E:25114 ||| JJ
in  ||| S:25114 E:25117 ||| IN
methanol  ||| S:25117 E:25136 ||| NN
( ||| S:25136 E:25137 ||| -LRB-
-20C ||| S:25137 E:25142 ||| NNP
)  ||| S:25142 E:25144 ||| -RRB-
for  ||| S:25144 E:25148 ||| IN
2  ||| S:25148 E:25150 ||| CD
minutes ||| S:25150 E:25157 ||| NNS
.  ||| S:25157 E:25159 ||| .
Coverslips  ||| S:25159 E:25170 ||| NNP
were  ||| S:25170 E:25175 ||| VBD
rinsed  ||| S:25175 E:25182 ||| VBN
with  ||| S:25182 E:25187 ||| IN
TBS  ||| S:25187 E:25201 ||| NNP
containing  ||| S:25201 E:25212 ||| VBG
0.1 ||| S:25212 E:25215 ||| CD
%  ||| S:25215 E:25217 ||| NN
Triton  ||| S:25217 E:25224 ||| NNP
X-100  ||| S:25224 E:25230 ||| NNP
( ||| S:25230 E:25231 ||| -LRB-
TBS-Tx ||| S:25231 E:25237 ||| NNP
)  ||| S:25237 E:25239 ||| -RRB-
and  ||| S:25239 E:25243 ||| CC
blocked  ||| S:25243 E:25251 ||| VBN
in  ||| S:25251 E:25264 ||| IN
TBS-Tx  ||| S:25264 E:25271 ||| JJ
with  ||| S:25271 E:25276 ||| IN
2 ||| S:25276 E:25277 ||| CD
%  ||| S:25277 E:25279 ||| NN
BSA  ||| S:25279 E:25283 ||| NNP
( ||| S:25283 E:25284 ||| -LRB-
AbDil ||| S:25284 E:25289 ||| NNP
)  ||| S:25289 E:25291 ||| -RRB-
for  ||| S:25291 E:25295 ||| IN
45  ||| S:25295 E:25298 ||| CD
minutes ||| S:25298 E:25305 ||| NNS
.  ||| S:25305 E:25307 ||| .
Antibodies  ||| S:25307 E:25328 ||| NNS
were  ||| S:25328 E:25333 ||| VBD
diluted  ||| S:25333 E:25341 ||| VBN
in  ||| S:25341 E:25344 ||| IN
AbDil  ||| S:25344 E:25350 ||| JJ
and  ||| S:25350 E:25354 ||| CC
incubated  ||| S:25354 E:25364 ||| NN
for  ||| S:25364 E:25368 ||| IN
45  ||| S:25368 E:25371 ||| CD
minutes ||| S:25371 E:25378 ||| NNS
.  ||| S:25378 E:25390 ||| .
Coverslips  ||| S:25390 E:25401 ||| NNP
were  ||| S:25401 E:25406 ||| VBD
rinsed  ||| S:25406 E:25413 ||| VBN
in  ||| S:25413 E:25416 ||| IN
TBS-Tx  ||| S:25416 E:25423 ||| JJ
and  ||| S:25423 E:25427 ||| CC
incubated  ||| S:25427 E:25437 ||| NN
with  ||| S:25437 E:25452 ||| IN
fluorescently  ||| S:25452 E:25466 ||| NN
labeled  ||| S:25466 E:25474 ||| VBD
secondary  ||| S:25474 E:25484 ||| JJ
antibodies  ||| S:25484 E:25495 ||| NNS
in  ||| S:25495 E:25498 ||| IN
TBS-Tx  ||| S:25498 E:25505 ||| JJ
for  ||| S:25505 E:25519 ||| IN
45  ||| S:25519 E:25522 ||| CD
minutes ||| S:25522 E:25529 ||| NNS
.  ||| S:25529 E:25531 ||| .
Coverslips  ||| S:25531 E:25542 ||| NNP
were  ||| S:25542 E:25547 ||| VBD
rinsed  ||| S:25547 E:25554 ||| JJ
and  ||| S:25554 E:25558 ||| CC
mounted  ||| S:25558 E:25566 ||| VBN
in  ||| S:25566 E:25569 ||| IN
90 ||| S:25569 E:25571 ||| CD
%  ||| S:25571 E:25583 ||| NN
glycerol  ||| S:25583 E:25592 ||| NN
with  ||| S:25592 E:25597 ||| IN
0.5 ||| S:25597 E:25600 ||| CD
%  ||| S:25600 E:25602 ||| NN
p-phenylenediamine  ||| S:25602 E:25621 ||| NN
in  ||| S:25621 E:25624 ||| IN
20  ||| S:25624 E:25627 ||| CD
mM  ||| S:25627 E:25630 ||| JJ
Tris-pH  ||| S:25630 E:25648 ||| JJ
8.8 ||| S:25648 E:25651 ||| CD
.  ||| S:25651 E:25663 ||| .
Antibodies  ||| S:25663 E:25674 ||| NNS
used ||| S:25674 E:25678 ||| VBN
:  ||| S:25678 E:25680 ||| :
rabbit  ||| S:25680 E:25687 ||| CD
Arp3  ||| S:25687 E:25692 ||| CD
antibodies  ||| S:25692 E:25703 ||| NNS
( ||| S:25703 E:25704 ||| -LRB-
gift  ||| S:25704 E:25709 ||| NN
from  ||| S:25709 E:25714 ||| IN
C.  ||| S:25714 E:25727 ||| NNP
Egile  ||| S:25727 E:25733 ||| NNP
using  ||| S:25733 E:25739 ||| VBG
the  ||| S:25739 E:25743 ||| DT
same  ||| S:25743 E:25748 ||| JJ
peptide  ||| S:25748 E:25756 ||| NN
as  ||| S:25756 E:25759 ||| IN
described  ||| S:25759 E:25769 ||| VBN
[  ||| S:25769 E:25771 ||| -LRB-
33  ||| S:25771 E:25774 ||| CD
]  ||| S:25774 E:25776 ||| CD
)  ||| S:25776 E:25778 ||| -RRB-
used  ||| S:25778 E:25793 ||| VBN
at  ||| S:25793 E:25796 ||| IN
1 ||| S:25796 E:25797 ||| CD
: ||| S:25797 E:25798 ||| :
500  ||| S:25798 E:25802 ||| CD
dilution ||| S:25802 E:25810 ||| NN
,  ||| S:25810 E:25812 ||| ,
mouse  ||| S:25812 E:25818 ||| FW
actin  ||| S:25818 E:25824 ||| FW
antibodies  ||| S:25824 E:25835 ||| FW
( ||| S:25835 E:25836 ||| -LRB-
Santa  ||| S:25836 E:25842 ||| NNP
Cruz  ||| S:25842 E:25857 ||| NNP
SC-8432 ||| S:25857 E:25864 ||| NNP
)  ||| S:25864 E:25866 ||| -RRB-
used  ||| S:25866 E:25871 ||| VBN
at  ||| S:25871 E:25874 ||| IN
1 ||| S:25874 E:25875 ||| CD
: ||| S:25875 E:25876 ||| :
10,000  ||| S:25876 E:25883 ||| CD
dilution ||| S:25883 E:25891 ||| NN
,  ||| S:25891 E:25893 ||| ,
rabbit  ||| S:25893 E:25900 ||| FW
VASP  ||| S:25900 E:25915 ||| FW
antibodies  ||| S:25915 E:25926 ||| FW
( ||| S:25926 E:25927 ||| -LRB-
gift  ||| S:25927 E:25932 ||| NN
from  ||| S:25932 E:25937 ||| IN
F.  ||| S:25937 E:25940 ||| NNP
Southwick ||| S:25940 E:25949 ||| NNP
)  ||| S:25949 E:25951 ||| -RRB-
used  ||| S:25951 E:25956 ||| VBN
at  ||| S:25956 E:25959 ||| IN
1 ||| S:25959 E:25960 ||| CD
: ||| S:25960 E:25961 ||| :
100 ||| S:25961 E:25964 ||| CD
,  ||| S:25964 E:25966 ||| ,
rabbit  ||| S:25966 E:25983 ||| FW
WAVE1  ||| S:25983 E:25989 ||| FW
antibodies  ||| S:25989 E:26000 ||| FW
( ||| S:26000 E:26001 ||| -LRB-
gift  ||| S:26001 E:26006 ||| NN
from  ||| S:26006 E:26011 ||| IN
S.  ||| S:26011 E:26014 ||| NNP
Eden  ||| S:26014 E:26019 ||| NNP
as  ||| S:26019 E:26022 ||| RB
described  ||| S:26022 E:26032 ||| VBN
[  ||| S:26032 E:26034 ||| -LRB-
26  ||| S:26034 E:26037 ||| CD
]  ||| S:26037 E:26039 ||| CD
)  ||| S:26039 E:26051 ||| -RRB-
used  ||| S:26051 E:26056 ||| VBN
at  ||| S:26056 E:26059 ||| IN
1 ||| S:26059 E:26060 ||| CD
: ||| S:26060 E:26061 ||| :
100  ||| S:26061 E:26065 ||| CD
and  ||| S:26065 E:26069 ||| CC
Alexa-dye  ||| S:26069 E:26079 ||| NNP
labeled  ||| S:26079 E:26087 ||| VBD
secondary  ||| S:26087 E:26097 ||| JJ
antibodies ||| S:26097 E:26107 ||| NNS
,  ||| S:26107 E:26119 ||| ,
goat  ||| S:26119 E:26124 ||| JJ
anti-rabbit  ||| S:26124 E:26136 ||| JJ
and  ||| S:26136 E:26140 ||| CC
goat  ||| S:26140 E:26145 ||| JJ
anti-mouse  ||| S:26145 E:26156 ||| NN
( ||| S:26156 E:26157 ||| -LRB-
Molecular  ||| S:26157 E:26177 ||| NNP
Probes ||| S:26177 E:26183 ||| NNP
) ||| S:26183 E:26184 ||| -RRB-
.  ||| S:26184 E:26214 ||| .
GFP-Arp3  ||| S:26214 E:26223 ||| NNP
cell  ||| S:26223 E:26228 ||| NN
line  ||| S:26228 E:26243 ||| NN
A  ||| S:26243 E:26245 ||| DT
stable  ||| S:26245 E:26252 ||| JJ
BS-C-1  ||| S:26252 E:26259 ||| CD
cell  ||| S:26259 E:26264 ||| NN
line  ||| S:26264 E:26269 ||| NN
was  ||| S:26269 E:26273 ||| VBD
made  ||| S:26273 E:26278 ||| VBN
by  ||| S:26278 E:26281 ||| IN
transfection  ||| S:26281 E:26294 ||| NN
of  ||| S:26294 E:26307 ||| IN
GFP-Arp3  ||| S:26307 E:26316 ||| NNP
( ||| S:26316 E:26317 ||| -LRB-
gift  ||| S:26317 E:26322 ||| NN
from  ||| S:26322 E:26327 ||| IN
D.  ||| S:26327 E:26330 ||| NNP
Schafer  ||| S:26330 E:26338 ||| NNP
as  ||| S:26338 E:26341 ||| RB
described  ||| S:26341 E:26351 ||| VBN
[  ||| S:26351 E:26353 ||| -LRB-
34  ||| S:26353 E:26356 ||| CD
]  ||| S:26356 E:26358 ||| CD
)  ||| S:26358 E:26370 ||| -RRB-
using  ||| S:26370 E:26376 ||| VBG
Fugene6  ||| S:26376 E:26384 ||| NNP
( ||| S:26384 E:26385 ||| -LRB-
Roche ||| S:26385 E:26390 ||| NNP
)  ||| S:26390 E:26392 ||| -RRB-
and  ||| S:26392 E:26396 ||| CC
selection  ||| S:26396 E:26406 ||| NN
with  ||| S:26406 E:26411 ||| IN
500  ||| S:26411 E:26415 ||| CD
ug ||| S:26415 E:26417 ||| FW
/ ||| S:26417 E:26418 ||| FW
ml  ||| S:26418 E:26431 ||| FW
Geneticin ||| S:26431 E:26440 ||| FW
.  ||| S:26440 E:26442 ||| .
GFP  ||| S:26442 E:26446 ||| NNP
expressing  ||| S:26446 E:26457 ||| VBG
colonies  ||| S:26457 E:26466 ||| NNS
were  ||| S:26466 E:26471 ||| VBD
picked  ||| S:26471 E:26478 ||| VBN
and  ||| S:26478 E:26492 ||| CC
expanded ||| S:26492 E:26500 ||| VBN
.  ||| S:26500 E:26530 ||| .
Live  ||| S:26530 E:26535 ||| JJ
imaging  ||| S:26535 E:26543 ||| NN
of  ||| S:26543 E:26546 ||| IN
GFP-Arp3  ||| S:26546 E:26565 ||| CD
GFP-Arp3  ||| S:26565 E:26574 ||| CD
cells  ||| S:26574 E:26580 ||| NNS
were  ||| S:26580 E:26585 ||| VBD
split  ||| S:26585 E:26591 ||| VBN
onto  ||| S:26591 E:26596 ||| IN
25  ||| S:26596 E:26599 ||| CD
mm  ||| S:26599 E:26602 ||| FW
PLL  ||| S:26602 E:26606 ||| FW
coated  ||| S:26606 E:26623 ||| FW
coverslips  ||| S:26623 E:26634 ||| FW
4-6  ||| S:26634 E:26638 ||| FW
hrs  ||| S:26638 E:26642 ||| FW
before  ||| S:26642 E:26649 ||| IN
imaging ||| S:26649 E:26656 ||| NN
.  ||| S:26656 E:26658 ||| .
Cells  ||| S:26658 E:26664 ||| NNS
were  ||| S:26664 E:26669 ||| VBD
transferred  ||| S:26669 E:26691 ||| VBN
to  ||| S:26691 E:26694 ||| TO
Liebovitz  ||| S:26694 E:26704 ||| NNP
L-15  ||| S:26704 E:26709 ||| NNP
media  ||| S:26709 E:26715 ||| NNS
with  ||| S:26715 E:26720 ||| IN
10 ||| S:26720 E:26722 ||| CD
%  ||| S:26722 E:26724 ||| NN
fetal  ||| S:26724 E:26730 ||| JJ
calf  ||| S:26730 E:26735 ||| JJ
serum  ||| S:26735 E:26741 ||| NN
in  ||| S:26741 E:26744 ||| IN
a  ||| S:26744 E:26756 ||| DT
heated  ||| S:26756 E:26763 ||| JJ
( ||| S:26763 E:26764 ||| -LRB-
37C ||| S:26764 E:26768 ||| NNP
)  ||| S:26768 E:26770 ||| -RRB-
open-air  ||| S:26770 E:26779 ||| JJ
chamber  ||| S:26779 E:26787 ||| NN
15  ||| S:26787 E:26790 ||| CD
minutes  ||| S:26790 E:26798 ||| NNS
prior  ||| S:26798 E:26804 ||| RB
to  ||| S:26804 E:26817 ||| TO
imaging ||| S:26817 E:26824 ||| VB
.  ||| S:26824 E:26826 ||| .
Images  ||| S:26826 E:26833 ||| NNS
were  ||| S:26833 E:26838 ||| VBD
captured  ||| S:26838 E:26847 ||| VBN
on  ||| S:26847 E:26850 ||| IN
a  ||| S:26850 E:26852 ||| DT
Nikon  ||| S:26852 E:26858 ||| NNP
TE300  ||| S:26858 E:26864 ||| NNP
inverted  ||| S:26864 E:26883 ||| JJ
microscope  ||| S:26883 E:26894 ||| NN
with  ||| S:26894 E:26899 ||| IN
appropriate  ||| S:26899 E:26911 ||| JJ
neutral  ||| S:26911 E:26919 ||| JJ
density  ||| S:26919 E:26927 ||| NNS
filtering  ||| S:26927 E:26947 ||| VBP
using  ||| S:26947 E:26953 ||| VBG
an  ||| S:26953 E:26956 ||| DT
Apo  ||| S:26956 E:26960 ||| NNP
100  ||| S:26960 E:26964 ||| CD
  ||| S:26964 E:26966 ||| CD
/ ||| S:26966 E:26967 ||| CD
1.4  ||| S:26967 E:26971 ||| CD
NA  ||| S:26971 E:26974 ||| JJ
oil  ||| S:26974 E:26978 ||| NN
emersion  ||| S:26978 E:26987 ||| NN
phase  ||| S:26987 E:26993 ||| NN
objective  ||| S:26993 E:27013 ||| NN
and  ||| S:27013 E:27017 ||| CC
captured  ||| S:27017 E:27026 ||| VBN
on  ||| S:27026 E:27029 ||| IN
a  ||| S:27029 E:27031 ||| DT
CCD  ||| S:27031 E:27035 ||| NNP
camera  ||| S:27035 E:27042 ||| NN
( ||| S:27042 E:27043 ||| -LRB-
Hammamatsu-OrcaER ||| S:27043 E:27060 ||| NNP
)  ||| S:27060 E:27062 ||| -RRB-
using  ||| S:27062 E:27078 ||| VBG
Metamorph  ||| S:27078 E:27088 ||| JJ
software ||| S:27088 E:27096 ||| NN
.  ||| S:27096 E:27098 ||| .
Images  ||| S:27098 E:27105 ||| NNS
were  ||| S:27105 E:27110 ||| VBD
taken  ||| S:27110 E:27116 ||| VBN
every  ||| S:27116 E:27122 ||| DT
15  ||| S:27122 E:27125 ||| CD
s  ||| S:27125 E:27127 ||| NN
with  ||| S:27127 E:27132 ||| IN
an  ||| S:27132 E:27145 ||| DT
exposure  ||| S:27145 E:27154 ||| NN
of  ||| S:27154 E:27157 ||| IN
200-1000  ||| S:27157 E:27166 ||| CD
ms ||| S:27166 E:27168 ||| NNS
.  ||| S:27168 E:27201 ||| .
Authors ||| S:27201 E:27208 ||| NNP
'  ||| S:27208 E:27210 ||| POS
contributions  ||| S:27210 E:27232 ||| NNS
JY  ||| S:27232 E:27235 ||| VBP
prepared  ||| S:27235 E:27244 ||| VBN
the  ||| S:27244 E:27248 ||| DT
manuscript  ||| S:27248 E:27259 ||| NN
and  ||| S:27259 E:27263 ||| CC
performed  ||| S:27263 E:27273 ||| VBD
the  ||| S:27273 E:27277 ||| DT
time-lapse  ||| S:27277 E:27296 ||| JJ
microscopy ||| S:27296 E:27306 ||| NN
,  ||| S:27306 E:27317 ||| ,
Listeria  ||| S:27317 E:27326 ||| NNP
,  ||| S:27326 E:27328 ||| ,
and  ||| S:27328 E:27332 ||| CC
myosin  ||| S:27332 E:27339 ||| JJ
ATPase  ||| S:27339 E:27354 ||| JJ
experiments ||| S:27354 E:27365 ||| NNS
.  ||| S:27365 E:27367 ||| .
Remaining  ||| S:27367 E:27377 ||| VBG
experimentswere  ||| S:27377 E:27393 ||| NNS
done  ||| S:27393 E:27398 ||| VBN
in  ||| S:27398 E:27409 ||| IN
collaboration  ||| S:27409 E:27423 ||| NN
with  ||| S:27423 E:27428 ||| IN
TL ||| S:27428 E:27430 ||| NNP
.  ||| S:27430 E:27432 ||| .
RL  ||| S:27432 E:27435 ||| NNP
and  ||| S:27435 E:27439 ||| CC
TM  ||| S:27439 E:27442 ||| NNP
supervised  ||| S:27442 E:27453 ||| VBD
this  ||| S:27453 E:27458 ||| DT
work  ||| S:27458 E:27463 ||| NN
and  ||| S:27463 E:27475 ||| CC
provided  ||| S:27475 E:27484 ||| VBN
funding  ||| S:27484 E:27492 ||| NN
and  ||| S:27492 E:27496 ||| CC
support ||| S:27496 E:27503 ||| NN
.  ||| S:27503 E:27505 ||| .
All  ||| S:27505 E:27509 ||| DT
authors  ||| S:27509 E:27517 ||| NNS
read  ||| S:27517 E:27522 ||| VBP
and  ||| S:27522 E:27526 ||| CC
approved  ||| S:27526 E:27543 ||| VBD
the  ||| S:27543 E:27547 ||| DT
final  ||| S:27547 E:27553 ||| JJ
manuscript ||| S:27553 E:27563 ||| NN
.  ||| S:27563 E:27580 ||| .
